Protocol Title: A Randomised, Double-blind, Multicentre Phase III Study to Assess the Efficacy and 
Safety of RGB-14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis
Protocol number: RGB-14-101
ClinicalTrails.gov Identifier: [STUDY_ID_REMOVED]
Date of protocol: 28-March-2023
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 1 of 124 28Mar2023  
 Title Page  
Protocol  Title:  A Randomised , Double -blind, Multicentre 
Phase  III Study to Assess the Efficacy and 
Safety of RGB -14-P Compared to Prolia® in 
Women with Postmenopausal Osteoporosis  
Short Title:  Comparative Efficacy and Safety Study of 
RGB -14-P and Prolia® in Women with 
Postmenopausal Osteoporosis 
Compound : RGB -14-P (test product ) and  
Prolia® (reference product)  
Indication:  Postmenopausal Osteoporosis  
Study Sponsor:  Gedeon Richter Plc.  
[ADDRESS_1065190], Gyömrői út  19-21 
Hungary  
Protocol  Number:  RGB -14-101 
Study Phase:  Phase  III 
Regulatory Agency Identifying 
Number : IND 146025  
European Clinical Trials Database 
(EudraCT) Number:  2020 -006017 -38 
Approval Date : Final Version  5.0 28Mar2023  
This clinical study will be conducted in accordance with the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) Tripartite Guideline for Good Clinical Practice (GCP) 
E6(R2), the protocol an d its amen dments, the Declaratio n of Helsinki  and with other applicable regulatory 
requirements.  
Confidentiality Statement  
This document contains confidential information of Gedeon Richter Plc .  Do not copy or distribute without written 
permission from the Sponsor.  
  
[COMPANY_003]
[COMPANY_003]
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 3 of 124 28Mar2023  
 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Document  Version  Date  
Non-Substantial Amendment  2; Global 
Amendment  Final 5.0  28 Mar 2023  
Substantial Amendment  3; Global 
Amendment  Final  4.0 19 Jan 2023  
Substantial Amendment  2; Global 
Amendment  Final  3.0 10 Jan 2022 
Substantial Amendment  1; Country 
Specific – [LOCATION_002]  Final  2.0 03 Aug 2021  
Non-Substantial Amendment  1; 
Country Specific - Czech Republic  Final  1.1 20 July  2021  
Original Protocol  Final  1.0 10 March2021  
 
Non-Substantial Amendment  2 (28 Mar 2023 ) 
This amendment is considered to be  non-substantial because it neither significantly impacts the 
safety or physical/mental integrity of participants nor the scientific value of the study  
Overall Rationale for the Amendment : 
The protocol is mainly amended to incorporate and implement  respons es and suggestions made 
by [CONTACT_24623] (US) Food and Drug Administration (FDA) . 
Non-Substantial Amendment 2 Summary of Changes : 
Section # and Name  [CONTACT_11029]  
9.4.2 Estimands (Table  9-3) Text added to include the 
composite variable strategy of 
ICE Strategy.  
 
Text added to include and specify 
that robustness of the main 
estimator will be assessed by 
[CONTACT_256653] -dimensional tippi[INVESTIGATOR_775495].  Amended following the 
sugges tion from the US FDA.  
9.4.[ADDRESS_1065191] not been 
summarized.  
  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 4 of 124 28Mar2023  
 Table of Contents  
 
Protocol Amendment Summary of Changes Table  ................................ ................................ .........  3 
Table of Contents  ................................ ................................ ................................ ............................  4 
1 Protocol Summary  ................................ ................................ ................................ ....................  9 
1.1 Synopsis  ................................ ................................ ................................ ................................  9 
1.2 Schema  ................................ ................................ ................................ ...............................  14 
1.3 Schedule of Activi ties (SoA)  ................................ ................................ ..............................  16 
2 Introduction ................................ ................................ ................................ .............................  21 
2.1 Background ................................ ................................ ................................ .........................  22 
2.1.1  Summary of N on-clinical Studies  ................................ ................................ ..................  23 
2.1.2  Summary of Clinical Studies  ................................ ................................ ..........................  25 
2.2 Benefit/Risk Assessment  ................................ ................................ ................................ .... 25 
2.2.1  Risk Assessment  ................................ ................................ ................................ .............  25 
2.2.2  Benefi t Assessment  ................................ ................................ ................................ .........  28 
2.2.3  Overall Benefit: Risk Conclusion  ................................ ................................ ...................  29 
3 Objectives and Endpoints  ................................ ................................ ................................ ....... 30 
4 Study Design  ................................ ................................ ................................ ...........................  31 
4.1 Overall Design  ................................ ................................ ................................ ....................  31 
4.2 Scientific Rationale for Study Design  ................................ ................................ ................  33 
4.3 Justification for Dose  ................................ ................................ ................................ ..........  33 
4.4 End of Study Definition ................................ ................................ ................................ ...... 34 
5 Study Population  ................................ ................................ ................................ .....................  35 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................  35 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............  36 
5.3 Lifestyle Considerations and Restrictions  ................................ ................................ ..........  40 
5.4 Screen Failures  ................................ ................................ ................................ ...................  40 
5.4.1  Screening and Enrolment Log  ................................ ................................ ........................  41 
6 Study Treatments  ................................ ................................ ................................ ....................  42 
6.1 Study Treatments Administered  ................................ ................................ .........................  42 
6.1.1  Study Treatment Devices  ................................ ................................ ................................  43 
6.1.2 Medical Device Events  ................................ ................................ ................................ ... 43 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 5 of 124 28Mar2023  
 6.2 Preparation, Handling, Storage, and Accountability  ................................ ..........................  44 
6.3 Measures to Minimise Bias: Randomisation and Blinding  ................................ ................  [ADDRESS_1065192] and Participant 
Discontinuation/Withdrawal from the Study  ................................ ................................ ..........  [ADDRESS_1065193], Participant 
Discontinuation/Wi thdrawal from the Study  ................................ ................................ ...... [ADDRESS_1065194]  ................................ .......................  55 
8.2 Screening and Eligibility Assessments  ................................ ................................ ...............  56 
8.2.1  Eligibility Criteria  ................................ ................................ ................................ ...........  56 
8.2.2  Demography  ................................ ................................ ................................ ...................  56 
8.2.3  Medical and Surgical History  ................................ ................................ .........................  56 
8.2.4  Prior and Concomitant Medications Review  ................................ ................................ .. 56 
8.2.5  Screening Assessment  ................................ ................................ ................................ .... 57 
8.2.6  Recommended Order of Assessments  ................................ ................................ ............  58 
8.3 Efficacy Assessments  ................................ ................................ ................................ .........  58 
8.3.1  Dual Energy X -ray Absorptiometry Measurement  ................................ .........................  58 
8.3.2  Lateral Spi[INVESTIGATOR_050] X -ray ................................ ................................ ................................ ........  59 
8.3.3  Fracture Assessment  ................................ ................................ ................................ ....... 59 
8.4 Safety Assessments  ................................ ................................ ................................ .............  60 
8.4.1  Physical Examinations  ................................ ................................ ................................ .... 60 
8.4.2  Vital Signs  ................................ ................................ ................................ ......................  60 
8.4.3  Electrocardiograms  ................................ ................................ ................................ .........  61 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 6 of 124 28Mar2023  
 8.4.4  Clinical Safety Laboratory Assessments  ................................ ................................ ........  61 
8.4.5  Local Tolerance (Skin Examination)  ................................ ................................ ..............  62 
8.5 Adverse Events and Serious Adverse Events  ................................ ................................ ..... 63 
8.5.1  Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event 
Information  ................................ ................................ ................................ .....................  63 
8.5.2  Method of Detecting Adverse Events and Serious Adverse Events  ...............................  64 
8.5.3  Follow -up of Adverse Events and Serious Adverse Events  ................................ ...........  64 
8.5.4  Regulatory Reporting Requirements for Serious Adverse Event  ................................ ... 65 
8.5.5  Pregnancy  ................................ ................................ ................................ .......................  66 
8.6 Treatment of Overdose  ................................ ................................ ................................ ....... 67 
8.7 Immunogenicity Assessments  ................................ ................................ ............................  67 
8.8 Serum Drug Concentration  ................................ ................................ ................................ . 68 
8.9 Pharmacodynamics  ................................ ................................ ................................ .............  69 
8.10  Genetic s ................................ ................................ ................................ ..............................  69 
8.11  Biomarkers  ................................ ................................ ................................ .........................  69 
8.12  Medical Resource Utilisation and Health Economics  ................................ ........................  69 
9 Statistical Considerations ................................ ................................ ................................ ........  70 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .........  70 
9.2 Sample Size Determination  ................................ ................................ ................................  71 
9.3 Populations for Analyses  ................................ ................................ ................................ .... 73 
9.4 Statistical Analyses  ................................ ................................ ................................ .............  73 
9.4.1  General Considerations  ................................ ................................ ................................ .. 74 
9.4.2  Estimands  ................................ ................................ ................................ .......................  74 
9.4.3  Primary phar macodynamic analysis  ................................ ................................ ...............  77 
9.4.4  Additional analyses  ................................ ................................ ................................ ........  77 
9.4.5  Handling of Missing Data  ................................ ................................ ..............................  79 
9.4.6  Other Analyses  ................................ ................................ ................................ ................  80 
9.5 Interim Analyses  ................................ ................................ ................................ .................  82 
9.6 Data Monitoring Committee ................................ ................................ ...............................  82 
10 Supporting Documentation and Operational Considerations  ................................ .................  83 
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ............................  83 
10.1.1  Regulatory and Ethical Considerations  ................................ ................................ ..........  83 
10.1.2  Financial Disclosure  ................................ ................................ ................................ ....... 83 
10.1.3  Informed Consent Process  ................................ ................................ ..............................  84 
10.1.4 Data Protection  ................................ ................................ ................................ ...............  84 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 7 of 124 28Mar2023  
 10.1.5  Dissemination of Clinical Study Data  ................................ ................................ ............  85 
10.1.6  Data Quality Assurance  ................................ ................................ ................................ .. 85 
10.1.7 Source Documents  ................................ ................................ ................................ ..........  87 
10.1.8  Study and Site Start and Closure  ................................ ................................ ....................  87 
10.1.9  Publication Policy  ................................ ................................ ................................ ...........  88 
10.1.10  Protocol Approval and Amendment  ................................ ................................ ...............  89 
10.1.11  Liability and Insurance  ................................ ................................ ................................ ... 89 
10.2  Appendix  2: Clinical Laboratory Tests  ................................ ................................ ...............  91 
10.3  Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ................................ ... 93 
10.3.1  Definition of Adverse Event  ................................ ................................ ...........................  93 
10.3.2  Definition of Serious Adverse Event  ................................ ................................ ..............  95 
10.3.3  Definition of Medical Device Events  ................................ ................................ .............  97 
10.3.4  Recording and Follow -up of Adverse Event and Serious Adverse Event  ......................  97 
10.3.5  Reporting of Serious Adverse Events  ................................ ................................ ...........  102 
10.4  Appendix 4: Coronavirus Disease 2019 (COVID -19) Related Considerations  ...............  107 
10.5  Appendix 5: Abbre viations and Trademarks  ................................ ................................ .... 108 
10.6  Appendix 6: Protocol Amendment History  ................................ ................................ ....... [ADDRESS_1065195] of Figures  
Figure 1 –1: Study Design – Main Period only  ................................ ................................ .........  14 
Figure 1 –2: Study Design – Main and Transition Period  ................................ .........................  [ADDRESS_1065196] of Tables  
Table  1-1 Schedule of Activities (SoA) – Main Period ................................ .........................  16 
Table  1-2 Schedule of Activities (SoA) – Transition Period  ................................ .................  [ADDRESS_1065197] One Participant with a Given Adverse Event  ..... 72 
Table  9-2 Populations for Analysis  ................................ ................................ .......................  73 
Table  9-3 Summary of the primary and secondary estimands  ................................ ..............  74 
Table  10-1 Protocol -Required Laboratory Assessments  ................................ .........................  91 
 
 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 9 of 124 28Mar2023  
 1 Protocol Summary  
1.1 Synopsis  
Protocol Title:  A Randomised , Double -blind, Multicentre Phase  III Study to Assess the Efficacy 
and Safety of RGB -14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis  
Sponsor Protocol  No.: RGB -14-101 
Study Phase:  Phase  III 
Sponsor:  Gedeon Richter Plc.  
Rationale : 
Gedeon Richter Plc. is developi[INVESTIGATOR_775496] -14-P (test product) as a biosimilar to Prolia® (reference 
product) by [CONTACT_96239] a global development program me.  The Sponsor is also developi[INVESTIGATOR_775497] -14-X, as a proposed biosimilar to Xgeva®.  Following a step -wise approach subsequent to 
demonstrating high level of similarity between the proposed bios imilar s RGB -14-P and 
RGB -14-X and the respective reference product s Prolia® and Xgeva® at the quality and in vitro  
non-clinical levels, Gedeon Richter Plc., intends to demonstrate clinical comparability by 
[CONTACT_775521]  (PK) /pharmacodynamic  (PD)  study of RGB -14-X as 
well as a comparative  efficacy and safety study between RGB -14-P and Prolia®.  Although the 
comparative PK/PD study will commence earlier, essentially the two studies will run in parallel.  
Objectives and Endpoint s: 
Objectives  Endpoints  
Primary  
Efficacy  
To demonstrate similar efficacy and effect of 
RGB -14-P with US -licensed Prolia® on BMD at the 
lumbar spi[INVESTIGATOR_624383]  52 in female participants with 
postmenopausal osteoporosis  
  
Efficacy  
%CfB in lumbar spi[INVESTIGATOR_110075]  52 
Pharmacodynamics  
To demonstrate similar pharmacodynamics (AUEC of 
%CfB in sCT X) of RGB -14-P with US -licensed 
Prolia® in female participants with postmenopausal 
osteoporosis (only required for EMA)  Pharmacodynamics  
AUEC  of %CfB  sCTX0-m6 until Week  26 
(secondary for US FDA submission)  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 10 of 124 28Mar2023  
 Objectives  Endpoints  
Secondary  
Efficacy  
To provide additional comparative efficacy data of 
RGB -14-P with US -licensed Prolia® in female 
participants with postmenopausal osteoporosis    
Efficacy  
• %CfB  in total hip BMD at Weeks  26, 52 and 78  
• %CfB  in lumbar spi[INVESTIGATOR_110085]  26 and 78  
• %CfB  in femoral neck BMD at Weeks  26, 52 
and 78 
• Vertebral fragility fracture incidence at Weeks  52 
and 78  
• Non-vertebral fragility fracture incidence at 
Weeks  52 and 78  
 
Pharmacodynamics  
To provide additional comparative pharmacodynamic 
data of RGB -14-P with US -licensed Prolia® in female 
participants with postmenopausal osteoporosis  
 Pharmacodynamics  
• %CfB  in serum P1NP at Weeks  4, 26, 52 and 78  
• %CfB  in sCT X at Weeks  4, 26, 52 and 78  
Safety  
To compare the safety and tolerability of RGB -14-P 
with US -licensed Prolia® in female participants with 
postmenopausal osteoporosis  Safety  
• AE, SAE, clinical laboratory safety assessments 
(haematology, clinical chemistry and urinalysis), 
vital signs, physical examination, ECG , injection 
site reaction  and fracture assessment  up to 
Week  78 
 
Immunogenicity  
To compare the immunogenicity of RGB -14-P with 
US-licensed Prolia® in female participants with 
postmenopausal osteoporosis  Immunogenicity  
• Incidence of binding  ADAs  and NAb s at Weeks  0, 
2, 4, 26, 28, 30, 52, 54, 56 and 78  
• Titre determination of binding ADAs at Weeks  0, 
2, 4, 26, 28, 30, 52, 54, 56 and 78  
ADA  = anti-drug antibody; AE  = adverse event; AUEC  = area under the effective curve; 
AUEC sCTX0-m6 = AUEC after the first dose until Day 183 of %CfB in serum type I collagen C -telopeptide; 
BMD  = bone mineral density; %CfB  = percent change from baseline; ECG  = electrocardiogram; 
EMA  = European Medicines Agency;  FDA  = Food and Drug Administration;  NAbs  = neutralising antibodies;  
P1NP  = serum procollagen type 1 N -terminal propeptide; SAE  = serious adverse event; sCT X0-m6 =  serum type I 
collagen C -telopeptide up to month  6; US  = [LOCATION_002]  
 
Overall Design : 
This is a randomised, double -blind, multicentre , multiple fixed -dose, 2 -arm parallel -group study  
(Main Period)  with a Transition Period  to assess the efficacy, PD, safety, tolerability and 
immunogenicity of RGB -14-P compared to US -licensed Prolia® in participants with 
postmenopausal osteoporosis, in a comparative manner.  
Participa nts will attend a Screening Period  within [ADDRESS_1065198] dosing.  Participants 
meeting eligibility criteria will enter into the Main Period of the study.  The Main Period 
(52 weeks) consists of Treatment Period  1 (26  weeks) and Treatment Period  2 (26 weeks).  The 
primary endpoint of the study is assessed at the end of the Main Period.  The Transition Period 
consists of Treatment Period  3 (26  weeks) , the Transition Period will be applicable to a subset of 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 11 of 124 28Mar2023  
 participants  (see Figure 1–2).  Day [ADDRESS_1065199] (IMP)  on 2 occasions  
(Weeks  0 and 26), on Day  [ADDRESS_1065200] occasion (Week  52), Day  1 of Treatment 
Period  3.  One Treatment Period will take 6  months ( 26 weeks, 183 days).  
Participants will attend ambulatory  site visits on the following timepoints for efficacy, PD, 
immunogenicity and safety assessment as indicated in the Schedule of Activities ( Table  1-1 and 
Table 1-2). 
Main Period : 
On Day 1 of Treatment Period  1, prior to dosing,  participants will be randomised in a 1:1 ratio to 
receive either RGB -14-P or Prolia®.  Administration of IMP will take place on two occasions in a 
double -blinded manner (Main Period), on Day  1 of both Treatment Periods  1 and  2 (Weeks  0 and 
26). 
Visits dur ing the Main Period:  
• Days  1, 8, 15, 30, 60, 90, 120 and 150 postdose during Treatment Period  1. 
• Days  1, 8, 15, 30 and 90 postdose during Treatment Period  2. 
An End-of-Study  Visit is planned on Day  183 (Week  52) postdose  during Treatment Period  2 for 
participants not continuing participation in Transition Period .  Please see  Section  6.7 for 
additional information on the transition treatment for participants not continuing in Transition 
Period of study.  
Transition Period:  
On Day  1 of Treatment Period  3 (Week  52) a total of approximately 198 participants will enter 
the Transition Period.  A  subset of approximately 132 participants  continuing in the Transition 
Period who receiv ed Prolia® during the Main Period will be re -randomised 1:1 to receive either a 
dose RGB -14-P or Prolia® in a double -blinded manner.  A subset of approximately 
66 participants  continuing in the Transition Period who  receiv ed RGB -14-P during the Main 
Period  will continue to receive a dose of RGB -14-P but will also follow the randomisation 
procedure to maintain blinding . 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 12 of 124 28Mar2023  
 Visits during the Transition Period:  
• Days  1, 8, 15, 30 and 90 postdose during Treatment Period  3. 
An End -of-Study Visit is planned on Day  183 (Week  78) postdose during Treatment Period  3.  
Please see Section  6.[ADDRESS_1065201] completed the Week  52 study visit.  The data obtained in the Transition Per iod 
will be added as a Final  Clinical Study Report.  
Disclosure Statement:  
This is a randomised , double -blind, multicentre , multiple fixed -dose, 2 -arm parallel -group study 
with a double -blind  transition  period . 
Number of Participant s: 
Approximately 434  women with postmenopausal osteoporosis are planned to be enrolled 1:1 
(217 participants per arm, including 17% drop -out) in the study to have 362  evaluable 
participants to evaluate the primary efficacy endpoint at 90%  power  during the Main Period .  
Participants will be stratified b y previous use of bisphosphonates and geographical region.  
It is planned that  [ADDRESS_1065202] 180 evalu able participants ; approximately 66 participants will continue on 
the RGB -14-P arm, where as approximately 132 participants  initially assigned to the Prolia® arm 
will be re -randomised 1:1 whereby [CONTACT_3450] 66 participants will continue to receive Prolia® 
and approximately 66 participants will be switched to RGB -14-P. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 13 of 124 28Mar2023  
 Intervention  Groups  and Duration : 
On Day 1 of Treatment Period  1, prior to dosing,  participants will be randomised in a 1:1 ratio to 
receive either RGB -14-P or Prolia®. 
Main Period : Participants will receive s ubcutaneous injection of RGB -14-P or Prolia®, into the 
thigh, abdomen or upper arm, administered on Day  1 of Treatment Periods  1 and 2  (Weeks  0 
and 26). 
Transition Period : A subset of approximately 66 participants  in the RGB -14-P dose group  will 
follow the randomisation procedure and  receive one subcutaneous injection of RGB -14-P, into 
the thigh, abdomen or upper arm, administered on Day  1 of Treatment Period  3 (Week  52).  A 
subset of approximately 132 participants in the Prolia® dose group will be re -randomi sed to 
receive a subcutaneous injection of RGB -14-P or Prolia®, into the thigh, abdomen or upper arm, 
administered on Day  1 of Treatment Period  3 (Week  52). 
 
Gedeon Richter Plc.   Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 14 of 124 28Mar2023  
 1.2 Schema  
Figure 1–1: Study Design  – Main Period only  
  Main Period  
   
                 
                 
                 
                 
                 
                 
                 
                 
Dayc -35 to 0  1d 8 15 30 60 90 120 150 1d, e 8 15 30 90 183f  
Week  -5 to 0  0 1 2 4 8 12 17 21 26 27 28 30 38 52  
                 
                 
                 
                 
  Treatment Period  1 Treatment Period  2 
    
EOS  = End-of Study ; n = number of participants  
a. Test product  
b. Reference product  
c. Day(s) refer to days within Screening or Treatment Period  
d. Dosing Visits  
e. Day [ADDRESS_1065203] an End -of-Study visit on Week  52 but will proceed to Day 1 of 
Treatment Period  3 (Week  52), see Figure 1–2. 
 RGB -14-Pa (n = 217) 
Screening 
and Informed 
Consent 
procedures  Proliab = (n = 217) 
Randomi sation  Screening  EOS  

Gedeon Richter Plc.   Clinical Study Protocol  
RGB -14-101 CONFIDENTIAL  
 
Version  5.0 15 of 124 28Mar2023  
 Figure 1–2: Study Design – Main and Transition Period  
  Main Period  Transition Period  
     
                     
                     
                     
                     
                     
                     
                     
                     
Dayc -35 to 0  1d 8 15 30 60 90 120 150 1d, e 8 15 30 90 1d, e, f 8 15 30 90 183 
Week  -5 to 0  0 1 2 4 8 12 17 21 26 27 28 30 38 52 53 54 56 64 78 
                     
                     
                     
                     
  Treatment Period  1 Treatment Period  2  Treatment Period  3 
      
EOS  = End-of Study ; n = number of participants  
a. Test product  
b. Reference product  
c. Day(s) refer to days within Screening or Treatment Period  
d. Dosing Visits  
e. Day 1 of Treatment Periods  2 and 3 is also Day 183 of the preceding treatment period.  
f. Participants continuing to the Transition Period who previously received Prolia® during the Main Period will be re -randomised 1:1 to either receive RGB -14-P or Prolia® in a 
double -blinded manner.  Participants continuing to the Transition Period who received RGB -14-P during the Main Period will continue to receive a dose of RGB -14-P but 
will also follow the randomisation procedure to maintain blinding.  
 
Randomi sation  
 Screening  
 Re-randomi sation  
 EOS  
Screening 
and Informed 
Consent 
procedures  
RGB -14-Pa(n = 217) 
RGB -14-Pa(n = 66) 
Proliab(n = 217) 
Proliab(n = 66) 
RGB -14-Pa(n = 66) 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 16 of 124 28Mar2023  1.3 Schedule of Activities  (SoA)  
Table  1-1 Schedule of Activities (SoA)  – Main Period  
Study Period  Days (weeks after first IMP administration)  
Screeningb Treatment Period  1 Treatment Period  2c 
Day(s)a 
(Week)  -35 to 0  
(-5 to 0)  
 1 
(0) 8 
(1) 15 
(2) 30 
(4) 60 
(8) 90 
(12) 120 
(17) 150 
(21) 1 
(26) 8 
(27) 15 
(28) 30 
(30) 90 
(38) 183 
(52)c/ 
EOS/  
ET  
Window Period (Days)    ± 1 ± 1 ± 3 ± 4 ± 4 ± 4 ± 4 ± 4 ± 1 ± 1 ± 3 ± 4 ± 4 
General Assessments  
Informed Consent  X               
Recording of Demographic Data  X               
Inclusion/Exclusion Criteria 
Assessment  X Xd              
Medical and Surgical History  X               
Weight, Height, BMIe X Xd        Xd     X 
Randomisation   Xd              
IMP Administration   X        X      
Pre-visit Phone Callf  X X X X X X X X X X X X X X 
Participant Identification and Visit 
Reminder Cardg X X X X X X X X X X X X X X X 
Safety Assessments  
Physical Examinationh X Xd X       Xc     X 
Haematology and Clinical Chemistry  X Xd, i X Xj X  X   Xd, i X Xj X X X 
HBV, HCV and HIV Screening  X               
Urinalysisk X Xd        Xd     X 
12-lead ECG  X Xd        Xd     X 
Vital Signsl X Xm X X X X X X X Xd X X X X X 
Local Tolerance (Skin Examination)   Xn X       Xn X     
Prior and Concomitant Medicationo  
 
Adverse Events   
 
Medical Device  Eventsp  X        X      
Efficacy Assessment  
DXA Scan Assessment  Xq         Xr     X 
Lateral Spi[INVESTIGATOR_050] X -ray Xq              X 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 17 of 124 28Mar2023  Study Period  Days (weeks after first IMP administration)  
Screeningb Treatment Period  1 Treatment Period  2c 
Day(s)a 
(Week)  -35 to 0  
(-5 to 0)  
 1 
(0) 8 
(1) 15 
(2) 30 
(4) 60 
(8) 90 
(12) 120 
(17) 150 
(21) 1 
(26) 8 
(27) 15 
(28) 30 
(30) 90 
(38) 183 
(52)c/ 
EOS/  
ET  
Window Period (Days)    ± 1 ± 1 ± 3 ± 4 ± 4 ± 4 ± 4 ± 4 ± 1 ± 1 ± 3 ± 4 ± 4 
Immunogenicity Assessment/Serum Drug Concentration Assessment  
Immunogenicity (binding ADAs and 
NAbs) Sampling   Xd  X X     Xd  X X  Xd 
Serum Drug Concentration Sampling   Xd  X X     Xd  X X  Xd 
PD 
PD (Serum CTX) Samplings  Xd X X X X X X X Xd     Xd 
PD (Serum P1NP) Samplings  Xd   X     Xd     Xd 
ADA  = anti-drug antibody; BMI  = body mass index;  CTX = collagen C -telopeptide; DXA  = dual energy x -ray absorp tiometry ; ECG  = electrocardiogram;  EOS  = End-of-Study,  
ET = early termination ; HBV  = hepatitis  B virus ; HCV  = hepatitis  C virus ; HIV = human immunodeficiency virus ; IMP = investigational medicinal product;  NAbs  = neutralising 
antibodies;  P1NP  = procollagen type 1 N -terminal propeptide;  PD = pharmacodynamic (s) 
a. Day(s) refer to days within Scree ning or Treatment Period . 
b. The Screening visit may be conducted over the Screening  period  (i.e., more than 1  day can be utili sed for Screening du ring to the Screening period ), if necessary , for logistical 
reasons . 
c. Participants who will continue to receive the IMP during Treatment Period  [ADDRESS_1065204] an End -of-Study visit on Week  52 but will proceed to  Day 1 of Treatment Period  3 
(Week  52), see Table 1-2.  Please see Section  6.7 for additional information on the  transition treatment for participants not continuing in Transition Period of study.  
d. Procedure (s)/assessment/blood collection  to be performed  predose.  
e. Height will be measured  without shoes  at Screening  and at all timepoints when BMI is mea sured . 
f. All pa rticipants  will be contact[CONTACT_3012] [ADDRESS_1065205] with a pers on 
who has tested positive for severe acute respi[INVESTIGATOR_6507] 2.  During the  pre-visit call participant s will be reminded of fasting condition s for blood analysis (as 
applicable ). 
g. At each visit p articipants will be provided with a participant identification and visit reminder card .  The Investigator must  update the visit reminder card at each visit with the 
details for the next visit.  
h. A comprehensive physical examination will include an assessment of general appearance and a review of systems (head, eyes, ears, nose, mouth/oral ca vity, throat/neck, 
thyroid, lymp h nodes, dermatologic, respi[INVESTIGATOR_696] , cardiovascular, gastrointestinal, extremities, musculoskeletal and neuro logic systems ). 
i. Additional local calcium testing predose  may be performed according to local practice or at Investigator’s discretion . 
j. Albumin -adjusted s erum calcium only.  
k. Sites will perform a urine dipstick .  In case of abnormal  results , a urine  sample may be sent to  the central lab oratory  for full analysis  if deemed necessary by [CONTACT_737] .  
See Appendix  2 (Section  10.2). 
l. Vital signs include measurement of blood pressure, pulse  and body temperature.   Respi[INVESTIGATOR_775498].  Systolic and diastolic 
blood pressure and pulse measurements will be assessed after the participant has been sitting for at least 5  minutes with back supported and both feet on the floor.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 18 of 124 28Mar2023  m. Assessments to be done predose and 1 hour postdose.  
n. Injection site reaction  assessment  should be done predose and  approximately  1 hour postdose , during this 1 hour period (i.e., from dosing to the injection site assessment) the 
participant will stay in the clinic for general safety observation .  Any further  assessment of the injection site or prolonged observation of the participant  may be done at the 
discretion of the Investigator . 
o. Compliance with daily calcium and vitamin D intake will be monitored and assessed throughout the study.  
p. Information on medical device  events (e.g., needle broken, dose not administered properly, syringe condition problem) and medical device events  (device incident/deficiency)  
that caused  adverse events or events that led to  serious adverse events are to be reported by [CONTACT_775522] t Complaint Form and electronic case report form 
(adverse events  and serious adverse events  only)  as described in the Addendum to Investigator Manual and the Product Complaint Procedure .  A medical device event  related 
to Prolia® will qualify as a device incident  and a medical device event related to RGB -14-P will qualify as a device deficiency .  See Section s 6.1.[ADDRESS_1065206]  be performed before dosing  at Week 26 and Week 52 ; however , it can be performed on the same day o r in the  days before dosing, but 
within the visit window . 
s. A minimum of [ADDRESS_1065207] to be collected in the morning between  a window of  7:30 and 10:00 a.m.  Participants  should 
refrain from extensive physical exercise  for 24  hours before blood collection . 
 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 19 of 124 28Mar2023  Table 1-2 Schedule of Activities (SoA)  – Transition Period  
Study Period  Days (weeks after first IMP administration)  
Treatment Period  3 
Day(s)a 
(Week)  1 
(52) b 8 
(53) 15 
(54) 30 
(56) 90 
(64) 183 (78)  
EOS/  
ET 
Window Period (Days)  ± 4 ± 1 ± 1 ± 1 ± 3 ± 4 
General Assessments  
Inclusion/Exclusion Criteria Assessment  for the 
Transition Period  Xc      
Weight, Height, BMId Xc     X 
Re-randomisation  Xc      
IMP Administration  X      
Pre-visit Phone Calle X X X X X X 
Participant Identification and Visit Reminder Cardf X X X X X X 
Safety Assessments  
Physical Examinationg Xc     X 
Haematology and Clinical Chemistry  Xc, h X Xi X X X 
Urinalysisj Xc     X 
12-lead ECG  Xc     X 
Vital Signsk Xc X X X X X 
Local Tolerance (Skin Examination)  Xl X     
Prior and Concomitant Medicationm  
Adverse Events   
Medical Device  Eventsn X      
Efficacy Assessment  
DXA Scan Assessment  Xo     X 
Lateral Spi[INVESTIGATOR_050] X -ray X     X 
Immunogenicity Assessment/Serum Drug Concentration Assessment  
Immunogenicity (binding ADAs and NAbs) Sampling  Xc  X X  X 
Serum Drug Concentration Sampling  Xc  X X  X 
PD 
PD (Serum CTX) Samplingp Xc     X 
PD (Serum P1NP) Samplingp Xc     X 
ADA  = anti-drug antibody; BMI  = body mass index; CTX  = collagen C -telopeptide; DXA  = dual energy x -ray absorptiometry; ECG  = electrocardiogram; EOS  = End-of-Study, 
ET = early termination; HBV  = hepatitis  B virus; HCV  = hepatitis  C virus; HIV  = human immunodeficiency virus ; IMP  = investigational medicinal product; NAbs  = neutralising 
antibodies; P1NP  = procollagen type 1 N -terminal propeptide; PD  = pharmacodynamic(s)  
a. Day(s) refer to days within Screening or Treatment Period.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 20 of 124 28Mar2023  b. On Day  1 of Treatment Period  3 (Week  52) participants continuing to the Transition Period who received Prolia® during the Main Period will be re -randomised 1:1 to receive 
either a dose RGB -14-P or Prolia® in a double -blinded manner.  Participants continuing to the Transition Period who received R GB-14-P during the Main Period will continue 
to receive a dose of RGB -14-P but will also follow the randomisation procedure to maintain blinding.  
c. Procedure(s)/assessment/blood collection to be performed predose.  
d. Height will be measured without shoes at all  timepoints when BMI is measured.  
e. All participants will be contact[CONTACT_3012] [ADDRESS_1065208] with a person 
who has tested positive for severe acute respi[INVESTIGATOR_13521] y syndrome coronavirus 2.  During the pre -visit call participants will be reminded of fasting conditions for blood analysis (as 
applicable).  
f. At each visit participants will be provided with a participant identification and visit reminder card.  The Investi gator must update the visit reminder card at each visit with the 
details for the next visit.  
g. A comprehensive physical examination will include an assessment of general appearance and a review of systems (head, eyes, ea rs, nose, mouth/oral cavity, throat/ne ck, 
thyroid, lymph nodes, dermatologic, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, extremities, musculoskeletal and neurologi c systems).  
h. Additional local calcium testing predose may be performed according to local practice or at Investigator’s discreti on. 
i. Albumin -adjusted serum calcium only.  
j. Sites will perform a urine dipstick.  In case of abnormal results, a urine sample may be sent to the central lab oratory  for full analysis  if deemed necessary by [CONTACT_737] .  
See Appendix  2 (Section  10.2). 
k. Vital signs include measurement of blood pressure, pulse and body temperature.  Respi[INVESTIGATOR_775499].  Systolic and diastolic 
blood pressure and pulse measurements will be assessed afte r the participant has been sitting for at least 5  minutes with back supported and both feet on the floor.  
l. Injection site reaction assessment should be done predose and  approximately  1 hour postdose , during this 1  hour period (i.e., from dosing to the injec tion site assessment) the 
participant will stay in the clinic for general safety observation .  Any further  assessment of the injection site  or prolonged observation of the participant  may be done at the 
discretion of the Investigator . 
m. Compliance with daily calcium and vitamin D intake will be monitored and assessed throughout the study.  
n. Information on medical device events (e.g., needle broken, dose not administered properly, syringe condition problem) and med ical device events  (device incident/deficie ncy) 
that caused adverse events or events that led to serious adverse events are to be reported by [CONTACT_775523] 
(adverse events and serious adverse events only) as described in the Adden dum to Investigator Manual and the Product Complaint Procedure .  A medical device event related 
to Prolia® will qualify as a device incident and a medical device event related to RGB -14-P will qualify as a device deficiency .  See Section s 6.1.[ADDRESS_1065209]  be performed before dosing  at Week 52 ; however, it can be performed on the same day or in the days before dosing, but within the 
visit window . 
p. A minimum of [ADDRESS_1065210] to be co llected in the morning between  a window of  7:30 and 10:[ADDRESS_1065211]  (IMP)  under development inten ded to be a 
biosimilar to Prolia®.  The Sponsor is also developi[INVESTIGATOR_775496] -14-X, as a proposed biosimilar to 
Xgeva®. 
Prolia® and Xgeva® are authorised in the European Union (EU)  and are licensed in the United 
States (US).  Prolia® and Xgeva® share almost identi cal formulations and the mechanism of 
action of  denosumab is the same in all approved indications.  Therefore, the two products may be 
regarded as two different strengths of the same product.  Consequently, the Sponsor is 
undertaking a common global development programme for RGB -14-X and RGB -14-P.  
Subsequently to demonstrat ing high level of similarity between the proposed biosimilars 
(RGB -14-X and RGB -14-P) and their respective reference products (Prolia® and Xgeva®) at the 
quality and in vitro  non-clinical levels, the Sponsor intends to demonstrate clinical comparability 
by [CONTACT_746] a comparative pharmacokinetic (PK) and pharmacodynamic (PD) study of 
RGB -14-X and Xgeva® and a comparative efficacy/safety study between RGB -14-P and Prolia®.  
Although the comparative PK/ PD study will commence earlier, essentially the two studies will 
run in parallel.  
For further details  regarding the programme  please refer to the current version of the 
Investigator’s Brochure (IB)  [1]. 
Since  in the comparative efficacy and safety study RGB -14-P will be compared to Prolia® in 
women with postmenopausal osteopo rosis, the subsequent sections will focus on these 
compounds only . 
The active pharmaceutical ingredient in RGB -14-P is denosumab, a fully human  
immunoglobulin G  (IgG) 2 monoclonal antibody  hetero -tetramer consisting of 2  heavy chains of 
gamma 1 subclass (488 amino acids per chain) and 2 light chains of the kappa subclass 
(215 amino acids per chain).  It is  produced in the mammalian cell line (Chinese hamster ovary 
cells) by [CONTACT_16238]  (DNA) technology . 
Denosumab belongs to the class of drugs affecting bone structure and mineralisation .  The 
proposed indic ations for RGB -14-P are the same as those of the reference product, Prolia®. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 22 of 124 28Mar2023  Therapeutic indications of Prolia according to the Summary of Products  Characteristics (SmPC, 
EU) [2]: 
• Treatment of osteoporosis in postmenopausal women and men at increased risk of fractures.  
• Treatment of bone loss associated with hormone ablation in men with prostate cancer at 
increased ris k of fractures.  
• Treatment of bone loss associated with long -term systemic glucocorticoid therapy in adult 
patients at increased risk of fracture.  
Therapeutic indications of Prolia according to the  Prescribing Information (US)  [3]: 
• Treatment of postmenopausal women with osteoporosis at high risk for fracture.  
• Treatment to increase bone mass in men with osteoporosis at high risk for fracture.  
• Treatment of glucocorticoid -induced osteoporosis in men at high risk for fracture . 
• Treatment to increase bone mass in men at high risk for fracture receiving androgen 
deprivation therapy for non -metastatic prostate cancer.  
• Treatment to increase bone mass in women at high risk for fracture receiving adjuvant 
aromatase inhibitor therapy for breast cancer.  
The term “ IMP” throughout the protocol, refers to the study drug  (RGB -14-P, test product ) 
and/or active comparator (Prolia®, reference product ), supplied as a single -dose pre -filled syringe  
(see Section  6.1).  In addition, the terms participant and subject are used interchangeably . 
2.1 Background  
Osteoporosis is defined as a systemic skeletal disease characterised by [CONTACT_775524], and increased bone fragility and 
susceptibility to fracture [ 4].  Common sites for osteoporotic fracture ar e the spi[INVESTIGATOR_050], hip, distal 
forearm and proximal humerus.  Fractures resulting from osteoporosis become increasingly 
common in women after age 55  years and men after age 65  years; resulting in substantial 
bone -associated morbidities, and increased mortality a nd health -care costs [ 5].  As women age 
the rate of bone turnover increases, resulting in accelerated bone loss because of lack of 
oestrogen after menopause.  Due to its prevalence worldwide, osteoporosis is considered a 
serious public health concern.  Osteoporosis is preventable and treatable, but only a small 
proportion of those at increased risk for fracture are evaluated and treated.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 23 of 124 28Mar2023  Recept or activator of nuclear factor kappa -B ligand (RANKL) is a trans membrane or soluble 
protein, a member of the tumour necrosis factor (TNF) ligand superfamily.  It binds to receptor 
activator of nuclear factor kappa -B (RANK), a member of the TNF receptor sup erfamily.  
Receptor ac tivator of nuclear factor kappa -B ligand is also known as TNF related activation 
induc ed cytokine (TRANCE), osteoprotegerin ligand (OPGL) and osteoclast differenti ation 
factor (ODF) because of its role in the regulation of bone metabo lism.  Receptor activator of 
nuclear factor kappa -B ligand plays and essential role in osteoclast (OC) formation, activity and 
survival [ 6].  Osteocl asts are bone -resorbing tissue resident immune cells that are derived from 
pluripotent haematopoietic stem cells.  Osteoclastogenesis requires stimulation by 
[CONTACT_385912] -colony stimulating factor (M -CSF) and the binding of RANKL, expressed on 
osteoblasts, t o RANK receptor on the OC precursors [ 7].  Binding of RANKL to the RANK 
receptor on the cell surface of osteoclasts initiates a complex signalling cascade, which is 
mediated by [CONTACT_775525] (TRAF)6, TRAF3 and c -Fos transcription factor 
proteins, which leads to activation of mitogen activated protein kinases (MAPKs), nuclear factor  
(NK) -κB and activator protein (AP) -1.  These signalling pathways result in the translocation of 
transcriptional activators and subsequent ly to the expression of numerous effector genes 
involved in bone resorption [ 8, 9]. 
As a “decoy” receptor, denosumab binds with high affinity and specificity to RANKL, 
preventing activation of RANK on the surface of OC precursors and OCs.  Binding of 
denosumab with RANKL prevents the RANKL/RANK in teraction, resulting in impaired OC 
formation, function and survival, thereby [CONTACT_775526] -induced bone destruction.  Bone strength is mainly determined by [CONTACT_775527].  Thus, loss of cor tical bone contributes to a higher frequency of bone fractures.  
Denosumab affects not only the thickness of the cortex bus also bone strength, porosity and bone 
mineral density (BMD) [ 10]. 
2.1.1 Summary of Non -clinical Studies  
[IP_ADDRESS]  In vitro  Studies  
In order to demonstrate analytical similarity between RGB -14-P and Prolia®, extensive 
physiochemical/structural and in vitro  biological/functional characterisation has been carried out 
using a panel of comprehensive state -of-the-art analytical methods.  This analytical panel was 
endorsed by [CONTACT_12721].  
The results of the comprehensive non -clinical in vitro  PD studie s available to date demonstrated 
compar ability between RGB -14-P and its reference medicinal product Prolia®. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 24 of 124 28Mar2023  For further details please refer to the current version of the IB [ 1]. 
[IP_ADDRESS]  In vivo  Studies  
Following the current regulatory guidance principles and scientific advices, no comparative 
in vivo toxicological or PD studies have been performed between RGB -14-P and Proli a®.  
Relevant information on the reference product, Prolia®, is presented based on the public 
assessment reports, SmPC and US package inser t (USPI) of Prolia® [2, 3]. 
Non-clinical PK studies were conducted in mice, rats and cynomolgus monkeys.  While 
denosumab does not bind to RANKL in  mice and rat it recognises and neutralises RANKL in 
non-human primates . 
In rodents the intravenous  PK of denosumab were linear over the dose range 0.1 to 10  mg/kg, 
volume of distribution was similar to plasma volume and clearance was low with long terminal 
half-lives of [ADDRESS_1065212], clea rance was 6 - to 15 -fold higher 
in knock -in mice that express a chimeric form of RANKL and in knock -out mice that lack 
expression of the Fc neonatal receptor.  
In the cynomolgus monkey PK were linear over both intravenous and subcutaneous dose range 
of 1 to 3 mg/kg but were non -liner at doses below 1  mg/kg.  The non -linearity in monkeys may 
reflect that binding of denosumab to RANKL leads to accelerated, but saturable, elimination and 
that elimination also involves the neo natal Fc receptor (FcRn) and the r eticuloendothelial system.  
After repeated subcutaneous doses of 0.1 to 50  mg/kg in monkey approximately linear PK were 
reported.  Metabolism may be mediated through internalisation followed by [CONTACT_775528].  Antibodies may be protected f rom lysosomal 
degradation through binding to the Fc region of the neonatal receptor FcRn, at acidic pH in the 
endosome prior to releasing the antibody at the cell surface.  The role of FcRn was studied using 
FcRn knock -out mice .  Compared with wild -type mice  a much shorter elimination half -live, that 
was similar to the half -life reported for a murine antibody, was recorded in FcRn knock -out mice 
and data indicated that FcRn protects denosumab f rom elimination and so influences t issue 
distribution.  
[IP_ADDRESS]  Toxicology  
The non -clinical toxicology profile of denosumab is known f rom registration studies for Prolia®.  
Denosumab has been shown to be highly specific to RANKL.  In single and repeated dose 
toxicity studies, denosumab doses resulti ng in [ADDRESS_1065213] on cardiovascular physiology, male or female 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 25 of 124 28Mar2023  fertility or produced specific target organ toxicity  [2].  Moreover, in non -clinical  toxicology 
studies no major differences were revealed regarding the possible immunomodulatory effect of 
denosumab.  
Standard tests to investigate the genotoxicity potential of denosumab have not been evaluated, 
since such tests are not relevant for this large molecule.  Due to it s characteristics it is unlikely 
that denosumab has any potential for genotoxicity.  
2.1.[ADDRESS_1065214] IMP.  The Sponsor is also developi[INVESTIGATOR_775496] -14-X as a biosimilar to Xgeva® and is 
undertaking a comparative PK/PD  study of RGB -14-X and Xgeva®.  Both RGB -14-P and 
RGB -14-X contain the same active ingredient (denosumab).  Although the comparative PK/PD 
study will commence earlier, essentially the two studies will run in parallel.  
The PK profile of denosumab in humans is know n from relevant information on the reference 
product s, Prolia® and Xgeva®.  In healthy participants and postmenopausal women, the PK of 
denosumab following subcutaneous administration is character ised by [CONTACT_22705] -order absorption, 
linear distribution to the pe ripheral compartment and parallel linear and RANKL mediated 
non-linear elimination.  
2.2 Benefit/Risk Assessment  
There are potential benefits and risks with the administration of any ne w investigational 
medicine as the effects are not fully known.  Based on the  potential benefit of RGB -14-P, it is 
being  developed for the aforementioned indications ( Section  2).  Since no clinical studies have 
been performed to date with RGB -14-P the information in this section is pro vided based on the 
SmPC  [2] and USPI  [3] of Prolia®. 
Postmenopausal osteoporotic women participating in the study are expected to directly benefit 
from the treatment  with the IMPs.  In addition, the availability of biosimilars o n the market will 
improve patient access to a highly effective treatment benefiting a wider community.  
2.2.1 Risk Assessment  
Based on current available data, it is anticipated that the adverse event ( AE) profile of RGB -14-P 
will be similar to  that of Prolia®, therefore the same contraindications, precautions and warnings 
for Prolia® will also apply to RGB -14-P. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 26 of 124 28Mar2023  The adverse reactions associated with Prolia® are as follows  [2]: 
• Very common (≥  1/10):  pain in limbs, musc uloskeletal pain. 
• Common (≥  1/100 to <  1/10):  urinary tract infection, upper respi[INVESTIGATOR_1092], 
sciatica, constipation, abdominal discomfort, rash, eczema, alopecia.  
• Uncommon (≥  1/1000 to <  1/100 ): diverticulitis, cellulitis, ear infections, lichenoid drug 
eruptions.  
• Rare (≥  1/[ZIP_CODE] to <  1/1000):  drug hypersensitivity, anaphylactic reaction,  hypocalcaemia,  
osteonecrosis of the jaw (O NJ), atypi[INVESTIGATOR_407328].  
• Very rare (<  1/[ZIP_CODE] ): hypersensitivity vasculitis . 
• Not known:  osteonecrosis of the external auditory canal.  
In postmenopausal women with osteoporosis the most common adverse reactions (> 5% and 
more common than  placebo) included back pain, pain in extremit ies, hypercholesterolemia, 
musculoskeletal pain , cystitis  and vertigo .  Pancreatitis has also been reported in clinical trials 
[3]. 
Adverse reactions reported in ≥  2% of patients with osteoporosis and more frequently than in 
placebo -treated patients  with Prolia® include; anaemi a, angina pectoris, atrial fibrillation, upper 
abdominal pain, flatulence, gastroesophageal reflux disease, peripheral oedema, asthenia, 
vertigo, upper respi[INVESTIGATOR_1092], pneumonia, pharyngitis, herpes zoster, bone pain, 
myalgia, spi[INVESTIGATOR_775500], sciatica, insomnia, rash, pruritus  [3]. 
Other adverse reactions reported in <  2% of patients with osteoporosis and more frequently than 
in placebo -treated patients with Prolia® include: hypocalcaemia, serious infections in the 
abdomen, serious urinary tract infections, serious ear infections, endocarditis, erysipelas, 
cellulitis,  ONJ, atypi[INVESTIGATOR_167655]  [3]. 
Vasculitis and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome has 
also been reported in postmarketing experience.  
A detailed description of adverse reactions is provided in the SmPC [ 2] and USPI [ 3] of Prolia®. 
The protocol ha s been designed to minimise the risk to the study participants.  Special warnings 
and precautions for the use of denosumab are reflected in strict inclusion and exclusion criteria 
for this study.  From Day  1 through the End -of-Study /Early Termination  Visit , supplementation 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065215] of the re gular  monitor ing of 
haematology, clinical chemistry, urinalysis, regular measurements of vital signs, physical 
examinations , injection site reactions and fracture assessments , electrocardiogram ( ECG)  as well 
as monitoring and recording of AEs and serious adverse events ( SAEs ). 
Participants might also experience procedural complications (e.g.,  blood draws, slight skin 
irritation from the adhesive on the ECG electrodes , device incident or device def iciency  AEs). 
No serious adverse events a re considered expected by [CONTACT_775529] ( S[LOCATION_003]Rs ) and identification of 
S[LOCATION_003]Rs in the “Cumulative summary tabulation of serious adverse reactions” in the 
development safety update report  for the IMP.  
Risk Assessment for Coronavirus Disease 2019  Pandemic  
The IMP is a human monoclonal IgG2 antibody targeting and binding RANKL  and is believed 
not to cause immune suppression.  
The risk of exposure to infected people cannot be completely excluded as the participants may 
need to expose themselves to public areas (e.g.,  commute to the site) and have additional human 
contact (e.g., w ith site staff and other participants of the clinical study).  
Measures to mitigate the additional risks caused by [CONTACT_711910] 2019 ( COVID -19) are: 
• This study is going to start enrolling only when the Sponsor and contract research 
organisation (CRO ) in collaboration deem it is safe to start the study.  In addition, the study 
will not start until the local confinement measures or other safety restrictions linked to the 
COVID -19 pandemic  preventing safe study start  are lifted by [CONTACT_775530]. 
• Current national laws and local recommendations for prevention of pandemic will be strictly 
adhered to.  
• Participants will be closely monitored for any signs and symptoms of COVID -19, including 
fever, dry cough, dyspn oea, sore throat , fatigue  and loss o f sense of taste or smell  throughout 
the study.  Once clinical signs of infection are reported by [CONTACT_4317], the Investigator needs 
to determine whether samples can be collected, and safety data can be recorded on site.  If 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 28 of 124 28Mar2023  not, AEs and concomitant medi cations will be obtained via phone calls.  Body temperature 
measurements during visits will be implemented.  
• In case of suspected COVID -[ADDRESS_1065216] the Medical Monitor to discuss if 
the participant can continue in the study.   The next dose administration should be considered 
after recovery and after fulfilling local requirements . 
• Confirmation of COVID -19 infection by [CONTACT_718149] (test capacity and turnaround time) of approved tests and on 
Investigator’s discretion.  Severe acute respi[INVESTIGATOR_6507]  2 (SARS -CoV-2) 
analys is can be per formed at Screening and at any time point as deemed required by [CONTACT_775531] .  It is the Investigator’s responsibility to adhere to local 
regulations and requirements for COVID -19 testing of asymptomatic as well as symptomatic 
participants.  
• The probability of virus transmission will be controlled as much as possible by:  
o Advice for participant to adhere to local requirements for reduction of the public 
exposure while ambulatory.  
o All participants are contact[CONTACT_775532] -[ADDRESS_1065217] restrictions will be applied during site 
visits and in -house confinement  (if applicable) . 
o Where physical distancing is not possible personal protective equipment will be used by 
[CONTACT_111186] (surgical face mask, gloves) and staff (for example but not limited to 
masks, gloves, protectors, medical suits) if deemed appropriate by [CONTACT_775533].  
2.2.2 Benefit Assessment  
Denosumab is marketed in the EU  and US  under the trade names Prolia® and Xgeva®.  Prolia® 
was approved in [ADDRESS_1065218] been demonstrated in many double -blind and 
open -label trials for postmenopausal women [ 11, 12, 13, 14].  In osteoporosis, it is proven to 
increase BMD and protect bones from fracture.   Since the  authorisation extensive experience has 
been gained about Prolia® further substantiating its safe and efficacious use which has been 
associated with a positive benefit/risk ratio in the target population.  
Postmenopausal osteoporotic women partici pating in this study are expected to directly benefit 
from the denosumab  effect of decreasing fracture risk .  In addition, they might also derive some 
health benefits from participating in the study through the rigorous medical assessments 
performed at the time of Screening and throughout the study.  Since biosimilar products improve 
patient access to highly effective treatments, their development and subsequent availability on 
the mark et come with significant socioeconomic benefits as well.  
2.2.3 Overall Benefit:  Risk Conclusion  
Since its marketing authorisation, extensive experience has been gained with Prolia® further 
substantiating its safety and efficacious use which has been associated with a positive/risk ratio 
in the target population.  
RGB -14-P has a potential to reduce osteoporosis and improve quality of life in study 
participants.   This study in women with postmenopausal osteoporosis will continue to evaluate 
the safety profile of RGB -14-P. 
RGB -14-P is expected to have a similar clinical outcome to  Prolia® based on the physiochemical 
and biological similarity.  
Taking into account the measures taken to minimise risk to participants participating in this 
study, the potential risks identified in association with RGB -14-P are justifie d by [CONTACT_775534] . 
More detailed information about the know n and expected benefits, risks and AE profile can be 
found in the current version of the IB [ 1]. 
 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065219] of 
RGB -14-P with US -licensed Prolia® on BMD  at the 
lumbar spi[INVESTIGATOR_624383]  52 in female participants with 
postmenopausal osteoporosis  
  
Efficacy  
%CfB in lumbar spi[INVESTIGATOR_110075]  52 
Pharmacodynamics  
To demonstrate similar pharmacodynamic s (AUEC of 
%CfB  in sCT X) of RGB -14-P with US -licensed 
Prolia® in female participants with postmenopausal 
osteoporosis  (only required for EMA)  Pharmacodynamics  
AUEC of %CfB  sCTX 0-m6 until Week  26 
(secondary for US FDA submission)  
Secondary  
Efficacy  
To provide additional comparative efficacy data of 
RGB -14-P with US -licensed Prolia® in female 
participants with postmenopausal osteoporosis    
Efficacy  
• %CfB  in total hip BMD  at Weeks  26, 52 and 78  
• %CfB  in lumbar spi[INVESTIGATOR_775501]  26 and 78  
• %CfB  in femoral neck BMD at Weeks  26, 52 
and 78 
• Vertebral fragility fracture incidence at Weeks  52 
and 78  
• Non-vertebral fragility fracture incidence at 
Weeks  52 and 78  
 
Pharmacodynamics  
To provide additional comparative pharmacodynamic 
data of RGB -14-P with US -licensed Prolia® in female 
participants with postmenopausal osteoporosis  
 Pharmacodynamics  
• %CfB  in serum P1NP at Weeks  4, 26, 52 and 78  
• %CfB  in sCTX at Weeks  4, 26, 52 and 78  
Safety  
To compare the safety and tolerability of RGB -14-P 
with US -licensed Prolia® in female participants with 
postmenopausal osteoporosis  Safety  
• AE, SAE, clinical laboratory safety assessments 
(haematology, clinical chemistry and urinalysis), 
vital signs, physical examination, ECG , injection 
site reaction  and fracture assessment  up to 
Week  78 
 
Immunogenicity  
To compare the immunogenicity of RGB -14-P with 
US-licensed Prolia® in female participants with 
postmenopausal osteoporosis  Immunogenicity  
• Incidence of binding ADAs and NAb s at Weeks  0, 
2, 4, 26, 28, 30, 52, 54, 56 and 78  
• Titre determination of binding ADAs at Weeks  0, 
2, 4, 26, 28, 30, 52, 54, 56 and 78  
ADA  = anti-drug antibody; AE  = adverse event;  AUEC  = area under the effective curve;  
AUEC sCTX 0-m6 = AUEC after the first d ose until Day  183 of %CfB in serum type I collagen C -telopeptide; 
BMD  = bone mineral density; %CfB  = percent change from baseline; ECG  = electrocardiogram; 
EMA  = European Medicines Agency;  FDA  = Food and Drug Administration;  NAbs  = neutralising antibodies;  
P1NP  = serum procollagen type 1 N -terminal propeptide;  SAE  = serious adverse event;  sCTX 0-m6 =  serum type I 
collagen C -telopeptide up to month  6; US  = [LOCATION_002]  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 31 of 124 28Mar2023  4 Study Design  
4.1 Overall  Design  
This is a randomised , double -blind, multicentre , multiple fixed -dose, 2-arm paralle l-group study  
(Main Period)  with a  Transition  Period  to assess the efficacy,  PD, safety, tolerability  and 
immunogenicity of RGB -14-P compared to  US-licensed  Prolia® in participants with 
postmenopausal osteoporosis , in a comparative manner . 
Participants will attend a Screening Period  within [ADDRESS_1065220] dosing.  Participants 
meeting eligibility criteria will enter into  the Main Period of the study.  The Main Period 
(52 weeks) consists of Treatment Period  1 (26  weeks) and Treatment Period  2 (26  weeks).  The 
primary endpoint of the study is assessed at the end of the Main Period.  The Transition Period 
consists of Treatme nt Period  3 (26  weeks) , the Transition Period will be applicable to a subset of 
participants (see Figure 1–2).  Day 1 of Treatment Periods  2 and 3 are th e same as  Day 183 of 
the preceding Treatment Period.  Timepoints of ambulatory site visits for Treatment Periods  2 
and 3 are calculated from the Day  1 of the respective Treatment Period.  
All p articipants will receive the IMP  on 2 occasions  (Weeks  0 and 26), on Day  [ADDRESS_1065221] 
occasion (Week  52), Day  1 of Treatment Period  3.  One Treatment Period wil l take 6  months 
(26 weeks , 183 days).  
Participants will  attend ambulatory  site visits on the following timepoints for efficacy, PD, 
immunogenicity and safety assessment  as indicated in the Schedule of Activities (SoA) 
(Table  1-1 and Table 1-2). 
Main Period:  
On Day 1 of Treatment Period  1, prior to dosing,  participants will be randomised in a 1:1 ratio to 
receive either RGB -14-P or Prolia®.  Administration of IMP will take place on two occasions in 
a double -blinded manner (Main Period) , on Day  1 of both Treatment Periods  1 and  2 (Weeks  0 
and 26).  
Visits dur ing the Main Period:  
• Days  1, 8, 15, 30, 60, 90, 120 and 150 postdose during  Treatment Period  1. 
• Days  1, 8, 15, 30 and 90 postdose during  Treatment Period  2. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 32 of 124 28Mar2023  An End -of-Study Visit is planned on Day  183 (Week  52) during Treatment Period  2 for 
participants not continuing participation in the Transition Period.   Please see Section  6.7 for 
additional information on the  transition treatment for  participants not continuing in Transition 
Period of study.  
Transition Period:  
On Day  1 of Treatment Period  3 (Week  52) a total of approximately 198 participants will enter 
the Transition Period.  A  subset of approximately 132 participants  continuing in the Transition 
Period who  receiv ed Prolia® during the Main Period will be re -randomised  1:1 to receive either a 
dose of RGB -14-P or Prolia® in a double -blinded manner .  A subset of approximately 
66 participants  continuing in the Transition Period who  receiv ed RGB -14-P during the Main 
Period  will continue to receive a dose of RGB -14-P but will also follow the randomisation 
procedure to maintain blinding  (see Section  9.2). 
Visits during the Transition Period:  
• Days  1, 8, 15, 30 and 90 postdose during Treatment Period  3. 
An End -of-Study Visit is planned on Day  183 (Week  78) postdose during Treatment Period  3.  
Please see Section  6.7 for additional information on the transition treatment for participants at 
the end of the study.  
The estimated duration of the  clinical phase  for participants in the Main Period from the 
Screening to the End -of-Study Visit is approximately 13  months and for participants continuing 
in the Transition period  from the Screening Period  until the End -of-Study Visit  is approximately 
19 months.  
The primary outcome of this study is determined based on the results of the efficacy analysis at 
Week  52.  To evaluate the efficacy and safety of transitioning from Prolia® to RGB -14-P 
anticipated in a real -world setting, the study will continue up to Week  78. 
Details of the blind ing strategy will be described in the Blinding Maintenance Plan. 
The Main Clinical Study Report will be completed based on the data obtained after all 
participants have completed the Week  52 study visit.  The dat a obtained in the Transition Per iod 
will be added as a Final  Clinical Study Report.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 33 of 124 28Mar2023  4.2 Scientific Rationale for Study Design  
The clinical development program me for RGB -14-P follows the scientific and ethical principles 
as stated in the European Medicines Agency ( EMA ) regulations for biosimilar products: 
CHMP/437/04 Rev.  1., EMEA/CHMP/BMWP/[ZIP_CODE]/2005  Rev. 1, 
EMEA/CHMP/BMWP/[ZIP_CODE]/2006 Rev. 1, EMA/CHMP/BMWP/[ZIP_CODE]/2010, 
EMA/CHMP/BMWP/403543/201 and follows the Food and Drug Administration ( FDA ) 
regul ations (Scientific Considerations in Demonstrating Biosimilar ity to a Reference Product) 
and is designed based on Scientific Advices received from Paul-Ehrlich -Institut , the EMA and 
the FDA.  
This study forms part of the clinical development program me and i s aimed  to assess the efficacy 
and safety of RGB -14-P compared to Prolia® in women with postmenopausal osteoporosis as a 
randomised, double -blind, multicentre phase  III study.   Of all therapeutic indications of Prolia® 
postmenopausal osteoporosis is consid ered to be the most sensitive one as postmenopausal 
osteoporotic females  are exempt from underlying disease conditions and concomitant 
medications that might influence the efficacy and the safety of the IMPs consequently , they 
represent the most homogenous study population.  
In light of the outcome of a follow -up Scientific Adv ice at EMA, demonstration of analytical 
comparability between the US - and the EU -sourced reference materials serves as an adequate 
bridge, allowing Gedeon Richter Plc. to utilise only US -sourced reference material throughout 
the clinical development.  
The s afety assessments for the study are accepted measures for ensuring safety of participants 
during a clinical study.  The sample size is considered adequate and sufficient to allow for a 
meaningful comparison between RGB -14-P and Prolia®.  The rationale for dose selection is 
discussed in Section  4.3.  The study design is deemed appropriate  for conduct during the 
COVID -19 pandemic.  
4.3 Justification for Dose  
The approved dose for Prolia® is 60  mg administered every 6  months as a subcutaneous injection 
in the upper arm, upper thigh or abdomen [ 3].  The dose, frequency and route of administration 
of RGB -14-P have been selected to be consistent with that of Prolia® for the therapy of women 
with postmenopausal osteoporosis , as described in the Prolia® SmPC  and USPI  [2, 3]. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065222] scheduled procedure shown in the SoA 
(Table 1-2) for the last participant in the study.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065223] be able to provide written consent and meet all the inclusion criteria and none 
of the exclusion criteria.  
5.1 Inclusion Criteria  
Participant s are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant is ≥ 60 to ≤ 90 years of age at the time of signing the informed consent.  
Type of Participant  and Disease Characteristics  
2. Participan t is an ambulatory postmenopausal woman , diagnosed  with osteoporosis , able to 
walk and not bedridden.  A woman is considered postmenopausal if she meets any of the 
following criteria:  
a. Has 12  months of spontaneous amenorrhea without an alternative medical cause wit h 
serum follicle -stimulating hormone ( FSH) levels falling in the normal postmenopausal 
range at the central laboratory at the time of  the Screening Period . 
b. Female participant underwent bilateral oophorectomy (with or without hysterectomy) at 
least 6 weeks prior to the Screening Period . 
3. Participant has an absolute BMD consistent with T -score ≤  -2.5 and ≥  -4.0 at the lumbar 
spi[INVESTIGATOR_775502] X -ray absorptiometry (DXA)  during the Screening Period  
and at least 2 lumbar vertebrae (from L1 to L4) must be evaluable by [CONTACT_11324].  
Weight  
4. Participant has b ody weight ≥ 50 and ≤ 90 kg at the Screening Period . 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 36 of 124 28Mar2023  Informed Consent  
5. Participant is  willing and  able to give  signed informed consent as described in Appendix 1  
(Section  10.1.3 ) which includes compliance with the requirements and restrictions listed  in 
the informed consent form (ICF) and in this protocol.  
6. Participant has provided informed consent prior to any study -specific activities/procedures.  
Participant must meet the following criteria to be enrolled in the Transition Period:  
7. Have been enrolled , received both doses of IMP , adequately complied with the protocol  and 
completed the scheduled Main Period ( up to Week  52) of the RGB -14-101 study.  
5.2 Exclusion Criteria  
Participant s are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Participant has a history and/or presence of a severe or more than two moderate vertebral 
fractures as determined by [CONTACT_775535][INVESTIGATOR_050] X -ray during the Scre ening Period.  
2. Participant has a history and/ or presence of hip fracture.  
3. Participant has a history and/or presence of atypi[INVESTIGATOR_11280].  
4. Participant presents with  an active healing fracture according to the assessment of the 
Investigator.  
5. Participant has a bilateral hip replacement (unilateral is  allowed if the other hip i s evaluable 
with DXA).  
6. Participant has a vitamin D deficiency (defined as a serum 25  hydroxyvitamin D level 
< 50 nmol /L [20 ng/mL]), the assessment may be repeated once  after vitamin D 
supplementation  (including calcitriol) .  Appropriate vitamin D dosing  in addition to 
vitamin  D supplementation is permitted at the discretion of the Investigator during the 
Screening Period.  
7. Participant has hypocalcaemia or hypercalcaemia (defined as albumin -adjusted serum 
calcium for hypocalcaemia <  2.1 mmol/L  [8.4 mg/dL] or for hypercalca emia >  2.62 mmol/L 
[10.6  mg/dL]) at the Screening Period , the assessment m ay be repeated once in the case of 
hypercalcaemia.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 37 of 124 28Mar2023  8. Participant has a history and/or  presence of bone metastases, renal osteodystrophy,  
osteomyelitis,  any metabolic, endocrine or traumatic bone disease  (except  postmenopausal  
osteoporosis) that may interfere with the interpretation of the results, e.g., Page t’s disease, 
rheumatoid arthritis, ankylosing spondylitis, osteomalacia, osteogenesis imperfecta,  
acromegaly, achondroplasia,  osteopetrosis, Cushing’s disease, hyperprolactinemia or 
malabsorption syndrome.   Participants with history of childhood rickets ma y be eligible 
provided that the condition had been cured before the age of 25  years.  
9. Participant has a current uncontrolled status of hypothyroidism or hyperthyroidism.   
Uncontrolled means if any of the following are present: a) clinical signs and symptoms  of 
active hyper/hypothyroidism, b) thyroid -stimulating hormone (TSH) is below the reference 
range of the central laboratory, c) TSH is above the reference range of the central laboratory 
which necessitates the initiation of treatment or if the treatment i s already given it is deemed 
insufficient by [CONTACT_775536] . 
10. Participant has a history  (within 5  years prior to Screening)  and/or current 
hypoparathyroidism or hyperparathyroidism other than clinically not significant secondary 
hyperparathyroidism.  
11. Participant has had major surgery within 8 weeks prior to the Screening Period or planned, 
anticipated major surgery during the s tudy.  
12. Participant has malignancy  within 5  years  before Screening  (except completely cured in situ 
cervical carcinoma or non -metastatic squamous or basal cell carcinoma of the skin).  
13. Participant has a history and/or presence of significant cardiac disease  or ECG abnormalities 
indicating significant risk for participating in the study  as judged by [CONTACT_24342].  
14. Participant has a known intolerance or malabsorption of calcium or vitamin D supplements.  
15. Participant has a known hypersensitivity (including seve re allergic reaction) to monoclonal 
antibodies or a history of systemic hypersensitivity to any components of the IMPs. 
16. Participant shows contraindications to denosumab thera py (e.g., hypocalcaemia), or calcium 
or vitamin D supplementation before starting IMP administration.  
17. Participant has a latex allergy.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 38 of 124 28Mar2023  18. Participant has  a history and/or presence of  ONJ or risk factors for ONJ such as  heavy 
smoking,  invasive dental procedures  without complete healing or planned du ring the study  
(e.g., tooth extraction, dental implants, oral surgery),  planned radiotherapy to head and neck,  
poor oral hygiene,  poor fitting dentures,  periodontal, and/or pre -existing dental disease 
checked as required by [CONTACT_775537] t o be at unacceptable risk for 
denosumab use by [CONTACT_737] . 
19. Participant has history and/or presence of osteonecrosis of the external auditory canal.  
Prior/Concomitant Therapy  
20. Participant requir ing ongoing use of any osteoporosis treatment (other than calcium and 
vitamin D supplements).  
21. Participant has previously received denosumab  or biosimilar denosumab . 
22. Participant has previously received the following medicines : 
a. Romosozumab  (dose received at any time ). 
b. Cathepsin K inhibitors (dose received at any time ). 
c. Strontium or fluoride (for osteoporosis) (dose received at any time ). 
d. Any investigation al medicinal product not specified in the protocol for treatment of 
osteoporosis  (dose re ceived at any time).  
e. Intravenous bisphosphonates (dose received within 5  years prior to the Screening Period ). 
f. Oral bisphosphonates ( more than 3 years o f cumulative use prior to the Screening Period  
or any dose received within 1  year prior to the Screening Period ). 
g. Teriparatide , abaloparatide  or any parathyroid hormone ( PTH ) analog ues (dose received 
within 1  year prior to the Screening Period ). 
h. Tibolone, oral or topi[INVESTIGATOR_2855] (e.g., transdermal, intravagin al) oestrogen,  antioestrogens , 
selective oestrogen receptor modulators ( SERMs ) and aromatase -inhibitors  (dose 
received within 1  year prior to the Screening Period ). 
i. Calcitonin  or its derivates  and calcimimetics  (such as cinacalcet or etelcacetide)  (dose 
received within 6  months prior to the Screening Period ). 
j. Systemic glucocorticostero ids (≥ 5 mg prednisone or equivalent per day for ≥  10 days or 
a total cumulative dose of ≥  50 mg) within the past 3 months prior to the Screening 
Period .  Topi[INVESTIGATOR_775503].  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 39 of 124 28Mar2023  k. Other bone active drugs including heparin  (also low molecular weight heparins) , 
vitamin  K (supplementation or therapeutic dose) , vitamin  K anta gonists (e.g., warfarin, 
acenocum arol), emtricita bine, tenofovir, ad efovir,  anti-convulsants (with the exception of 
benzodiazepi[INVESTIGATOR_1651] , gabapentin  and pregabalin ), systemic ketoconazole, adrenocorticotropic 
hormone ( ACTH ), lithium, protease  inhibitors, gonadotropin -releasing hormone ( GnRH ) 
agonists  or anabolic steroids within the past 3  months prior to the Screening Period . 
Prior/Concurrent Clinical Study  Experience  
23. Participant is receiving or has received any investigational drug (or is currently using an 
investigational device)  withi n [ADDRESS_1065224] 10  times the 
respective elimination half -life (whichever period is longer).  
Diagnostic Assessments  
24. Participant has weight or girth measure ments  which may preclude accurate DXA 
measurements  in Investigator’s opi[INVESTIGATOR_1649] . 
25. Participant has inadequate renal and hepatic function at the Screening Period defined as 
patient on dialysis or estimated glomerular  filtration rate  (eGFR)  < 30 mL/min (calculated 
using the modification of diet in renal disease [MDRD ] formula ) and alanine 
aminotransferase  (ALT) or aspartate aminotransferase  (AST)  ≥ 2 ×upper limit of normal 
(ULN) or total bilirubin ≥  1.5 ×ULN  (except in Gilbert’s syndrome, where the total bilirubin 
is accepted if ≤ 2.5 × ULN ). 
26. Participant presents with  clinically significant leukopenia, neutropenia or an aemia as judged 
by [CONTACT_737];  the assessment may be repeated once if the condition i s deemed to be 
temporary by [CONTACT_737] . 
27. Participant has an active infection, including, but not limited to SARS -CoV-2, 
hepatitis  B/hepatitis  B surface antigen (HBsAg) positivity and/or participant who has 
anti-hepat itis B core antigen (HBcAg) positivity with anti -HBsAg negativity , hepatitis C  and 
human immunodeficiency virus  infections  during  the Screening Period . 
Other Exclusions  
28. Current or past  alcohol or drug abuse . 
29. Any other clinically significant disorder/condition/disease or laboratory abnormality that in 
the opi[INVESTIGATOR_35261] a risk to participant safety or interfere with the 
study evaluation, procedures or completion . 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065225] not be enrolled in the Transition Period:  
31. Treatment continuation in the study is against the best interest of the participant as deemed 
by [CONTACT_737].  
5.[ADDRESS_1065226] blood samples taken for each PD analysis (bone turnover markers 
[serum type I collagen C -telopeptide (sCTX ) and procollagen type 1 N -terminal propeptide  
(P1NP )]) after a  minimum  of 8 hours  fasting .  During the pre -visit phone call participants 
will be reminded of fasting conditions for blood analysis (as applicable) . 
2. Blood for PD sampling  must be collected in the morning between 07:30 and 10:00 am.  
3.  Participants should refrain  from extensive physical  exercise for  24 hours  before each blood 
collection for PD analysis.  
4. On the day of Baseline PD assessment (Treatment Period  1, Day  1 [Week  0]), calcium should 
not be given before the PD blood sampling.  
5. Participants  are encouraged to maintain good oral hygi ene and receive routine dental 
check -ups.  During the study treatment phase invasive dental procedures should be 
performed only after careful consideration  (if required for AE/SAE management ). 
6. Participants should seek prompt medical attention if they devel op signs or symptoms of OJN, 
hypocalcaemia, infections, dermatological reaction or hypersensitivity.  
7. Participants are encouraged to adhere to country level and/or local COVID -19 regulations for 
prevention and monitoring of pandemic.  The guidance from Competent Authorities may 
continue to evolve, Investigators are encouraged to check for updates regularly and provide 
participants with appropriate instructions.   Please see Secti on 2.2.1  and Appendix 4 
(Section  10.4) for additional information.  
5.4 Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequently randomised .  Eligible but surplus participants will no t be screen failures.   A 
minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participant s to meet the Consolidated Standards of Reporting Trials publishing 
requi rements and to respond to queries from regulatory authorities.  Minimal information 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 41 of 124 28Mar2023  includes demography, reason for screen failure (e.g., eligibility requirements failed),  and any 
SAE s. 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
considered for  rescreen ing, only once,  unless participants  screen  fail due to safety reasons which 
are significant and not likely to resolve, or if participati on in the study would unacceptably 
jeopardise the safety of the participant as deemed by [CONTACT_737].  In all cases without 
exception the rescreening  is conditional upon approval of the Medical Monitor i.e., prior to 
rescreening, the Investigator must  contact [CONTACT_775538] a 
case-by-case basis.   All screening procedures will be repeated during rescreening with the 
following exceptions: DXA, if it is within 5  weeks of the initial scan and l ateral spi[INVESTIGATOR_050] X -ray, if it 
is within 3  months of the initial scan.   In the event of rescreening the data gathered during 
rescreening  should prevail.  
In the case of failure to meet criteria for vitamin D or calcium ( Section  5.2, exclusion criteria  6 
and 7, respectively), vitamin D and calcium testing may be repeated  (i.e., the partici pant is 
retested for those parameters)  once  during the screening period without rescreening the 
participant provided that the other criteria are met.   These retest cases will not be considered as 
rescreening.  
5.4.1 Screening and Enrolment  Log 
All screened partic ipants will be assigned a unique enrolment  number which is study specific.  
Enrolled participants who drop out of the clinical study before randomisation will retain their 
enrolment  number.  The participant’s enrolment  will be recorded in the Screening and Enrolment  
Log.  After enrolment , prior to dosing, participants will be randomised and receive a 
randomisation number.   Prior to dosing in  Treatment Period 3, participants will be re -randomised 
and receive a second ran domisation number.   Participant numbers must not be re -used for 
different partic ipants.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 42 of 124 28Mar2023  6 Study Treatments  
Study treatment  (IMP)  is defined as the test product (RGB -14-P) and the reference product 
(US-sourced Prolia®), which are collectively referred to as I MP throughout the protocol .  The 
IMP is to be administered to the study participants according to the study protocol during this 
study.  
In light of the outcome of a follow -up scienti fic advi ce at the EMA, demonstration of analytical 
comparability between the US - and EU -sourced reference products serve s as an adequate bridge 
allowing the Sponsor to utilise  only the US -sourced reference product throughout the clinical 
development.  
6.1 Study Treatments  Administered  
The study treatments that will be administered in this study are outlined in Table  6-1. 
Table  6-1 Study Treatments  Administered  
Arm Name:  [CONTACT_775608] -14-P Prolia® 
Intervention Name:  [CONTACT_775608] -14-P (test product)  US-licensed Prolia® (reference product)  
Type:  Drug  Drug  
Dosage Formulation:  Pre-filled syringe  Pre-filled syringe  
Unit Dose Strength(s):  60 mg 60 mg 
Dosage Level(s):  60 mg 60 mg 
Route of 
Administration:  Subcutaneous injection  Subcutaneous injection  
Use:  Experimental  Active comparator  
IMP:  IMP IMP 
Sourcing:  Provided centrally by [CONTACT_1034] . Provided centrally by [CONTACT_147029] . 
Dosing Instructions:  Main Period : 
On Day 1 of Treatment Period  1, prior to dosing,  participants will be randomised in 
a 1:1 ratio to receive either RGB -14-P or Prolia®.  Participants will receive 
subcutaneous injection of RGB -14-P or Prolia®, into the thigh, abdomen or upper 
arm, a dministered on Day  1 of Treatment Periods  1 and 2  (Weeks  0 and 26) . 
 
Transition Period : 
On Day  1 of Treatment Period  3 (Week  52) a subset of approximately 
66 participants  in the RGB -14-P dose group  will follow the randomisation procedure  
and receive one subcutaneous injection of RGB -14-P, into the thigh, abdomen or 
upper arm.   A subset of approximately 132 participants in the Prolia® dose group 
will be re -randomised to receive either one subcutaneous injection of RGB -14-P or 
Prolia® into the thigh, abdomen or upper arm.  
 
IMP will be administered in the morning.  
Device Description : IMP will be provided as a single -dose 
(1 mL solution)  pre-filled s yringe  made 
from type I glass with 27 gauge needle, 
plunger stopper, staked -in needle and 
needle shield . IMP will be provided as a single -dose 
(1 mL solution) pre-filled syringe  made 
from type I glass  with 27 gauge needle, 
plunger stopper and needle shield . 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 43 of 124 28Mar2023  Arm Name:  [CONTACT_775608] -14-P Prolia® 
Storage : IMP will be stored in a secure area at 2 to 
8°C (35.6 to 46.4°F ) and in accordance 
with applicable regulatory requirements.  IMP will be stored in a secure area at 
2 to 8°C  (35.6 to 46.4°F)  and in 
accordance with applicable regulatory 
requirements.  
IMP = investigational medicinal product; US = [LOCATION_002]  
Please see Section  6.5.2  for information on  calcium  and vitamin D  administration.  
6.1.1 Study Treatment Devices  
[IP_ADDRESS]  RGB -14-P 
RGB -14-P is supplied in a single -use disposable, handheld 1  mL long pre -filled syringe with a 
staked -in needle (27  gauge  × ½ inch).  In order to prevent  accidental needlesticks, the syringe is 
assembled with a needle guard .  Further information on packaging, labelling, storage, handling 
and administration of RGB -14-P can be found in the Investigato r Manual.   Further description on 
the device will be provided in the Addendum to Investigator  Manual.  
[IP_ADDRESS]  Prolia® 
US-licensed Prolia® is supplied in a single -use disposable, handheld 1  mL long pre -filled syringe 
with a staked -in needle (27  gauge  × ½ inch).  In  order to prevent  accidental needlesticks, the 
syringe is assembled with a needle guard .  Further information on packaging, labelling, storage, 
handling and administration of Prolia® can be found in the Investigator Manual.   Further 
description on the devi ce will be provided in the Addendum to Investigator Manual.  
6.1.2 Medical Device Events  
Medical device e vents related to Prolia® will qualify as device incident s (any malfunction or 
deterioration in the characteristics or performance of a device made available on the marke t, 
including use  error due to ergonomic features, as well as any inadequacy in the information 
supplied by [CONTACT_651568] -effects ).  M edical device events related to 
RGB -14-P will qualify as device deficienc ies (any inadequacy in the identity, quality, durability, 
reliability, safety or performance of an investigational device, including malfunction, use  errors 
or inadequacy in information supplied by [CONTACT_3455] ). 
Information on a device incident or dev ice deficiency  (e.g., needle broken, dose not administered 
properly, syringe condition problem ) will be reported in the Product Complaint Fo rm by 
[CONTACT_209779].   The Addendum to Investigator Manual and Product Complaint Form should 
only be accessible to unblinded staff.  Details pertaining to processing and reporting medical 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065227] aint Procedure . 
Adverse event s and SAEs  caused by [CONTACT_775539] (eCRF)  according to Safety Procedures (see 
Section s 8.5 and 10.3), in addition, a Product Complaint Form should be completed and reported 
by [CONTACT_775540] . 
6.[ADDRESS_1065228] be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the label led storage conditions with 
access limited to the Investigator and authorised site staff.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for IMP accountability, reconciliation, and record maintenance ( e.g., receipt, 
reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused IMP are provided in the 
IMP handling instructions . 
6.3 Measures to Minimise Bias: Randomisation and Blinding  
6.3.1 Randomisation  
At randomisation (Treatment Period  1, Day  1) all eligible participants will be randomised via  
Interactive Response  Technology (IRT) to one of the treatment groups.  The Investigator or 
his/her delegate will contact [CONTACT_775541]/exclusion criteria  and Parexel Medical Monitor ha s no objection against inclusion of 
the participant .  The IRT will assign a randomisation number and will specify a unique 
medication number for the first package of IMP to be dispensed to the participant.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065229] will be produ ced by [CONTACT_775542] a validated system that 
automates the random assignment of enrolment  (participant) numbers to randomisation numbers .  
In effect there will be a separate randomisation list for each stratum (combination of 
geographical region  and prior bisphosph onate use).  These randomisation numbers are lined to 
the different treatment groups, which in turn are linked to medication numbers.  
6.3.2 Re-randomisation  and Participa nt Subset in Transition Period  
A subset of approximately 198 participants who complete the  Main Period  (Treatment Periods  1 
and 2)  and continue participation in Treatment Period  3, will be allocated treatment for 
Treatment Period  3 at the beginning of Treatment Period  3 via IRT in a blinded fas hion.  
Enrolment  during the Transition Period will be consecutive  (the next eligible participant will be 
enrolled) .  A subset of approximately 132 participants in the Treatment Periods  1 and 2 Prolia® 
dose group will be re -randomised in a 1:1 ratio to either transition to receive RGB -14-P in 
Treatment  Period  3 or continue on Prolia®.  A subset of approximately 66 participants originally 
randomised to RGB -14-P in Treatment Periods  1 and  2 will automatically continue on 
RGB -14-P in Treatment Period  3 but this will also be performed via the IRT system to maintain 
the blind of treatment assignment (i.e., all participants in the RGB -14-P dose group will be 
re-randomised to continue on RGB -14-P during Treatment Period  3). 
Investigat ional medicinal product  will be administered at the study visits summarised in 
Section  6.1. 
6.3.3 Blinding and Breaking the Blind  
A double -blind design will be used  during  the Main and Transition Periods  to avoid  any bias that 
may result from the Sponsor or staff being aware of the  treatment  sequence assignment for an 
individual participant, e.g., assigning relationship of A Es to IMP, bioanalysis o f samples, 
exclusion of bioanalytical data from the evaluation and determination of analysis populations.  
During the Main Period , all participants and site personnel  (except for  delegated unblinded  
pharmacy  staff, unblinded healthcare professional responsible for IMP administration) , Parexel 
personnel  (except for the logistics team, random isation biostatistician and unblinded monitor) as 
well as subcontracted laboratory personnel will be blinded to the study treatment.   The Sponsor , 
including the bioanalytical laboratory , will be blinded to the assignment of study treatment 
during the 12 -month double -blinded phase (Main Period).  However, the Sponsor’s Clinical 
Safety Unit , Clinical Good Manufacturing Practice Quality Assurance and Quali fied Person  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 46 of 124 28Mar2023  colleagues of Total Quality Management Directorate and  Regulatory Science Division  Medical 
Device Experts  will serve as unblinded personnel throughout the whole study for safety reporting 
purposes.  Part of Parexel’s personnel will be unblinded  after database lock for the [ADDRESS_1065230] 
Complaint F orm and share with the unblinded clinical team at Parexel.   In any circumstances, the 
unblinded study team members should not disclose any information that may le ad to unblinding 
to treatment allocation.  
If an SAE occurs during the study that meets the criteria for expedited reporting (i.e., is a 
S[LOCATION_003]R) as assessed by [CONTACT_1034], the blind should be broken by [CONTACT_775543]  (after Sponsor’s approval)  for that specific participant only (peek 
blind) .  The blind will be maintained for persons responsible for the ongoing conduct of the 
study (such as the study management, monitors and Investigators), and those responsible for da ta 
analysis and interpretation of results at the con clusion of the study such as biometric personnel.  
Unblinded information will only be accessible to those who need to be involved in the safety 
reporting to regulatory authorities and Independent Ethics Committees ( IECs ).  Treatment codes 
will not be broken for the planned analyses of data until all decisions on the evaluability of the 
data from each individual participant have been made and documented.  
The IRT will be programmed with b lind-breaking instructions.  The assignment of study 
treatment may be unblinded in emergency situation when the knowledge of the study treatment 
assignment is considered absolutely necessary for the medical mana gement of the participant or 
for clinical dec ision -making (i.e., when knowledge of the study treatment assignment would 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065231] a treatment decision , unblinding might not be required in many cases due to the 
biosim ilarity and treatment options not being different between RGB -14-P and Prolia®).  The 
Investigator has the sole responsibility for determining if unblinding of a participant’s study 
treatment assignment is warranted.  Participant safety must always be the first consideration in 
making such a decision.  The Investigator should make an effort t o contact [CONTACT_775544], if possible, prior to unblinding.  The applicable Parexel standard operating procedure 
(SOP) will be followed for blind -breaking procedures.  In case of unblinding for safety reporting 
reasons, Parexel Pharmacovigilan ce reporting team has an IRT system access to obtain the 
treatment for a specific participant .  In case of a medical emergency healthcare professionals 
should contact [CONTACT_737].  If the Investigator is no t available, non -study healthcare 
professiona l may contact [CONTACT_775545] b lind if necessary (see Section  8.1.2 ).  The treatment code may only be 
broken in case of emergency when knowledge of the treatment received is necessary for the 
proper medical management of the participant.  
When a participant’s s tudy treatment assignment is unblinded, a comprehensive source note must 
be completed by [CONTACT_775546], the name [CONTACT_775609](s) the participant’s treatment code was unblind ed.  
The source note must also include a record of the discussion with the Medical Monitor.   All 
unblinding information is captured by [CONTACT_775547].  The 
safety processing team who manag es SAEs  as well as the SAE Reporti ng Form remains blinded.  
In all unblinding cases, Parexel should contact [CONTACT_775548] n as possible.  In addition, the 
Clinical Research Associate, Clinical Operational Lead  and the P roject Lead  should be informed.  
Following emergency unblinding, the participant’s further participation such as safety follow -up 
examinations in the study should be discussed with the Sponsor  by [CONTACT_147029] . 
In the event of a quality assurance audit, the auditor(s) will  be allowed access to unblinded study 
intervention records at the site(s) to verify that randomisation/administration has been done 
accurately.  
Further details regarding blinding, unblinding and communication routes can be found in the 
Blinding Management Plan.  
6.[ADDRESS_1065232].  When participants are dosed at the site, they will receive 
study intervention under supervision from the Investigator or designee, under medical 
supervision.   The date and time of each dose administered at the chosen site of administration 
(e.g., abdomen, thigh, upper arm, etc.)  will be recorded in the source documents and recorded in 
the eCRF .  The dose of IMP and study par ticipant identification will be confirmed at the time of 
dosing by a member of the study site staff other than the person administering the IMP. 
At the investigational site, all activities related to the handling of IMP until administration to a 
participan t should be performed by [CONTACT_274666] /authorised designee.   Unblinded site staff 
must not perform any clinical assessment .  This person should be assigned by [CONTACT_775549]:  
• Receipt of IMP.  
• Preparation of IMP for administrati on. 
• Storage of IMP.  
• Dispensing of IMP.  
• Accountability and reconciliation of IMP.  
• Preparation of IMP for destruction (used, expi[INVESTIGATOR_5697], not fit to use, unused after last participant 
last visit).  
For medical device events  procedures  see Section  6.1.[ADDRESS_1065233] dose of 
IMP and as conco mitant if ongoin g or if started after IMP dosing . 
The use of medications listed in exclusion criteria  20, 21 and 22 (Section  5.2) should be sought 
without time frame restrictions.  
All restrictions on medications as listed in Section  6.5.1  are applicable for the entire duration of 
the study.  Other concomi tant medications that the participant receives on a regular basis may 
continue, if in the opi[INVESTIGATOR_689],  it doe s not put the participant at undue risk or does 
not interfere with the study evaluations.   Concomitant medication use may be warranted for the 
treatment of A Es.  All concomitant medications necessary for the health and well -being of a 
participant will be p ermitted.   Any medication or vaccine (including over -the-counter or 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 49 of 124 28Mar2023  prescription medicines, vitamins, and/or herbal supplements) that the participant is receiving at 
the time of enrolment  or receives during the study must be recorded along with:  
• Brand name  [CONTACT_775610]/ international non -proprietary  names (INN)  name.  
• Route of administration.  
• Reason for medication (e.g. , AE, medical history, prophylaxis).  
• Indication.  
• Dates of administration including start and end dates . 
• Dosage information including dose and frequency . 
Any changes in the dosage or regimen of a concomitant medication will be recorded.  
The Medical Monitor should be contact[CONTACT_63193].  
6.5.1 Prohibited Therapy  
The medications and intervention s which are listed below will be prohibited during the study 
period unless required for AE/SAE management.  If any of these prohibited therapi[INVESTIGATOR_775504].  
Participants must abstain from the use of the following concomitant treatment:  
• Any osteoporosis treatment (other than calcium and vitamin D supplements).  
• Products containing denosumab  (e.g., Xgeva®) or biosim ilar denosumab . 
• Romosozumab.  
• Cathepsin K inhibit ors. 
• Strontium or fluoride  (except topi[INVESTIGATOR_775505]) . 
• Intravenous or oral bisphosphonates.  
• Teriparatide , abaloparatide  or any PTH analog ues. 
• Tibolone, oral or topi[INVESTIGATOR_2855] (e.g., transdermal, intravaginal) oestrogen, antioestrogens, SERMs  
and aromatase -inhib itors. 
• Calcitonin  or its derivates  and calcimimetics (such as cinacalcet or etelcacetide) . 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 50 of 124 28Mar2023  • Systemic glucocorticosteroids  (≥ 5 mg prednisone or equivalent per day for ≥  10 days or a 
total cumulative dose of ≥  50 mg).  Topi[INVESTIGATOR_775503].  
• Other bone active drugs including heparin  (also low molecular weight heparins) , vitamin  K 
(supplementatio n or therapeutic dose) , vitamin  K antago nists (e.g., warfarin , acenocumarol) , 
emtricitabine, tenofovir, adefovir,  anti-convulsants (with the exception of benzodiazepi[INVESTIGATOR_1651] , 
gabapentin  and pregabalin ), systemic ketoconazole, ACTH, lithium, protease inhibitors, 
GnRH agonists, anabolic steroids.  
• Invasive dental procedures (e.g., dental implants or oral surgery) and ma jor surgeries or bone 
surgeries (unless required for AE/SAE management  after careful consideration ) will be 
prohibited during the study p eriod.  
See Section  5.2 for specific restrictions on prohibited medications.  
6.5.2 Additional Study Treatments  
According to the Prolia® USPI [3] and a s indicated in the IB [1], as preca utionary measure for 
denosumab use, all participants should have an adequate intake of calcium and vitamin D.  
Therefore, at latest from the first day of IMP dosing  until the End-of-Study /Early Termination  
Visit  all participants must take at least [ADDRESS_1065234] the calcium and/or vitamin D dosage if needed , according to local practice .  
The change should be reported in the eCRF and hypercalcaemia or hypocalcaemia should be 
reported as an AE if clinically significant.  
Intolerance to non-IMP may occur , especially for calcium.  Calcium intolerance can manifest as 
bloating or constipation.  The formulation and/or dose frequency (e.g., dose divided t wice daily) 
can be changed to reduce intolerance and increase compliance at the Investigator’s discretion.  If 
intolerance continues after lowering the dose, temporary dis continuation may be considered.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 51 of 124 28Mar2023  Permanent discontin uation  of calcium and/or vitamin D should be discussed with the Medical 
Monitor  in the CRO and should be document ed in the source data.  
6.6 Dose Modification  
Not applicable . 
6.7 Intervention  After the End of the Study  
Discontinuation of treatment with denosumab has been associated with a rebound increase in 
bone turnover accompanied by [CONTACT_775550], 
including multiple vertebral fractures, therefore administration of denosumab should not be 
delayed or stopped without transitioning the participant to another antiresorp tive agent 
(e.g.,  bisphosphonates, hormone replacement therapy or SERMs) or in some cases other therapy 
may also be considered  [15].  Consequently , the Investigator must ensure that in line wit h the 
local guidelines appropriate follow -up osteoporosis treatment is prescribed to all participants 
upon conclusion of the therapy with the study drug either due to early termination or upon 
completion of the study at [ADDRESS_1065235]  and Participant 
Discontinuati on/Withdrawal from the Study  
7.[ADDRESS_1065236] , Participant 
Discontinuation/Withdrawal from the Study  
It may be necessary for a participant to discontinue IMP.  If IMP is discontinued, the participant 
may remain in the study to be evaluated , unless the participant withdraws consent , or it is against 
the participant’s best medical interest  or does not serve  the well -being of the participant as 
deemed by [CONTACT_9304] . 
Participant s will discontinue IMP  if any of the following events occurs : 
• Adverse drug reactions of grade 3 or 4 severity including but not limited to:  
o Drug -related hypersensitivity, anaphylactic reaction  
o Osteonecrosis of the jaw, osteonecrosis of the external auditory canal  
o Atypi[INVESTIGATOR_147167]  
• Any r elevant AE or SAE, if the Sponsor or Investigator deems it as medical reason to warrant 
IMP discontinuation .  The Investigator must notify the Medical Monitor immediately if a 
participant discontinued the IMP  because of an AE/SAE . 
• Participant is pregnant  or breastfeeds , see Sectio n 8.5.5 . 
• Unsatisfactory therapeutic effect of the IMPs or disease progression (e.g.,  decrease of BMD 
or new osteoporotic fracture) that requires change of osteoporosis treatment, agreed by [CONTACT_474295].  
If a participant experiences BMD reduction of ≥  5% from baseline at the total hip , femoral 
neck  and/or the lumbar spi[INVESTIGATOR_775506], the Investigator is required to 
explore if factors other than postmenopausal osteoporosis, such as non-comp liance with 
vitamin D/calcium supplementation or secondary ca uses of osteoporosis could contribute to 
the BMD decrease, discuss implication s for individual fracture risk, alternative treatment 
options and options for continuing in the study with the participant, and to document that 
discussion.  If a decision is made to begin alternative treatment, the IMP must be 
discontinued.  Please refer to  Section  6.7 for details on the transition to another osteoporosis 
treatment at the conclusion of IMP therapy.  
• Prohibited concomitant medication, unless a written confirmation is provided by [CONTACT_775551] I MP. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 53 of 124 28Mar2023  • Following emergency unblinding.  
• At the discretion of the Investigator or Sponsor any circumstances that could prevent the 
participant to comply with the protocol requirements and study objectives.  
• Withdrawal of consent.  A participant may withdraw from the study at any time at her own 
request without giving any reasons.  
If discontinuation of IMP or withdrawal of consent occurs, the Investigator should make effort to 
understand the primary reason for the participant’s premature discontinuati on or withdrawal of 
consent and record this information.  
If the participant withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  If a participant 
withdra ws from the study, she may request destruction of any samples taken and not tested, and 
the Investigator must document this in the study site records.  
Every case of early discontinuation from study treatment should be discussed with the Medical 
Monitor and  all reasonable effort should be made to  retain the participant until all remaining 
study procedures are completed , except IMP administration until Week  52.  If the participant 
opts not to continue with the completion of all remaining study procedures unti l Week  52, all 
reasonable effort should be made to  complete the End -of-Study/Early Termination proc edures as 
shown in the SoA ( Table  1-1 and Table 1-2).  Refer to the SoA (Table  1-1 and Table 1-2) for 
assessments to be done at the time of  study  discontinuation  or early withdrawal . 
7.[ADDRESS_1065237] be taken if a participant  fails to return to the clinic for a required 
study visit:  
• The site mus t attempt to contact [CONTACT_47995] m issed visit as soon as 
possible (and within the visit window, where one is defined) and counsel the participant  on 
the importance of maintaining the assigned visit schedule and ascertain whether or not the 
participant  wishes to and/or should continue in the study.  
• In cases in which the participant  is deemed lost to follow -up, the I nvestigator or designee 
must make every effort to regain contact [CONTACT_6635]  (where possible, 3 telephone 
calls and , if necessary , a certified letter to the participant ’s last known mailing address or 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 54 of 124 28Mar2023  local equivalent methods).  These contact [CONTACT_13140] ’s 
medical record . 
• Should the participant  continue to be unreachable, she will be considered to  have withdrawn 
from the study.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 55 of 124 28Mar2023  8 Study Assessments and Procedures  
Study procedures and their timing are summarised in the SoA  (Table  1-1 and Table 1-2).  
Protocol waivers or e xemptions are not allowed.  
Immediate safety concerns should be discussed with the Medical Monitor  immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue IMP. 
Adherence to the study design requirements, including those specified in the SoA  (Table  1-1 and 
Table 1-2), is essential and required for study conduct.   The criteria for the assessment and 
reporting of protocol deviations will be stipulated in a separate study -specific protocol deviations 
specification s document.  
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria.   The Investigator  will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record reasons for screening failure, as 
applicable.  
A summary blood log including volume as well as instruction for all sample collection, 
processi ng, storage and shipment information will be available in the Labora tory Manual.  
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.   In the case of repeated measurements , the new results and the reason f or repeat must be 
documented in the eCRF.   Investigators and site staff should make reasonable effort to 
understand the reason for missing data and document it in the source data and eCRF.  This 
requirement will be part of the Investigators’ training and s ite staff will be re -trained in case of 
noncompliance.  
8.[ADDRESS_1065238] be documented according to Appendix 1  (Section  10.1.3 ). 
8.1.[ADDRESS_1065239] information (including direct telephone 
numbers) to be used in the event of an emergency.  The Investigator or qualified designee will 
provide the participant with a participan t identification card immediately after the participant 
provides written informed consent.  At the time of intervention allocation/randomisation, site 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 56 of 124 28Mar2023  personnel will add the intervention/randomisation number to the participant identification card.   
At each  visit participants will be provided with a participant identification and visit reminder 
card.  The Investigator must update the visit reminder card at each visit with the details for the 
next visit.  
The participant identification card also contains conta ct information for the emergency 
unblinding call cent re so that a healthcare provider can obtain information about IMP in 
emergency situations where the Investigator is not available.  
8.[ADDRESS_1065240] enter all screening data in the electronic data capture ( EDC ) 
system in a timely manner  to allow the Parexel Medical Monitor to review eligibility data  before 
participant is randomised .  Only after Medical Monitor approval (i.e., there is no objection 
against inclusion o f the participant), the Inves tigator or his/he r delegate may contact [CONTACT_6606].  
8.2.[ADDRESS_1065241] dose of 
IMP and as concomitant if ongoing or if started after IMP dosing .  The use of medications listed 
in exclusion criteria  20, 21 and 22 (Section  5.2) should be sought without time frame restrictions.  
The Investigator or qualified designee will record  concomitant  medication, if any, taken by [CONTACT_775552] -of-Study/Early Termination Visit  (or longer if related 
to an SAE).  
8.2.[ADDRESS_1065242] signed the informed consent will undergo the following proce dures and 
assessments:  
• Height, without shoes (cm).  
• Body weight, without shoes (kg).  
• Body mass index (kg/m2) to be calculated.  
• History and current use of alcohol and/or drugs  and tobacco products . 
• Medical and surgical history.  
• Physical examination (including oral cavity and dental health).  
• Examine for any signs and/or symptoms of any acute or chronic infections including 
COVID -19. 
• Vital signs.  
• 12-lead ECG.  
• Clinical laboratory tests including haematology, clinical chemi stry, urinalysis an d viral 
serology.  
• Prior medication.  
• Medical occurrence (A Es), if any, since the time of signing the ICF.  
• Review of inclusion and exclusion criteria.  
• Review of lifestyle restrictions.  
• Dual energy X-ray absorptiometry assessment  (see Section  8.3.1 ). 
• Lateral spi[INVESTIGATOR_050] X-ray (see Section  8.3.2 ). 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 58 of 124 28Mar2023  The Screen ing visit may be conducted over the Screening  period (i.e., more than 1  day can be 
utilised for Screening during the Screening period),  if necessary , for logistical reasons . 
8.2.[ADDRESS_1065243] when more than one assessment is required 
at time point , please also see to the SoA ( Table  1-1 and Table 1-2): 
• 12-lead ECG . 
• Vital signs : 
o Blood pressure.  
o Body temperature.  
• Blood sampling for sCT X/P1N P. 
• Blood sampling for immunogenicity  and serum drug concentration  assessment . 
• Blood sampling for safety assessment . 
• Urinalysis.  
• Physical examination and other assessment.  
8.3 Efficacy Assessments  
8.3.1 Dual Energy X -ray Absorptiometry Measurement  
Dual energy X -ray absorptiometry measurements will be used  to confirm participant eligibility 
and to determine the change in BMD  as indicated in the SoA ( Table  1-1 and Table 1-2).  If the 
participant  withdraws from the study early a measurement during the Early Termination Visit 
will not be required if the previous m easurement was taken within [ADDRESS_1065244] ent with a T -score ≤  -2.5 and 
≥ -4.[ADDRESS_1065245] be used (e.g., du e to 
implants) or is inadvertent ly used at Baseline, then it must be consistently used throughout the 
study.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065246] be submitted to and analysed central ly by [CONTACT_147029].  
Detailed instructions on DXA scan acquisition can be found in the separate Image Acquisition 
Guideline . 
8.3.2 Lateral  Spi[INVESTIGATOR_050]  X-ray 
Lateral  spi[INVESTIGATOR_050] X-ray assessment will be used  to confirm participant eligibility and  to determine 
the change in bone  imaging /occurrence of fractures  from Baseline as indicated in the SoA 
(Table  1-1 and Table 1-2).  Semi -quantitative assessment using Genant scoring method of 0  – 3 
for presence and severity of vertebral fractures (0  = normal, 1  = mild, 2  = moderate, 3  = severe) 
will be used  [16].  The responsibility of other (e.g., incidental findings) analyses of the lateral 
spi[INVESTIGATOR_050] X -ray, which are out of the scope of the central assessment (i.e., vertebral fracture 
assessment with Genant scoring method), remains with the Investigator.   If the participant 
withdraws from the study early a n image  during the Early Termination Visit will not be requi red 
if the previous image  was taken within [ADDRESS_1065247] be submitted to and 
analysed centrally by [CONTACT_147029].  
Detailed instruction s on lateral spi[INVESTIGATOR_050] X -ray can be found in the Image Acquisition Guideline . 
8.3.3 Fracture Assessment  
Fracture rates (the incidence of vertebral and non -vertebral  fragility  fractures) will be monitored 
and assessed  as a secondary efficacy endpoint  throughout the study.   In addition, any fracture 
(symptomatic and asymptomatic) that occurs during the study will be re corded as an AE  (see 
Section  8.4).  Fragility fractures are fractures that occur as a result of “low energy trauma”, often 
from a fall from standing height or less, that would not normally result in a fracture.  
[IP_ADDRESS]  Vertebral Frac ture 
Information on vertebral fractures will be centrally evaluated through the lateral thoraco -lumbar 
spi[INVESTIGATOR_050] X -ray (see Section  8.3.2 ) scheduled as in dicated in the SoA ( Table  1-1 and Table 1-2).  For 
central assessment of vertebral fractures by [CONTACT_448505][INVESTIGATOR_050] X -ray, a visual semiquantitative grading 
scale will be used [16] and further defined in the Independent Review Charter .  Details on  the 
X-rays acquisition requirements  are provided in the Image Acquisition Guideline . 
[IP_ADDRESS]  Non-vertebral Fracture  
The diagnosis of non -vertebral fractures will not require central X -ray reading and will be based 
on local radiological reports.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065248] of the regular monitoring of haematology, clinical chemistry , 
urinalysis , ECG,  regular measurement s of vital signs , physical examinations , injection site 
reactions  and fracture assessment (see Section  8.3.3 ) as well as monitoring and recording of all 
AEs and SAEs .  Any fracture (symptomatic  and asymptomatic) that occurs during the study will 
be recorded as an AE.   Consequently, any new or worsening fracture reported after central 
reading of lateral spi[INVESTIGATOR_050] X -ray should be documented as an AE by [CONTACT_737].  Severity of 
vertebral fractures will be defined and reported using the Genant score (i.e., 1  = mild, 
2 = moderate, 3  = severe).   Planned time points for all safety assessments are provided in the 
SoA (Table  1-1 and Table 1-2). 
8.4.1 Physical Examinations  
A comprehensive physical examination will be performed as outlined in the SoA ( Table  1-1 and 
Table 1-2) and will include assessments of general appearance  and review of systems  (head, 
eyes, ears, nose , mouth/oral cavity/ throat /neck , thyroid,  lymph nodes,  dermatologic, respi[INVESTIGATOR_696], 
cardiovascular , gastrointestinal, extremities, musculoskeletal, neurological systems) . 
At all other visits  physical examination might be performed as per the Investigator’s discretion . 
Height and weight will also be measured and recorded  and body mass index ( BMI ) will be 
calculated.  Height will be measured without shoes at the Screening Period  and at all timepoints 
when BMI is measured .  Weight will be measured as outlined in the SoA ( Table  1-1 and 
Table 1-2) in light clothes and without shoes . 
8.4.2 Vital Signs  
Body ( axillary, forehead or tympanic ) temperature  will be measured , pulse  and blood pressure 
will be assessed  as outlined in the SoA ( Table  1-1 and Table 1-2).  Respi[INVESTIGATOR_775507].  
Systo lic and diastolic b lood pressure and pulse measurements will be assessed after the 
participant has been sitting for at least 5  minutes with back supported and both feet on the floor, 
using a validated device .  All blood pressure measurements should be  performed on the same 
arm, as much as possible.  
When timepoint for procedures overlap, it is recommended that vital signs are to be collected 
before blood sample collection.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 61 of 124 28Mar2023  8.4.3 Electrocardiograms  
Single 12 -lead ECG will be obtained as outlined in the SoA (Table  1-1 and Table 1-2) after 
[ADDRESS_1065249] in supi[INVESTIGATOR_775508].  
According to the Prolia® label, rarely, patients receiving Prolia® may develop hypocalc aemia, 
which may also lead to Q T prolongation.  
Safety ECGs will be reviewed and interpreted on -site by [CONTACT_737].  Abnormalities in an 
ECG will be assessed as “clinically significant” or “not clinically significant”.  
8.4.4 Clinical Safety Laboratory Assessments  
Refer to Appendix  2 (Section  10.2) for the list of clinical laboratory tests to be performed and to 
the So A (Table  1-1 and Table 1-2) for the timing and frequency.  
A central laboratory will be used to measure laboratory parameters that are to be listed in the 
clinical study report .  All blood samples will be obtained by [CONTACT_99847] . 
Full instruction for collection, aliquoting, labelling, processing, storage  and shipment of samples 
will be provided in the Laboratory Manual.  The actual date and time (24 -hour clock  time) of 
blood sampling will be recorded.  Any deviation in the storage  conditions and sample processing 
defined in the Laboratory Manual should be  reported to the central laboratory analysing the 
samples and to the Clinical Research Associate . 
Sites will perform a urine dipstick  (all dipstick results should be reported in the eCRF) .  In case 
of abnormal  results , a urine  sample may be sent to  the central lab for full analysis  if deemed 
necessary by [CONTACT_737] .  See Appendix  2 (Section  10.2). 
The Investigator will evaluate the clinical relevance of each laboratory value outside of the 
reference range.  This evaluation will be based upon the nature and degree of the observed 
abnor mality.  Any abnormal clinical laboratory test result (haematology, clinical chemistry or 
urinalysis) that worsen from baseline and  is considered to be clinically significant in the medical 
and scientific judgement of the Investigator are to be recorded as  AEs or SAEs.  Additionally, 
abnormal laboratory values that induce clinical signs or symptoms or that require therapy must 
also be recorded as A Es in the eCRF.  
In case of an abnormal result, the Investigator may consider repeating the test once in order t o 
rule out laboratory error.  Unscheduled laboratory assessments may be obtained at any time 
during the study upon Investigator’s discretion.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065250] be recorded as either medical history/current medical 
conditions or A Es as appropriate.  
[IP_ADDRESS]  Hypocalcaemia  
Clinical monitoring of calcium level and vitamin D will be performed as indicated in the SoA 
(Table  1-1 and Table 1-2).  Hypocalcaemia ( albumin -adjusted serum calcium <  2.1 mmol/L 
[< 8.4 mg/dL]) must be corrected by [CONTACT_775553] D before 
initiating treatment and administration of IMP. 
According to local guideline or practice and upon the discretion of the Investigator, (preferably 
albumin -adjusted ) serum calcium level may be measured  prior to the administration of IMP or at 
any timepoint  at local laboratory .  The results, as well as the lower and upper limit of normal 
value of (albumin -adjusted ) serum calcium at the local laboratory should be documente d in the 
eCRF.  Clinically significant abnormal values should be reported as an AE.  However, for clinical 
study report purposes  the values from the central laboratory will be considered.  
In the case of hypocalcaemia,  the following procedures should be followed:  
• Temporar ily withhold IMP dosing.  
• Upon Investigator’s discretion, p erform a physical examination or additional assessments, 
e.g., ECG.  
• Administer additional calcium as per Investigator’s discretion  (see Section  6.5.2 ) as deemed 
acceptable as per local guidelines  or practice . 
• Repeat  albumin -adjusted  serum calcium test as many times as deemed appropriate , until 
hypocalcaemia resolves.  
• Continue with study tre atment only if hypocalcaemia is resol ved and is not contraindicated 
any more . 
• Contact [CONTACT_775554].  
8.4.5 Local Tolerance (Skin Examination)  
A local tolerance (skin examination) assessment  will be done by [CONTACT_775555] ( Table  1-1 and Table 1-2).  On dosing days, i njections site reaction assessment should 
be done predose  (i.e., for exclusion  of a pre-existing , not IMP injection induced condition)  and 
approximately 1 hour postdose , during this 1  hour period (i.e., from dosing to the injection site 
assessment) the participant will stay in the clinic for general safety observation .  Any further 
assessment of the injection site  or prolonged obse rvation of the participant  may be done at the 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 63 of 124 28Mar2023  discretion of the Inve stigator.   The grading of severity of each injection site  reaction  will be 
based on the Common Terminology Criteria for Adverse Events ( CTCAE ) v 5 criteria included 
in Table  8-1.  Injection site reactions with a grading of ≥  1 will be recorded as an AE.  
Table  8-1 Common Terminology Criteria for Adverse Events Injection Site 
Reaction Gradin g 
Grade  Reaction  
Grade 1  Tenderness with or without associated symptoms (e.g.  warmth, erythema, itching)  
Grade 2  Pain, lipodystrophy, edema, phlebitis  
Grade 3  Ulceration or necrosis, severe tissue damage, operative intervention indicated  
Grade 4  Life-threatening consequences, urgent intervention indicated  
Source: https://ctep.cancer.gov/protocoldevelopment/electronic_applicati ons/docs/CTCAE_v5_Quick_Reference_5x7.pdf  
8.5 Adverse Events  and Serious Adverse Events  
The definitions of A Es and SAE s can be found in Appendix 3 (Section  10.3).  The definitions of 
AEs and SAEs  caused by [CONTACT_775556] (Prolia®) or device deficiency (RGB -14-P) can be 
found in Appendix 3 (Section  10.3). 
Adverse event s will be reported by [CONTACT_2299]  (or, when appropriate , by a caregiver, 
surrogate, or the participant ’s legally authorised representative) .  Information on device 
incident/deficiency will be reported in the Product Complaint Form by [CONTACT_209779]  (see 
Section  6.1.2 ).  Device incident or device deficiency  that cause site staff related injury will be 
reported in the Product Complaint Form by [CONTACT_775557] . 
The Investigator and any qualified designees are responsible for detecting, documenting , and 
reporting events that meet the definition of an AE or SAE and remain responsible for following  
up AE, considered related to the IMP or the study, or that caused the participant  to discontin ue 
the IMP (see Section  7).  In order to  fulfil regulatory obligations, the Investigator is responsible 
for the documentation of any  AEs or SAEs ( whether or not caused by a device 
incident /deficiency)  that occur during the study.  
8.5.1 Time Period and Frequency for Collecting A dverse Event and S erious  
Adverse Event Information  
All AEs and SAE s will be collected from the signing of ICF until the End-of-Study or E arly 
Termination Visit  at the time  points specified in the SoA (Table  1-1 and Table 1-2) or anytime 
during the study . 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 64 of 124 28Mar2023  All SAE s including, but not limited to SAEs caused by [CONTACT_775558]/deficiencies , will be 
recorded and reported to Parexel  within 24  hours  of it being available , as indicated in  Appendix  
3 (Section  10.3).  The Investigator will submit any updated SAE data to Parexel  within 24 hours 
of it being available . 
In addition, a ll AEs caused by [CONTACT_775558]/deficiencies  are to be reported as AEs following 
the same reporting periods and procedures  as all study AEs .  Further details regarding device 
incident or device deficiency  AEs can be found in Appendix 3 (Section  10.3). 
Any adverse effect on health or safety, any life -threatening problem or death caused by, or 
associated with the devices needs to be recorded in the eCRF  and reported as it is defined in the 
SAE processing procedure , the Addendum to Investigator Manua l and the Product Complaint 
Procedure . 
Investigators are no t obliged to actively seek A Es or SAE s after the conclusion of  study 
participa tion.  However, if the Investigator learns of any SAE, including a death, at any time 
after a participant  has been discharged from the study, and he/she considers the event to be 
reasonably related to the IMP or study participation, the Investigator must promptly notify the 
Spons or. 
8.5.2 Method of Detecting A dverse Events and S erious Adverse Events 
The method of recording, evaluating, and assessing causality of A Es and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 
(Section  10.3). 
Care will be taken not to introduce bias when detecting A Es and/or SAE s.  Open -ended and 
non-leading verbal questioning of the participant  is the preferred method to inquire about 
AE occurrence.  
8.5.3 Follow -up of A dverse Events and S erious Adverse Events 
All participants with AE/SAEs that occur during the study will be treated according to daily 
clinical practice.  After the initial AE/SAE report, the Investigator is required to proactively 
follow each participant  at subsequent visits/contacts.   All AE/SAE s (caused by [CONTACT_775559]/deficiencies  or not) will be followed until resolution  (i.e., recovery or evident t rend 
towards recovery, recovery with sequalae) , stabilisation  or until the condition determined to be 
chronic or permanent , or the participant  is lost to follow -up (as defined in Section  7.2).  Further 
information on follow -up procedures is given in  Appendix 3 (Section  10.3). 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 65 of 124 28Mar2023  8.5.4 Regulatory Reporting Requirements for S erious Adverse Event 
Prompt notification (within 24  hours, see Appendix 3 [Section  10.3]) by [CONTACT_775560] s and the safety of the IMP under clinical investigation are met.  
The Sponsor (Parexel on  behalf of the Sponsor ) has a legal responsibility to notify both the local 
regulatory authority and other regulatory agencies about the safety of a n IMP under clinical 
investigation.   The Sponsor  will comply with country -specific regulatory requirements re lating to 
safety reporting to the regulatory authority, Institutional Review Board ( IRB)/IEC, and 
Investigators.  
The Sponsor  (Parexel on behalf of the Sponsor ) has a legal responsibility to  report, without delay 
to all Member States in which the clinical study is being conducted, including : 
1. any SAE that has a causal relationship with the investigational device, the comparator or the 
investigation procedure or where such causal relationship i s reasonably possible , 
2. any device event t hat might have led to a n SAE , if appropriate action had not been taken , if 
intervention had not occurred , or circumstances had been less fortunate , 
3. any new findings in relation to any event referred to in points 1 and 2 above.  
For all studies including those which use combination products such as RGB -14-P and Prolia®, 
Investigator safety reports must be prepared for S[LOCATION_003]R  according to local regulatory 
requirements and Sponsor  policy and forwarded to Investigators as necessary.  
On behalf of the Sponsor, after Sponsor’s approval, the Parexel Pharmacovigilance team shall 
report any S[LOCATION_003]Rs to the re gulatory agencies and IECs, if applicable.  The Parexel 
Pharmacovigilance team shall provide the Sponsor with  local regulatory reporting requirements 
related to pharmacovigilance activities.  The Parexel Pharmacovigil ance team shall inform the 
Investigator in the clinical study about the occurrence of S[LOCATION_003]Rs.  
In addition, on behalf of the Sponsor, after Sponsor’s  approval, the Parexel Pharmacovigilance 
team shall report any medical device incident or deficiency that qualifies for a reportable medical 
device event according to the above -mentioned criteria.  The Parexel Pharmacovigilance team 
shall provide the Spons or with local regulatory reporting requirement related to medical devices.  
An Investigator who receives an Investigator safety report describing a n SAE or other specific 
safety information ( e.g., summary or listing of SAE) from Parexel will file it along with the IB 
and will notify the IRB/IEC, if appropriate according to local requirements . 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 66 of 124 28Mar2023  8.5.5 Pregnancy  
For postmenopausal participants , pregnancy is not expected.  In the rare occurrence of 
pregnancy:  
• Details of all pregnancies in female participant s will be collected after signing  of the ICF . 
• If a pregnancy is reported , the Investigator should inform the Sponsor  within [ADDRESS_1065251] be discontinued . 
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion, foetal  death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered to be SAE s. 
As a general rule, the study medication must be discontinued, though the participant may stay in 
the study and follow the assessments, if s he wishes to do so.  Each pregnancy occurring after 
signing of the informed consent must be reported to Parexel within 24  hours of learning of its 
occu rrence.   Pregnancy should be recorded and reported by [CONTACT_775561].   The pregnancy should be followed up to determine the outcome, 
including spontaneous or voluntary termination, detail s of the birth and the presence or absence 
of any birth defects, congenital abnormalities or maternal and/or newborn complications.   
Generally, follow -up will not be required for longer than 8 weeks beyond the actual delivery 
date.  Any termination of the p regnancy will be reported, regardless of foetal  state (presence or 
absence of anomalies) or indication for the procedure.  
Pregnancy should be recorded and reported by [CONTACT_775562] .  Pregnancy follow -up should  be recorded on the same form and should include an 
assessment of the possible relationship to the study medication  and any pregnancy outcomes.   
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination  of a pregnancy will be reported as an AE or SAE.  A spontaneous abortion is 
always considered to be an SAE and will be reported as such.  Any post -study pregnancy -related 
SAE considered reasonably related to IMP by [CONTACT_775563] .  While the Investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through spontaneous 
reporting.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 67 of 124 28Mar2023  8.6 Treatment  of Overdose  
The Sponsor  does not recommend specific treatment for an overdose .  There is no experience 
with overdose in clinical studies  with RGB -14-P.  Denosumab has been administered in clinical 
studies using doses up to 180  mg every 4  weeks, with no additional adverse reactions observe d. 
[1]  As RGB -14-P and Prolia® are supplied in pre -filled syringes and participants will not 
self-administer the IMP , incidences of overdose are not expected.  
Accidental or intentional overdose of the intended dose of study drug require s reporting to the 
Parexel Medical Monitor within 24  hours of learning.  
In the event of an overdose , the Investigator should:  
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for AE/SAE  and laboratory abnormalities.  
3. Document the quantity of the excess dose in the eCRF.  
8.7 Immunogenicity Assessments  
Antibodies  to denosumab  (anti-RGB -14-P antibodies and anti -Prolia® antibodies ) will be 
evaluated in seru m samples collected from all participants according to the SoA  (Table  1-1 and 
Table 1-2).  Blood samples will be collected for determination of  binding  anti-drug antibodies 
(ADAs)  and neutralising  antibodies (NAbs) .  Additionally, serum samples should also be 
collected at the final visit from participants who discontinued IMP or were withdrawn from the 
study.  These samples will be tested by [CONTACT_1034].  
Full instruction for collection, aliquoting, labelling, processing, storage and shipment of samples 
will be provided in the Laboratory Manual.  The actual date and time (24 -hour clock  time) of 
blood sampling will be recorded.  Any deviation in the storage conditions and sample processing 
defined in the Laboratory Manual should be reported to the  central laboratory and  Sponsor’s 
laboratory analysing the samples.  
Serum immunogenicity samples will be assessed for ADAs according to the following stepwise 
analyt ical approach:  
1. Screening analysis (assay) . 
2. For those who had a positive screening result, confirmatory analysis will be done.  
3. Confirmed positive samples will be titrated.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065252] the neutralising potency of ADAs.   Other analyses may be performed to verify the stability 
of ADAs . 
The detection and characteri sation of ADAs  will be performed using validated assay method s by 
[CONTACT_1034].  In parallel, blood samples will be collected together wi th the immunogenicity 
samples for determination of denosumab serum concentration to enable interpretation of the 
antibody data ( Section  8.8). 
Samples may be stored for a maximum of [ADDRESS_1065253] participant’s last visit for 
the study at a facility selected by [CONTACT_775564] .  Samples may also be used for validation of the analytical methods and generation 
of human positive control.  
Participant confidentiality will be maintained.  
8.8 Serum Drug Concentration  
Blood  samples will be collected  at the time of immunogenicity sample coll ection for 
measurement of serum  concentrations of  denosumab (RGB-14-P and Prolia®) as specified in the 
SoA (Table  1-1 and Table 1-2), to support the interpretation of immunogenicity data .  These 
samples wil l be tested by [CONTACT_1034].  
Full instruction for collection, aliquoting, labelling, processing, storage and shipment of samples 
will be provided in the Laboratory Manual.  The actual date and time (24 -hour clock time) of 
each sample will be recorded .  Any deviation in the storage conditions and sample processing 
defined in the Laboratory Manual should be reported to the  central laboratory and  Sponsor’s  
laboratory analysing the samples.  
Samples collected for analyses of denosumab serum  concent ration may also be used to evaluate 
safety , efficacy  or immunogenicity  aspects that address concerns ar ising during or after the 
study .  Serum denosumab concentration will be determined using a validated assay method by 
[CONTACT_1034].  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065254] participant’s last visit for 
the study at a facility selected by [CONTACT_702388].  Samples may also be 
used for validation of the analytical methods and generation of human positive control . 
Participant confidentiality will be maintained.  
8.9 Pharmacodynamics  
In this study PD markers such as serum P1NP and CTX will be measured and compared as 
specified at the endpoints ( Section  3). 
Area under the effective curve (AUEC) after first dose until Day  183 percent change from 
Baseline (%CfB) in sCTX  will be estimated as key PD parameter.  
Blood samples will be collected for measurement of serum concentrations of sCTX and P1NP  as 
specified in the SoA  (Table  1-1 and Table 1-2). 
Instructions for the collection and handling of biological samples will be provided by [CONTACT_12113] .  Full instructions for collection, aliquoting, labelling, processing, 
storage and shipment of samples will be provided in the Laboratory Manual.   The actual date and 
time (24 -hour clock time) of blood sampling  will be recorded.   Any deviation in the storage 
conditions and sample processing defined in the Laboratory Manual shoul d be reported to the 
bioanalytical laboratory analysing the samples and to the Clinical Research Associate . 
Samples collected for analyses of sCTX and P1NP serum concentration may also be used to 
evaluate safety or efficacy aspects that address concerns arising during or after the study.  
Analysis will be performed in a blinded manner .  Participant confidentiality will be maintained.  
8.10 Genetics  
Genetics are not evaluated in this study.  
8.11 Biomarkers  
Biomarkers are not evaluated in this study.  
8.12 Medical R esource Utilisation and Health Economic s 
Medical Resource Utilisation and Health Economics  parameter s are not evaluated in this study.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 70 of 124 28Mar2023  9 Statistical Considerations  
9.1 Statistical Hypotheses  
The null hypothesis being tested is the RGB -14-P and Prolia® are not equivalent in favo ur of the 
alternative hypothesis that the two treatments  are equivalent.  
• Efficacy estimand for EMA submission  
  
  
Where:  
μRGB: BMD mean %CfB  in RGB -14-P study arm  
μProlia: BMD mean %CfB in Prolia® study arm  
δ = μ RGB -14-P – μProlia  
Significance level  = 0.05 (two -sided), i.e., 95% (two -sided) confidence interval ( CI) to be 
contained within acceptance region.  
• Efficacy estimand  for FDA submission  
Two separate hypothesis tests to be applied:  
o Non-superiority of RGB -14-P compared to Prolia® 
  
  
Significance level  = 0.05 ( one-sided)  
o Non-inferiority of RGB -14-P compared to Prolia® 
  
  
Significance level  = 0.05 (one -sided)  
CCI
CCI
CCI
CCI
CCI
CCI
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 71 of 124 28Mar2023  • PD endpoint  
Null Hypothesis H 0: Geometric Mean Ratio (GMR, RGB -14-P / Prolia®) not contained within 
[80.00%, 125.00%]  
Alternative Hypothesis H 1: GMR (RGB -14-P / Prolia®) contained within [80.00%, 125.00%]  
Significance level  = 0.05 (two -sided), i.e., 95% (two -sided) CI to be used. 
9.2 Sample Size Determination  
Approximately  434 women with postmenopausal osteoporosis are planne d to be enrolled 1:1 
(217 participants per arm, including 17% drop -out) in the study to have 362  evaluable 
participants to evaluate the primary efficacy endpoint at 90%  power  during the Main Period .  
Participants will be stratified by [CONTACT_775565].  
It is planned that  [ADDRESS_1065255] 180 evaluable participants ; approximately 66 participants will continue on 
the RGB -14-P arm,  where as approximately 132 participants initially assigned to the Prolia® arm 
will be re -randomised 1:1 whereby [CONTACT_3450] 66 participants will continue to receive Prolia® 
and approximately 66 participants will be switched to RGB -14-P. 
Based on a meta -analysis of 3  different studies conducted with denosumab [ 11, 12, 17], sample 
size was calculated from the following parameters:  
• The primary parameter is the %CfB  in lumbar spi[INVESTIGATOR_9210].  
•  
  
• The expected (true) value of the primary parameter in the reference arm is equal  to 5.35.  
• The expected (true) difference between the study arms equal -0.2675 (i.e., 5% of the 
expected reference arm value) ; such a difference between study arms is supposed t o be 
common across study strata . 
• The expected (true) common standard deviation is 3.44.  
 
  
With regards to the PD co -primary endpoint, healthy volunteer data [ 18] was used for the sample 
size calculations due to the lack of information on AU EC sCTX 0-m6 derived f rom the participants  
CCI
CCI
CCI
CCI
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 72 of 124 28Mar2023  population.  The expected variability to the proposed PD endpoint is considered to be 
significantly lower than that of the proposed efficacy endpoint (in study NCT2053753 the 
interCV of AU EC sCTX 0-m6 was approximately 28%).  Therefore,  no formal sample size 
calculation was performed for AU EC sCTX 0-m6. 
Calculating with a dropout  rate of 1/[ADDRESS_1065256] that even if all the 
2 × 217 = 434 participants are evaluable, the power will stay below 95%.  
A subset of  approximately  66 participants from the RGB -14-P arm and approximately 
132 participants from the Prolia® arm (approximately 198 participants in total) will participate in 
the Transition Period , which should ensure to have 60 eval uable participants per arm : 
• Approximately 66 participants who received RGB -14-P in the Main Period will continue 
with RGB -14-P in the Transition Period;  
• Approximately 66 participants who received Prolia® in the Main Period will switch to 
RGB -14-P in the Transition Period ; 
• Approximately 66 participants who received Prolia® in the Main Period will continue with 
Prolia® in the Transition Period.  
Sample size selection  for the Transition Period is not driven b y statistical assumptions for formal 
hypothesis testing but was based on the safety objective for this study period.  The  table below 
(Table  9-1) provides the probability for a sample size (N) of [ADDRESS_1065257] one participant with a given AE  
N = 60  N = 6 6 
5% 95.39%  96.61 % 
10% 99.82%  99.90% 
15% 99.99%  100.00 % 
20% 100.00%  100.00%  
25% 100.00%  100.00%  
AE = adverse event  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 73 of 124 28Mar2023  With 60  participants, events which occur at a frequency of 10% or more will be detected with at 
least 99% probability, while events which occur at a frequency of 5% or more will be detected 
with at least 95% probability.   It is understood that slightly increasing the number of evaluable 
participants in a range from 60 to 66, the probability of detecting events will slightly increase 
accordingly.  
9.3 Populations for Analyses  
For purposes of analysis, the following analysis sets are de fined:  
Table  9-2 Populations for Analysis  
Population   
(Analysis Set)  Description  
ENR  All participants who sign ed the informed consent form  (including screening failures).  
FAS The FAS comprises all participants to whom the IMP  has been randomised . 
PPS The PPS comprises a subset of the FAS. 
A participant will be completely excluded from the PPS in case of protocol deviations which 
can affect interpretability of the primary endpoint analy sis. 
SAF The SAF consists of all participants who received at least one  full or partial  dose of IMP.  
Participants will be analysed according to the IMP they actually receiv ed.  A precise definition 
of “as actually received” will be added in the SAP. 
PDS The PDS consists of all participants in the safety population  with at least one evaluable 
pharmacodynamic parameter (%CfB and AUEC) and do not have any protocol deviations that 
have a relevant impact on sCT X or serum P1NP measurements . 
IAS The IAS consists of all participants in the safety population who have at least one available 
immunogenicity assessment and do not have any protocol deviations that have a relevant 
impact on immunogenicity evaluations . 
AUEC  = area under the effective curve; %CfB  = percentage change from baseline; ENR  = Enrolled Analysis Set; 
FAS = Full Analysis Set;  IAS = Immunogenicity Analysis Set;  IMP = investigational medicinal product; 
P1NP = procollagen type 1N -terminal propeptide;  PDS = Pharmacodynamic Analysis Set; PPS  = Per Protocol 
Analysis Set; SAF  = Safety Analysis Set; SAP  = Statistical Analysis Plan; sCTX  = serum type I collagen 
C-telope ptide  
 
The roles of the  Full Analysis Set (FAS)  and Per Protocol Set (PPS)  will be detailed in 
Section  9.4. 
9.4 Statistical Analyses  
The Statistical Analysis Plan ( SAP) will be developed and finalised prior to Database Lock  and 
unblinding .  Below is a description  of planned statistical analyses.   Further  details are presented 
in the SAP. 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 74 of 124 28Mar2023  9.4.1 General Considerations  
Continuous data will be summarised by [CONTACT_2070] (number, 
mean, median, standard deviation [SD], minimum and maximum ).  Categorical data will be 
summarised by [CONTACT_310184] (frequency and percent).  
Unless otherwise specified, baseline will be taken as the last available assessment prior to 
randomisation .  Repeated and unscheduled assessments will be i ncluded in listing.  Except 
considered as baseline, the repeated and unscheduled assessments will not be included in the 
summaries (if the repeat was necessitated by a technical issue/e.g.,  incorrect sampling 
processing/i.e.,  there is not a result or the r esult is not valid because of the technical issue, the 
repeat value will be considered and included in the summaries).  
Similarity between RGB -14-P and Prolia® will be assessed based on the simultaneous success of 
hypothesis tests for all primary endpoints.   Alpha adjustment is not planned.  
Statistical tests will be two -sided and will be performed at the 5% level of significance, thus 95% 
CIs will be computed, unless otherwise stated.  
9.4.[ADDRESS_1065258] International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH)  E9 (R1) addendum on estimands and sens itivity analysis 
in clinical trials to the guideline on statistical principles for clinical trials  guidance.  From this 
end, efficacy analysis will be defined with terms used for the estimand concept.  
Table  9-3 Summary of the primary and secondary estimands  
Estimands  Primary: “Treatment Policy” 
estimand (TP)  Secondary: “Principal Stratum” 
estimand (PS)  
Clinical Question of 
Interest  Do RGB -14-P and US licensed Prolia® 
have a similar efficacy and a similar 
effec t on BMD at the lumbar spi[INVESTIGATOR_775509]  52 in females with 
postmenopausal osteoporosis regardless 
of the ICEs occurring during the Double -
Blind phase?  Do RGB -14-P and US licensed Prolia® 
have a similar efficacy and a similar effect 
on BMD at the lumbar spi[INVESTIGATOR_624383]  52 in 
females with postmenopausal osteoporosis 
in the Principal Stratum of participant s 
who would not experience any ICEs on 
either treatment arms?  
Variable  Percent increase in BMD from Baseline to Week 52, i.e., %CfB, is the primary study 
endpoint and is defined as:  
%CfB = (Post Baseline – Baseline) / Baseline * 100  
ICE ICE1 : The  first and/or the  second dose of randomised IMP is not administered  
ICE2: The participan ts received other medication alongside the IMP, which affects the 
primary variable  (please refer to Section  6.5.1  [Prohibited Therapy ]) 
ICE Strategy  ICE1: Treatment policy strategy  will be 
applied;  All follow -up is relevant to the Principal stratum casual estimand strategy 
will be used: Only participants  who would 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 75 of 124 28Mar2023  Estimands  Primary: “Treatment Policy” 
estimand (TP)  Secondary: “Principal Stratum” 
estimand (PS)  
clinical question, in line with the ITT -
principle.  
 
ICE2: Composite variable strategy  will 
be applied ; Intercurrent event is 
considered to be  informative about the 
outcome , so that the responses obtained 
after ICE occurrence will be  imput ed 
under the null  hypothesis.  not experience either ICE if exposed to 
either treatment are relevant to the clinical 
question.  
To control the validity of the es timand 
dropout and ICE rates  and reasons will be 
monitored.  
Treatments  Test product: RGB -14-P subcutaneous injection [ADDRESS_1065259]: Prolia® subcutaneous injection [ADDRESS_1065260] and reference arms in change from baseline 
BMD:  
δ = μRGB -14-P -μProlia 
μRGB: BMD mean %CfB in RGB -14-P study arm  
μProlia: BMD mean %CfB in Prolia® study arm  
Analysed  data points  All captured data points in the FAS are 
included to the analysis.  All captured data points in the PPS are 
included to the analysis.  
Main Estimator  For EMA submission:  
δ will be estimated by [CONTACT_775566] (SAS PROC GLM) with the 
following factors:  
• Randomised t reatment  
• Baseline BMD value  
• Previous use of bisphosphonates  
• Geographical region  
• Machine type  
• Machine type * Baseline BMD 
value interaction  
 
Missing data will be assumed to be 
MCAR and will not be imputed (see 
Section  9.4.5 ) δ will be estimated by [CONTACT_775566] (SAS PROC GLM) with the 
following factors:  
• Treatment  
• Baseline BMD value  
• Previous use of bisphosphonates  
• Geographical region  
• Machine type  
• Machine type * Baseline BMD value 
interaction  
 
In the event of missing primary endpoint, 
to help alleviate the concern on the 
uncertainty introduc ed by [CONTACT_775567], the strategy analysis with 
MI will be followed (as described 
Section  9.4.5 ) For US FDA submission:  
δ will be estimated by [CONTACT_775566] (SAS PROC GLM) with the 
following factors:  
• Treatment  
• Baseline BMD value  
• Previous use of bisphosphonates  
• Geographical region  
• Machine type  
• Machine type * Baseline BMD 
value interaction  
 
In the event o f missing primary 
endpoint, to help alleviate the concern on 
the uncertainty introduced by [CONTACT_775568].  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 76 of 124 28Mar2023  Estimands  Primary: “Treatment Policy” 
estimand (TP)  Secondary: “Principal Stratum” 
estimand (PS)  
data with potential impact on the 
integrity of randomisation, the strategy 
analysis with MI will be followed (as 
described in Section  9.4.5 ) 
Sensitivity Estimator  For EMA submission:  
As a sensitivity estimation for the 
primary analysis of the primary 
endpoint, missing data may be imputed 
using MI rules.  Criteria will be specified 
in the SAP, techniques proposed by 
[CONTACT_775569], 2017 will be considered 
[19]. 
In case MCAR assumption appears to be 
questionable due to high amount or 
imbalanced distribution of missing data, 
relevance of the Sensitivity Estimator 
may increase.  
 
For FDA  submission:  
Robustness of the main estimator will be 
assessed by [CONTACT_256653] -dimensional 
tippi[INVESTIGATOR_775510] , includ ing scenarios 
where the difference between imputed 
test and reference values is assumed to  
be beyond the predefined equivalence 
margin.  Details will be provided in t he 
SAP.  Due to the parallel design, robustness of 
the estimator will be assessed by [CONTACT_181458][INVESTIGATOR_47877] [ 20]. 
ANCOVA  = analysis of covariance; BMD  = bone mineral density; %CfB  = percentage change from baseline; 
EMA  = European Medicines Agency; FAS  = Full Analysis Set; FDA  = Food and Drug Administration; 
ICE = intercurrent event; M CAR = missing  completely  at random; MI  = multiple imput ation; MNAR  = missing 
non at random; PPS  = Per Protocol Analysis Set; SAP = Statistical Analysis Plan; US = [LOCATION_002]  
 
Descriptive analysis of the number, proportion, reasons and timing of intercurrent events 
(ICEs ) will be presented.  
[IP_ADDRESS]  Supplementary  (tertiary)  estimand  
The supplementary estimand of BMD %CfB at Week 52 will utilize a hypothetical ICE handling 
strategy as if the ICE did not occur, as a further, sensitive, investigation into whether differences 
in outco mes would emerge if the whole study population were fully compliant with treatment.  
Data points captured after the ICE will be left out from the FAS analysis set.   The same ICEs 
will be applied as for the primary and secondary estimands.  
Primary endpoint will be analysed by [CONTACT_775570] ( MMRM ) with 
the following factors : 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 77 of 124 28Mar2023  • Randomised t reatment  
• Baseline BMD value  
• Previous use of bisphosphonates  
• Geographical region  
• Machine type  
• Machine type * Baseline BMD value interaction  
• Study Week  
• Study Week * Treatment interaction  
Missing data will be assumed to be missing complete ly at random  (MCAR)  and will not be 
imputed.  
9.4.3 Primary pharmacodynamic analysis  
The individual serum concentration of sCTX and P1N P will be listed and summarised by 
[CONTACT_775571].  Percent change from 
baseline (%CfB) will be derived from sCTX concentrations (100 * (postdose sCTX – baseline 
sCTX) / baseline sCTX), listed and summarised in tabular and graphical format.  Percent change 
from baseline (%CfB) of P1NP will be calculated in a similar manner.  
To evaluate the AUEC sCTX 0-m6 (required as primary endpoint for EMA and secondary for 
FDA), the treatment comparison will be ma de using the analysis of variance ( ANOVA ) on 
log-transformed data.  Pharmacodynamic equivalence will be assessed if the 95%  CI of the 
treatment ratio is contained within the acceptance limits of 80% to 125%.  
9.4.4 Additional analyses  
[IP_ADDRESS]  Efficacy  
Below secondary end points will be analysed descriptively:  
• Percent change from Baseline in total hip BMD at Weeks  26, 52 and 78.  
• Percent change from Baseline in lumbar spi[INVESTIGATOR_110085]  26 and 78.  
• Percent change from Baseline in femoral neck BMD at Weeks  26, 52 and 78.  
• Verte bral fragility fracture incidence at Weeks  52 and 78.  
• Non-vertebral fragility fracture incidence at Weeks  52 and 78.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 78 of 124 28Mar2023  [IP_ADDRESS]  Pharmacodynamics  
Below secondary endpoints will be analysed descriptively:  
• Percent change from Baseline in serum P1NP at Weeks  4, 26, 52 an d 78.  
• Percent change from Baseline in sCTX at Weeks  4, 26, 52 and 78.  
[IP_ADDRESS]  Safety  
All safety analyses will be performed on the Safety Analysis Set.  
Safety information will be summarised with descriptive statistics when appropriate.  Tabulations 
will be provided  for categorical data.  
Safety analyses will be conducted “as treated”.  
[IP_ADDRESS].1  Adverse Events  
Assessment of safety will be done by [CONTACT_775572], 
including SAE.  
Reported AE terms will be mapped to current version of Medical Dictionary for Regulatory 
Activities (MedDRA) -preferred terminology.  All reported events will appear in AE listings; 
however, only treatment -emergent adverse events (TEAEs) will be summarised.  A TEAE is an 
AE that starts or increases in severity on or after the first administration of study treatment up to 
the End -of-Study/Early Termination Visit following the last administration of study treatment.  
Safety population data sets will be used for safety analysis:  
• Adverse events will be coded according to MedDRA.  
• The occurrence of A Es or adverse reactions, SAEs or serious adverse reactions and A Es or 
adverse reactions resulting in withdrawal will be summarised and analysed in the form of a 
frequency table (number of cases, number of participant s with cases and incidence).  
• The occurrence of varying severity orders of A Es or adverse reactions, SAEs or serious 
adverse reactions and A Es or adverse reactions resulting in withdrawal will be subject to 
descriptive statistical analysis in the form of a frequency table (number of cases, case and 
incidence) according to system organ class and preferred term.  
• A detailed list of various A Es or adverse reactions, SAEs or serious adverse reactions and 
AEs or adverse reactions resulting in withdrawal will be cr eated.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 79 of 124 28Mar2023  • Listing for  any device incident or device deficiency AE or SAE  will be created, including but 
not limited to seriousness, outcome and action taken . 
[IP_ADDRESS].2  Other Safety Data  
Other safety parameters (e.g., laboratory test values, ECGs, vital signs and injection site 
assessment) will be summarised using descriptive statistics such as mean, standard deviation, 
minimum and maximum values.  
Safety Analysis Set will be used for safet y analysis:  
• Changes in the clinical significance determination of laboratory indicators, ECG, physical 
examinations and local tolerance at each visit after administration and baseline test results 
will be described in the form of shift tables.  
• The laborato ry indices and vital signs examinations will be subject to descriptive statistical 
analysis according to treatment arm and visit as well as changes from baseline.  
• A detailed list of laboratory indices, ECG, vital signs, clinically significant physical 
abno rmalities and local tolerance will be created.  
• Number and intensity of injection site reaction.  
• Fracture assessment  (details on analysis will be further described in the SAP) . 
[IP_ADDRESS]  Immunogenicity  
All immunogenicity results (ADA confirmed positive or negative, ADA titr es and neutralising 
activity) will be listed and summarised by [CONTACT_1570], assay type and sampling point.  The 
incidence of participants who develop binding ADAs and NAbs will be compared by [CONTACT_775573].  More det ails will be provided in the SAP.  
9.4.5 Handling of Missing Data  
In general, if not stated otherwise, missing data will not be imputed.  
Missing BMD baseline values would  lead to impossibility to include the participant in the 
statistical analysis of the primary and secondary estimand , but due to eligibility review 
performed by [CONTACT_1689], the probability of this phenomenon is negligeable . 
Missing data in case of the analysis of the efficacy estimands (see Section  9.4.2 ) will be handled 
as follow:  
• For EMA submission, missing data will be assumed to be MCAR  and will not be imputed.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 80 of 124 28Mar2023  • For FDA submission, two separate one -sided tests, i.e., a test of non-inferiority and a test of 
non-superiority, will be conducted with each alpha  = 0.05 and with missing data imputed 
under the corresponding null using a multiple imputation (MI) method.  Specifically, for the 
first test, i.e., test of non -inferiority, mi ssing values for the RGB -14-P group will be imputed 
under the correspondin g ng ; for the second test, 
i.e., test of non -superiority, missing values for the RGB -14-P group will be imputed under the 
correspondin g .  Overall, RGB -14-P will be claimed 
to be equivalent to Prolia® in the event that both H 0(non -inf test)  and H 0(non-sup test)  are rejected; 
considering the use of MI, all randomized subjects will be included in th e analysis . In 
addition, a sensitivity tippi[INVESTIGATOR_775511], at both week [ADDRESS_1065261] 6  postbaseline available results of which:  
• Results within Week  1, Week  2 and Week  4. 
• At least one available result within Week  8 and Week  12. 
• At least one available result within Week  17 and Week  21 
• Results within Week  26. 
Participants with missing results from two consecutive timepoints will not be eligible for 
analysis.  
Serum CTX concentration below the limit of quantification (BLQ) will be considered as BLQ in 
summary tables and graphically representation, including derivation of AUEC.  
9.4.6 Other Analyses  
[IP_ADDRESS]  Disposition of Participants  
Participants entering and completing the study will be listed and summarised using number and 
percentage.  
Participants excluded from  each analysis sets will be listed including the reason for exclusion.  
Participants disposition will be summarised and will include the following information: number 
of participants randomised and dosed, number and percentage of participants completing the 
study and the number and percentage of participants who were withdrawn (including reasons for 
withdrawal).  Participants disposition will be summarised . 
CCI
CCI
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 81 of 124 28Mar2023  Participants dis continuations will be listed including the date of study exit, duration of treatment 
(i.e., number of IMP doses received) and reason for discontinuation.  A listing of informed 
consent response will also be presented.  
A randomisation listing will be presen ted which includes but is not limited to the following: each 
participant’s randomisation number, the participant’s full enrolment  number, the treatment to 
which the participant has been randomised and the location of the clinical unit.  
[IP_ADDRESS]  Protocol Deviations  
Protocol deviations will be listed by [CONTACT_3445], reasons and timing of the deviation.  Major 
protocol deviations which are considered to impact efficacy analyses will be identified prior to 
unblinding and  may lead to exclusion of participants from  the PPS analysis set . 
[IP_ADDRESS]  Demographics and Baseline Characteristics  
Demographic and anthropometric variables (age, sex, ethnicity, race, height, weight, and BMI) 
will be listed by [CONTACT_3445].  Demographic characteristics (age, sex, ethnicity, and race) a nd 
anthropometric characteristics (height, weight, and BMI) will be summarised descriptively by 
[CONTACT_237781], medians, quartiles minimum and maximum for continuous variable, and 
frequencies and percentages for categorical variables.  The denominator f or percentages will be 
the number of participants in the safety population for each treatment arm or for all participant as 
applicable.  
Medical history data will be listed by [CONTACT_720499], description of the 
disease/procedure, MedDRA system organ class, MedDRA preferred term, start date and stop 
date (or ongoing if applicable).  
[IP_ADDRESS]  Prior and Concomitant Medication  
Prior medications are those that started and stopped prior to the  first dose of IMP.  Concomitant 
medications are those taken after do sing (including medications that started prior to dosing and 
continued after).  
Prior and concomitant medication s will be listed by [CONTACT_775574]: brand name [CONTACT_775610]/INN name , preferred term, the route of adminis tration, 
dose, frequency, start date/time,  stop date/time  and indication.  
Prior and concomitant medication s will be coded according to the World Health Organization 
Drug Dictionary latest version.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 82 of 124 28Mar2023  [IP_ADDRESS]  Investigational Medicinal Product  Administration  
A listing of IMP administration will be created and will include the date , time and site of 
administration.  
9.[ADDRESS_1065262] . 
9.6 Data Monitoring Committee  
Not applicable.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 83 of 124 28Mar2023  10 Supporting Documentation and Operational Considerations  
10.1 Appendix 1: Regulatory , Ethical, and Study Oversight Considerations  
10.1.1  Regulatory  and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
International Ethical Guidelines . 
o Applicable ICH Good Clinical Practice ( GCP ) Guidelines . 
o Applicable laws  and regulations . 
• The protocol, protocol amendments, ICF, IB, and other relevant documents ( e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_78792]/IEC  before the study is initiated.  
• Any amendments to the protocol will require IEC/IRB approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediat e 
hazard to study participants.  
• The Investigator will be responsible for the following:  
o Providing wri tten summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/EC . 
o Notifying the IRB/IEC of SAE or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures . 
o Overall conduct of the study at the site and adherence to requirements of 21 Code of 
Federal Regulation ( CFR ), ICH  GCP  guidelines, the IRB/IEC, European regulation  
536/2014 for clinical studies (if applicable), and all other applicable l ocal regulations . 
10.1.2  Financial Disclosure  
Investigators and sub -Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities.   
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year  after completion of the study.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 84 of 124 28Mar2023  10.1.3  Informed Consent Process  
The Investigator or his/her representative will explain the nature of the study to the participant or 
her legally authorised representative and answer all  questions regarding the study.  
Participants must be informed that their participation is voluntary.  Participants  or their legally 
authorised representative  will be required to sign a statement of informed consent that meets the 
requirements of [ADDRESS_1065263] requirements, where applicable, a nd the IRB/IEC or study centre . 
The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date  and time  the written consent was obtained.  
The authorised person obtaining the informed consent must also sign the ICF.  
Participants must be re -consented to the most recent version of the ICF(s) during th eir 
participatio n in the study.  
A copy of the ICF(s) must be provided to the participant or the participant’s l egally authorised 
representative.  
Participants who are rescreened are required to sign a new ICF.  
If a protocol amendment is required, the ICF may need to be rev ised to reflect the changes to the 
protocol.   If the ICF is revised, it must be reviewed and approved by [CONTACT_69869]/ IRB 
and signed by [CONTACT_775575].  
10.1.4  Data Protec tion 
Parexel and the Sponsor will take appropriate measures to ensure the processing of personal data 
and the f ree movement of such data are handled according to the EU General Data Protection 
Regulation 2016/679.  
All clinical study findings and documents will be regarded as confidential.  Study documents 
(protocols, I Bs and other material) will be stored appropriately to ensure their confidentiality.  
The Investigator a nd members of his/her research team (including the IEC) must not disclose 
such information without prior written approval from the Sponsor, except to the extent necessary 
to obtain informed consent from participants who wish to participate in the study or to comply 
with regulatory requirements.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 85 of 124 28Mar2023  Participants will be assigned unique identifier s (enrolment  and randomisation number)  by 
[CONTACT_147029] .  Any participant records or datasets that are transferred to the Sponsor will contain the 
identifier only; participant  names or any information which would make the participant 
identi fiable will not be transferred.  
The participant must be informed that her personal study -related data will be used by [CONTACT_19490].  The level of d isclosure must also b e 
explained to the participant  who will be required to give consent for their data to be used as 
described in the informed consent . 
The participant must be informed that her medical records may be examined by [CONTACT_775576], by [CONTACT_99473]/IEC members, and by [CONTACT_90742].  
10.1.5  Dissemination of Clinical Study Data  
All clinical study findings and documents will be regarded as confidential.  Study documents 
(protocols, I Bs and other material) will be stored appropriately to ensure their confidentiality.  
The Investigator and members of his/her research team (including the IEC) must not disclose 
such information without prior wri tten approval from the Sponsor, except to the extent necessary 
to obtain informed consent from participants who wish to participate in the study or to comply 
with regulatory requirements.  
The ano nymity of participants must be maintained.  Participants will  be specified on study 
documents by [CONTACT_775577] /randomisation  number, initial or birth year, not by [CONTACT_2300].  
Documents that identify th e participant (e.g., the signed ICF) must be maintained in confidence 
by [CONTACT_737].  
The c linical study may be co nsidered for publication in the scientific literature irrespective of 
whether the results of the clinical study are positive or negative ( Appendix 1  [Section  10.1.9 ]).  
In addition, the results of clinical studies will be provided on the publicly funded websites such 
as www.ClinicalTrials .gov, www. clinicaltrialsre gister .eu, in line with the applicable regulations.  
10.1.6  Data Quality Assurance  
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 86 of 124 28Mar2023  • All participant data relating to the study will be recorded on  eCRF unless transmitted to the 
Sponsor or designee electronically ( e.g., laboratory data).  The Investigator is responsible for 
verifying that data entries are accurate and correct by [CONTACT_775578] t he 
eCRF.  
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency inspections and provide direct a ccess to source data documents.  
• Monitoring details describing strategies  (e.g., risk-based initiatives in operations and quality  
such as Risk Management and Mitigation Strategies  and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
non-compliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provide d in the Monitoring Plan . 
• Parexel  is responsible for the data management of this study including quality checking of 
the data.  
• The Sponsor assumes accountability for actions delegated  to other individuals ( e.g., CROs ). 
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_18029], complete, and verifiable from 
source documents; that the safety and rights of participants are being protecte d; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all appl icable regulatory  requirements.  
• Records and documents, including signed ICF, pertaining to the conduct of this study must 
be retained by [CONTACT_13177] 15 years after study completion unless local regulations 
or institutional policies require a longer retention period.  No records may be destroyed 
during the retention period without the written approval of th e Sponsor.  No records may be 
transferred to another location or party without written notification to the Sponsor.  
• All data generated by [CONTACT_775579].  Data from external sources (such as laboratory data) will be imported into the 
database.   Once the eCRF clinical data have been submitted to the central server at the 
independent data centre , corrections to the data fields will be captured in an audit trail.  The 
reason for change, the name [CONTACT_27501], together with the time 
and date will be logged to provide an audit trail.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 87 of 124 28Mar2023  • If additional corrections are needed, the responsible monitor or data manager will raise a 
query in the EDC application.  The appropriate staff at the study site will answer queries sent 
to the Investigator.  The name [CONTACT_95904], and time and date 
stamp will be captured to provide an audit trail.  Once all source data verification is complete 
and all queries are closed, the Clinical Research Associate will freeze the eCRF page.  
• The specific procedures to be used for data entry and query resolution using the EDC 
system/eCRF will be provided to study sites in a training manual.   In addition, site pe rsonnel 
will receive training on the EDC system/eCRF.  
• After database lock, the Investigator will receive copi[INVESTIGATOR_775512].  The data will also be extracted and provided to the Sponsor.  
• Monitoring vi sits at site might be limited to a minimum required as deemed appropriate 
during the COVID -19 pandemic.  
10.1.7  Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity  of the data collected.  Source documents  (including X -ray and DXA  films/images)  are 
filed at the Investigator’s site.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the 
source documents or the discrepancies mus t be explained.  The Investigator may need to request 
previous medical records or transfer records, depending on the study.  Also, current medical 
records must be available.  
10.1.8  Study and Site Start and Closure  
The study start date is the date on which the cli nical study will be open for recruitment of 
participants.  
The study may be halted for evaluation of possible risk to participants, prior to decision as to 
whether to terminate the study if any of the following criteria are met:  
• The occurrence of an SAE, if  considered to be at least possibly related to the IMP.  
• The occurrence of [ADDRESS_1065264] been 
collected and a study  site closure visit has been performed.  
The Investigator may initiate  study termination or  study  site closure at any time  after discussion 
with the Sponsor , provided there is reasonable cause and sufficient notice is  given in advance of 
the intended termination.   However, dosing  of a given participant  may be suspended immediately 
on safety grounds pending discussion between the Investigator and Sponsor.  
Reasons for the early closure of a study site by [CONTACT_9330]:  
• Significant violation of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor ’s procedures, or GCP guidelines . 
Reasons for early termination of the study by [CONTACT_108129]:  
• Occurrence of serious or severe adverse event(s) considered to be related to the IMP.  
• New information regarding the safety of the IMP that indicates a change in the risk/benefit 
profile f or the compound, such that the risk/benefit is no longer acceptable for participants 
participating in the study.  
• Discontinuation of further IMP development . 
• New data become available regarding COVID -19, which raises concern for the safe s tudy 
conduct so th at continuation would pose potential risks to the participants or study site staff.  
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory  authorities and any CROs  used in the study of the 
reason for termination or suspension, as specified by [CONTACT_211721].  
The Investigator shall promptly inform the participant  and should assure appropriate participant  
therapy and/or follow -up. 
10.1.[ADDRESS_1065265] any article utili sing an y data 
generated by [CONTACT_775580].  The Sponsor will also not use Parexel’s name [CONTACT_775611].  The Sponsor wil l comply with the requirements 
for publication of study results.  
• The results of this study may be published or presented at scientific meetings.   If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before 
submission.  This allows the Sponsor to protect proprietary information and to provide 
comments.  
• In accordance with standard editorial and ethical practice, the Sponsor will ge nerally support 
publication of multicentre studies only in their entirety and not as individual site dat a. 
• Authorship will be determined by [CONTACT_175067].  
10.1.10  Protoc ol Approval and Amendment  
Before the start of the study, the study protocol and/or other relevant documents will be approved 
by [CONTACT_6179]/IRB/Competent Authorities, in accordance with local legal  requirements.  The 
Sponsor must ensure that all ethical and legal requirements have been met before the first 
participant  is enrolled in the study.  
This protocol is to be followed exactly.  To alter the protocol, amendments must be written, 
receive approval from the appropriate personnel, and receive IRB/IEC/Competen t Authority 
approval prior to implementation (if appropriate).  
Administrative changes (not affecting the participant  benefit/risk ratio) may be made without the 
need for a formal amendment.  All amendments will be distributed to all protocol recipi[INVESTIGATOR_840], wi th 
appropriate instructions.  
10.1.[ADDRESS_1065266] s being tested or by 
[CONTACT_384304].  
[IP_ADDRESS]  Access to Source Data  
During the study, a monitor will make site visits to review protocol compliance, compare 
EDC/eCRF entries and individual participant ’s medical records, assess drug a ccountability, and 
ensure that the study is being conducted according to pertinent regulatory  requirements.  
Electronic data capture /eCRF entries will be verified with source documentation.   The review of 
medical records will be performed in a manner to en sure that participant confidentiality is 
maintained.  
Checking of the EDC/eCRF entries for completeness and clarity, and cross -checking with source 
documents, will be required to monitor the progress of the study.  Moreover, regulatory  
authorities of certai n countries, IRBs, IECs, and/or the Sponsor’s Clinical Quality Assurance 
Group may wish to carry out such source data checks and/or on -site audit s/inspections.  Direct 
access to source data will be required for these inspections and audits; they will be ca rried out 
giving due consideration to data protection and medical confidentiality.  The Investigator assures 
Parexel  and the Sponsor of the necessary support at all times.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 91 of 124 28Mar2023  10.2 Appendix  2: Clinical Laboratory Tests  
• The tests detailed in Table  10-1 will be performed by [CONTACT_775581] . 
According to local guideline or practice an d upon the discretion of the Investigator, (preferably 
albumin -adjusted ) serum calcium level may be measured prior to the administration of IMP or at 
any timepoint at local laboratory.  The results, as well as the lower and upper limit of normal 
value of (albumin -adjusted ) serum calcium at the local laboratory should be docume nted in the 
eCRF.  Clinically significant  abnormal  values should be reported as an AE.  However, for clinical 
study report purposes the values from the central laboratory will be considered.  
Local laboratory tests can be done  in the event that the central laboratory results are not available 
in time for IMP administration  and the Investigator considers it as necessary for the safe 
administration o f the IMP or for any other safety reason .  If a local sample is required, it is 
important that the sample for ce ntral analysis is obtained at the same time.   Additionally, if the 
local laboratory results are used to make either a n IMP decision or response evaluation, the 
results  as well as the normal values  must be entered into the eCRF.  
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section s 5.1and 5.2 of the protocol.  
• Additional tests may be performed at any time during the study as determined necessary by 
[CONTACT_9332] . 
Table  10-1 Protocol -Required Laboratory Assessments  
Laboratory Assessments  Parameters  
Haematology  Platelet Count  
RBC Count with MCV, MCH and 
MCHC  
Haemoglobin  
Haematocrit  WBC count, Total with Differential (in 
absolutes and percentages):  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Large Unstained cells  (if applicable)  
Clinical Chemistry  BUN  
Creatinine  
Uric acid  
Creatine kinase  
eGFR using MDRD form ula 
Glucose  
Potassium  
Sodium  
Calcium (Total)  
Albumin adjusted calcium  AST  
ALT  
Alkaline phosphatase  
GGT  
Total and direct bilirubin  
Total Protein  
Albumin  
Total cholesterol  
Triglyceride  
LDH  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 92 of 124 28Mar2023  Laboratory Assessments  Parameters  
Magnesium  
Phosphorus  CRP  (high -sensitivity)  
Lipase  
Routine Urinalysis  Specific gravity  
pH, Glucose , Protein, Blood, Ketones, Bilirubin, Urobilinogen, Nitrite, Leukocyte 
esterase  
Microscopic analysis will be performed if Blood, Protein, Leukocyte esterase o r 
Nitrite is positive  or if deemed  necessary by [CONTACT_737].  
Microscopic  urine sediment  examination (if required ) 
Hormonal Tests  FSH ( Screening only ) 
TSH  (Screening only)  
Vitamin D (25 -hydroxyvitamin D)  (Screening and day of IMP administration ) 
PTH  (Screening only)  
Serology  Tests  Serology (HIV-1 and HIV -2 antibod ies, anti-HBcAg total, HBsAg , anti-HBsAg  
and anti-HCV  IgG and IgM ) 
Bone Turnover Markers 
(PD marker)  sCTX  
Serum P1NP  
Immunogenicity Tests  Binding ADAs and NAbs  
Serum Drug 
Concentration  Denosumab concentration  
Note : All study -required laboratory assessments will be performed by a central 
laboratory, with the exception of:  
• Dipstick u rinalysis at all visits.  
• Immunogenicity and serum drug concentration samples (assessed by 
[CONTACT_2728]).  
ADAs  = anti-drug antibodies; ALT  = alanine aminotransferase;  AST  = aspartate aminotransferase; BUN  = blood 
urea nitrogen;  CRP  = c-reactive protein;  eGFR  = estimate glomerular filtration rate;  FSH = follicle -stimulating 
hormone;  GGT  = gamma -glutamyl transferase;  HBcAg = hepat itis B core antigen; HBsAg  = hepatitis  B surface 
antigen;  HCV  = hepatitis C virus;  IgG = immunoglobulin G; IgM  = immunoglobulin M;  IMP = investigational 
medicinal product;  LDH  = lactate dehydrogenase  MCH  = mean co rpuscular h aemoglobin;  MCHC  = mean 
corpuscular haemoglobin concentration;  MCV  = mean corpuscular volume;  MDRD  = modification of diet in 
renal disease;  NAbs  = neutralising antibodies;  P1NP  = procollagen type 1 N -terminal propeptide;  
PD = pharmacody namic(s); PTH  = parathyroid hormone; RBC  = red blood cell count;  sCTX = serum type I 
collagen C -telopeptide;  TSH  = thyroid -stimulating hormone;  WBC  = white blood  cell count  
 
Investigators must document their review of each laboratory safety report.  
Laboratory/analyte results that could unblind the study will not be reported to investigational  
sites or other blinded personnel until the study has been unblinded.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 93 of 124 28Mar2023  10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
The definitions and procedures detailed in this document related to medical device events  are in 
accordance with ISO  [ZIP_CODE] [ 25]. 
10.3.1  Definition of A dverse Event 
Adverse Event (or Adverse Experience)  Definition  
• An AE  or adverse experience  is any untoward medical occurrence in a patient or 
clinical investigation  participant  administered a pharmaceutical product  and which 
does not necessarily have to have a causal relationship with this treatment . 
• NOTE: An AE can therefore be any unfavo urable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use 
of a medicinal product , whether or not considered related to the medicinal product . 
 
Events Meeting  the A dverse Event Definition  
• Any abnormal laboratory test results , see Section  8.4.4  (haematology, clinical 
chemistry, or urinalysis) or other safety assessments ( e.g., ECG, radiological scans, 
vital signs measurements , local tolerance , fracture assessment ), including those th at 
worsen from baseline, considered clinically significant in the medical and scientific 
judgement of the Investigator ( e.g., not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including eith er an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after IMP administration even though it may 
have been present before the start of the study.  
• Signs, symptoms or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms or the clinical sequelae of a suspected overdose of either IMP or a 
concomitant medication.  Overdose per se will not be reported as an AE/SAE unless it 
is an intentional overdose taken with possible suicidal/self -harming intent.  Such 
overdoses should be reported regardless of sequelae.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 94 of 124 28Mar2023  • “Lack of efficacy ” or “failure of expected pharmacological a ction ” per se will not be 
reported as an AE or SAE.  Such instances will be captured in the efficacy 
assessments.  However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE or SAE if they fulfi l the defin ition of an AE or 
SAE.  
 
Events NOT  Meeting the A dverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_775582]’s condition.  
• The disease/disorder being studied or expected progression, signs or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.   However, fra gility fractures will be considered as AEs.  
• Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
 
 Definition : Adverse Event Caused by  [CONTACT_775583]/Deficiency  
• An AE caused by [CONTACT_775556]/deficiency  is any AE related to the use of a 
combination product  [23, 24] or medical device.  A dverse events caused by [CONTACT_775584]/deficiency  include AEs resulting fro m insufficient or inadequate instructions 
for use, AEs resulting from any malfunction of the device, or AEs resulting from use 
error or from intentional misuse of the device.   Therefore, an AE caused by [CONTACT_775584]/deficiency  could be any untoward medi cal occurrence, unintended disease or 
injury, or untoward clinical signs (including an abnormal laboratory finding) in 
participants, whether or not related to the investigational medical device.  
 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065267] medical occurrence that, at any 
dose:  
a. Results in death  
b. Is life -threatening  
The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the 
participant was at risk of death at the time of the event.  It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
c. Requires inp atient hospi[INVESTIGATOR_15574]  
• In general, hospi[INVESTIGATOR_775513] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or interven tion that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospi[INVESTIGATOR_31780].  If a 
complication prolongs hospi[INVESTIGATOR_222663], the event is 
serious.  Wh en in doubt as to whether “hospi[INVESTIGATOR_11956]” occurred or was necessary, the 
AE should be considered serious.  
• Hospi[INVESTIGATOR_775514] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
d. Results in persist ent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent 
everyday  life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 96 of 124 28Mar2023  f. Other situations  
• Medical or scientific judgement should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as importa nt medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_775515].  Th ese events should usually 
be considered serious.  
• Examples of such events include invasive or malignant cancers, intensive intervention 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_343639], or development of drug dependency 
or drug abuse.  
• Emergency room visits that do not result in admission to the hospi[INVESTIGATOR_775516] 
(e.g.,  life-threatening experience, important med ical event).  
• Symptomatic overdose if it results in any of the serious outcomes listed above.  
• Suicide attempt – with or without any sign or symptom – when considered to be 
threat of life.  
• Neoplasia (benign or malignant) if judged to be medically serious.  
• NOTE: In lethal cases, the cause of death shall be considered as an SAE and the death 
itself shall be considered as SAE outcome.  Death may be indicated as an SAE if the 
cause has not been established.  The Investigator should assess the event sci entifically 
and medically and decide whether the event should be immediately reported to 
Parexel.  
Definition : Serious Adverse Events Caused by [CONTACT_775583]/Deficiency  
• A serious adverse event  caused by [CONTACT_775556]/deficiency  is defined as an adverse 
event that led to any of the following:  
o Death . 
o Serious  deterioration in the hea lth of the subject  that resulted in any of the 
following:  
▪ life-threatening illness or injury , 
▪ permanent impairment of a body structure or a body function,  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 97 of 124 28Mar2023  ▪ hospi[INVESTIGATOR_775517],  
▪ medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function,  
▪ chronic disease.  
o Foetal distress, foetal death or a congenital physical or mental impairment or birth 
defect.  
Definition : Unanticipated Serious Adverse  Event  Caused by [CONTACT_775585]/Deficiency  
• An unanticipated serious adverse event  caused by [CONTACT_775556]/deficiency  is a 
serious adverse event  caused by [CONTACT_775556]/deficiency  which by [CONTACT_5942], 
incidence, severity  or outcome has not been identified in the current version of the 
risk analysis report.  
 
10.3.3  Definition of Medical Device Events  
Definition : Medical Device Events  
A medical device event could be a device incident (in the case of Prolia®) or a device 
deficiency (in the case of RGB -14-P). 
• A device incident is any malfunction or deterioration in the characteristics or 
performance of a device made available on the marke t, including use error due to 
ergonomic features, as well as any inadequacy in the information supplied by [CONTACT_775586] -effects . 
• A device deficiency is any inadequacy in the identity, quality, durability, reliability, 
safety or performance of an investigational device, including malfunction, use errors 
or ina dequacy in information supplied by [CONTACT_3455].  
 
10.3.4  Recording and Follow -up of Adverse Event and Serious Adverse Event  
Adverse Event and S erious Adverse Event Recording  
• When an AE/SAE occurs, it is the responsibility of the  Investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 98 of 124 28Mar2023  • The Investigator will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to Parexel  in lieu of completion of the AE/SAE eCRF page.  
• There may be instances when copi[INVESTIGATOR_775518] .  In this case, all participant identifiers, with the exception of 
the participant number, will be blinded on the copi[INVESTIGATOR_436228] . 
• The I nvestigator will attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical  information.   In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.   If a diagnosis is 
unknown, then the Investigator should report in detail signs and symptoms.  
• For AEs caused by [CONTACT_775558]/de ficiency, it is very important that the 
Investigator describes any corrective or remedial actions taken to prevent recurrence 
of the incident.  
 
Assessment of Intensity  
The I nvestigator will make an assessment of intensity for each AE /SAE reported during 
the study and assign it to one of the following categories : 
• Grade  1/Mild: The AE was an annoyance to the participant but did not further hinder 
baseline functioning; the AE may have been intermittent or continuous . 
• Grade  2/Moderate: The AE caused the participant to experience some discomfort or 
some interference with normal activities but was not hazardous to health; prescription 
drug therapy may have been employed to treat the AE.  
• Grade  3/Severe: The AE caused the participant to experie nce severe discomfort or 
severely limited or prevented normal activities and represented a definite hazard to 
health; prescription drug therapy and/or hospi[INVESTIGATOR_775519] y have been employed to 
treat the AE . 
• Grade  4/Life-threatening: The participant was at immediate risk of death form the 
event as it occurred . 
• Grade  5/Death: The participant died due to the event . 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 99 of 124 28Mar2023  An event is defined as ‘serious’ when it meets at least one of the predefined outcomes as 
described in the definition of an SAE,  NOT when it is rated as severe.   If AE severity or 
seriousness changed during its development, it should be recorded as a separate event.  
Please see Table  8-1 for the assessment of intensity of injection site reactions.  
 
Assessment of Causality  
• The I nvestigator is obligated to assess the relationship between IMP and each 
occurrence of each AE/SAE.  
• A “reasonable possibility ” of a relationship conveys that there are facts, evidence 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
• The I nvestigator will use clinical judg ement to determine the relationship.  
• Alternative causes, suc h as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to IMP administration will be 
considered and investigated.  
• The I nvestigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.  
• For each AE/SAE, the I nvestigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in whi ch an SAE has occurred,  and the I nvestigator has 
minimal information to include in the initial report to Parexel .  However, it is very 
important that the I nvestigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to Parexe l. 
• The Investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory  
reporting  requirements.  
Causal relationship should be assessed by [CONTACT_16134]: “Is there a 
reasonable possibility the IMP caused the event?” . 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 100 of 124 28Mar2023  • Yes: There is a possible or probable relationship (i.e., there is a reasonable or strong 
temporal rela tionship, and the events are likely to be at tributable to other drugs, 
underlying disease or other factors) . 
• No: The relationship is unlikely or non-existent (i.e., there is no strong temporal 
relationship and/or the use of other drugs, underlying diseases, or other factors 
provide plausible explanations for the event), or the participant did not take the 
investigational product . 
 
Follow -up of A dverse  Event and Serious Adverse Event (Caused by [CONTACT_775585]/Deficiency or Not)  
• The I nvestigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_171622]/or causality of the AE /SAE  (caused by [CONTACT_775587]/deficiency or not)  as fully as possible.  This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with 
other health care professionals.  
• If a participant dies during partic ipation in the study or during a recognised follow -up 
period, the I nvestigator will provide Parexel  with a copy of any post -mortem findings 
including histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• The I nvestig ator will submit any updated SAE data  on Follow -up SAE Report Form  
to Parexel  immediately  (but no later than 24 hours ) of receipt of the information.  
All A Es shall be followed up by [CONTACT_775588] -up 
assessment, whichever comes first.  Independently form the time of the next visit in case 
of AE the participant can revisit the Investigator.   If, during follow -up, any non -serious 
AE worsen and eventually meets the criteria for an SAE, that AE should be recorded as a  
new SAE.  Data privacy rules should be adhered to.  
To fully understand the nature of any SAE, it is important to obtain follow -up 
information.  Follow -up reports must reported promptly within 24  hours or receipt.  
Whenever possible, relevant medical recor ds such as discharge summaries, autopsy 
reports, medical consul tations , and the like should be obtained.  These records should be 
reviewed in detail, and the Investigator should comment on any event, laboratory 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 101 of 124 28Mar2023  abnormality, or an y other finding, noting whe ther it should be considered a serious or 
non-serious AE, or whether it should be considered as part of the participant’s history.  
In addition, all events or other findings determined to be SAEs should be identified on the 
follow -up SAE Report Form and the  Investigator should assess whether it is related or 
not related to IMP.  All SAEs are to be followed by [CONTACT_775589].  
It is the responsibility of the Investigator to report all relevant new information  using the 
same procedures and timelines as those for the initial report.   Serious adverse events 
occurring after the end of the study should be reported to the Sponsor/Parexel by [CONTACT_775590] a causal relationship w ith the IMP.  
For instruction on follow -up of medical device related events see Section  6.1.2 . 
 
Action Taken to an Adverse Event  
The Investigator will describe the action taken in the participant’s source documentation 
and in the appropriate field of the eCRF.  Action take to the AE will be documented as 
follows:  
• None.  
• Medication . 
• Intervention . 
• Medication and intervention . 
 
Assessment of Outcome of Adverse Events  
Outcome of an AE will be defined as:  
• Recovered without sequelae.  
• Recovered with sequelae . 
• Not recovered (AE continuing) . 
• Recovering.  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 102 of 124 28Mar2023  • Death.  
• Unknown.  
 
10.3.5  Reporting of S erious Adverse Events  
Serious Adverse Event Reporting to Parexel via Electronic Data Collection Tool  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available . 
• The Investigator shall report any SAEs  and pregnancy cases  immediately (within 
24 hours of the Investigator’s awareness ) to Parexel .  The Investigator is obliged to 
complete a separate SAE Report Form  and Pregnancy Report Fo rm in addition to the 
information in the eCRF.  
• In particular, if the SAE is fatal or life -threatening, Parexel must be notified 
immediately, irrespective of the extend of available AE information.  
• Parexel will then follow expedited reporting procedures  according to local and 
international regulations as appropriate.  
• The Investigator is obligated to pursue a nd provide information to Parexel on all 
SAEs in accordance with the timeframes and reporting specified above.  
• In addition, the Investigator may be requested by [CONTACT_775591] -up information  in an expedited fashion.  In the case of a participants ’ death, a 
summary of available autopsy findings must be submitted as soon as possible to 
Parexel.  
• The immediate report shall be followed by [CONTACT_197133] .  The immediate 
and follow -up repo rts shall identify participants by [CONTACT_775592].  For reported deaths, the Investigator shall supply the Sponsor and the local 
IECs  with an additional information requested.  
• For every AE, the Investigator should:  
o Provide a des cription (Investigator’s verbatim term describing the event).  
o Provide dates of onset and resolution.  
o Assess the severity.  
o Provide the relationship to IMP.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 103 of 124 28Mar2023  o Provide the outcome.  
o Provide action taken regarding IMP.  
o Advise if other action (treatment, non -drug therapy) is required.  
o Determination of “seriousness”.  
• Date and time of onset, outcome, date and time of off set and interventions,  if 
applicable in case of each AE should be recorded.  
• When calling Parexel’s designated agent to report an SAE, state that you are reporting 
an SAE and give the Investigator’s name, your name, the telephone number where 
you can be reached, and the protocol number and title.  Parexel’s designated agent 
will then inform the Sponsor of the receipt of a n ew SAE.  
• The Investigator and Parexel (or Parexel’s designated agent) will review each SAE 
report and Parexel will evaluate the seriousness and the causal relationship of the 
event to IMP.  In addition, Parexel (or Parexel’s designated agent) will evaluate the 
expectedness according to the reference document (IB, SmPC or USP I).  Based on 
the Investigator and Parexel’s assessment of the event, a decision will be made 
concerning the need for further action.  
• The Sponsor  (Parexel on behalf of the Sponsor)  has th e legal responsibility to  report, 
without delay to all Member States in which the clinical study is being conducted, 
including : 
o any SAE that has a causal relationship with the investigational device, the 
comparator or the investigation procedure or where such causal relationship is 
reasonably possible,  
o any device event  that might have led to a serious adverse event, if appropriate 
action had not been taken, intervention had not occurred, or circumstances had 
been less fortunate , 
o any new findings in relation to any event referred to in the above -mentioned bullet 
points.  
• On behalf of the Sponsor, after Sponsor’s approval, the Parexel Pharmacovigilance 
team shall report any medical device incident or deficiency that qualifies for a 
reportable medical device event according to the abovementioned criteria.  The 
Parexel Pharmacovigilance team shall provide the Sponsor with local regulatory  
reporting requirement related to medical devices.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 104 of 124 28Mar2023  • After the study is completed, the electronic data collection tool will be taken off -line 
to prevent the entry of new data or changes to existing data.  
• The contact [CONTACT_775593]. 
• If the site receives a report  of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information to the Sponsor’s Clinical 
Safety Unit by [CONTACT_756], fa x or email.  The contact [CONTACT_775594]:  
  
  
  
Phone:   
Fax:   
Email:  :   
• Further details on SAE /S[LOCATION_003]R  reporting , including notification of Sponsor by 
[CONTACT_775595]/S[LOCATION_003]R events  can be found in the  SAE processing procedure and 
Global Safety reporting plan.  
Serious Adverse  Event  Caused by [CONTACT_775583]/Deficiency  Reporting to Parexel  
• NOTE: There are additional reporting obligations for medical device 
incidents/ deficiencies that are potentially related to SAEs that must fulfil  the local 
responsibility to notify appropriate regulatory authorities and other entities about 
certain safety information relating to medical devices being used in clinical studies.  
• Any medical device incidents/ deficiencies  that is associated with an SAE  must be 
reported to Parexel  immediately  (but no later than  24 hours ) after the determin ation  
that the event meets the definition of a medical device incident/ deficienc y associated 
with an SAE  as it is described in the Addendum to Investigator Manual and the 
Product Complaint Procedure . 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 105 of 124 28Mar2023  • The Investigator and Parexel (or Parexel’s designated agent)  shall review all device 
incident s/deficiencies and determine and document in  writing whether they could 
have led to an SAE.   The Investigator will remain blinded.   These shall be reported to 
the regulatory authorities and IRBs/IECs as required by [CONTACT_2091].  
• The Sponsor is responsible for the final investigat ion of all device 
incidents/deficiencies.  
• The contact [CONTACT_775596] 
, the contact [CONTACT_775597]. 
 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R s) 
Any AE that is serious, associated with the use of the IMP, and unexpected (S[LOCATION_003]R) has 
additional reporting requirements, as described below.  
• If the S[LOCATION_003]R is fatal or life -threatening, associated with IMP, and unexpected, 
regulatory authorities and IECs will be notified  by [CONTACT_775598].  Additional follow -up (cause of death, autopsy report 
and hospi[INVESTIGATOR_27450]) information should be reported within an additional 8 days 
(15 days total).  
• If the S[LOCATION_003]R is not fatal or life -threatening but is otherwise serious, associated with 
IMP, and unexpected, regulatory authorities and IECs will be notified within 
15 calendar days after Parexel  learns of the event.  
Parexel  shall inform  the Investigators in the clinical study about the occurrence of 
S[LOCATION_003]Rs.  All relevant follow -up infor mation concerning S[LOCATION_003]Rs should be reported by 
[CONTACT_775599] a maximum 
of 15  calendar days after Parexel learns of the event .  Parexel on behalf of the Sponsor  
after Sponsor’s approval  will al so provide annual safety updates to the regulatory 
authorities and IECs responsible for the study.  These updates will include information on 
S[LOCATION_003]Rs and other relevant safety findings.  
 
[COMPANY_003]
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 106 of 124 28Mar2023  The minimum information required for an initial report is:  
• An identifiable Reporter.  
• One single identifiable participant.  
• At least one suspect adverse reaction.  
• At least one suspect medicinal product.  
However, as far as possible all points on the SAE form should be covered in the initial report, or 
the completed SAE form itself must be faxed to the Parexel Safety Contact.  The original SAE 
form must then be sent by [CONTACT_775600].  I n addition, the event must be 
document in the eCRF.  
In case the Parexel Safety Contact [CONTACT_775601] (e.g., out of normal working hours or at 
weekend), an automated reporting service is available.  The required information should be faxed 
and a messa ge should be left on the voicemail service (for phone/fax numbers see the numbers in 
the Section  10.3.5 ). 
After receipt of the initial report, the safety centre will review the information and, if necessary, 
contact [CONTACT_737], to obtain further information for assessment of the event.  Parexel will 
be responsible for all information processing and reporting according to local legal requirements.  
Details of the r eporting procedures are determined in the Safety Management Plan.  
 
 

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 107 of 124 28Mar2023  10.4 Appendix 4: Coronavirus  Disease  2019  (COVID -19) Related 
Considerations  
Background to Coronavirus Disease 2019  (COVID -19) 
There is currently an outbreak of COVID -[ADDRESS_1065268] participant s, 
site staff and society as a w hole.  
Both EMA [ 21] and FDA [ 22] as well as national health authorities in Europe have issued new 
guidelines that aim to provide recommendations for actions for conduct of clinical studies of 
medical products during COVID -[ADDRESS_1065269] restrictions will be applied and explained to participant s 
while staying at the study site.  Where physical distancing is not possible study participants will 
be asked to use surgical face masks and/or gloves if deemed appropriate by [CONTACT_775602].  

Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 108 of 124 28Mar2023  10.5 Appendix 5: Abbreviations and Trademarks  
ACTH  adrenocorticotropic hormone  
ADA anti-drug antibody  
AE adverse event  
ALT alanine aminotransferase  
ANCOV A  analysis of covariance  
ANOV A  analysis of variance  
AP activator protein  
AST  aspartate aminotransferase  
AUEC  area under the effective curve  
AUEC sCTX 0-m6 area under the effective curve after the first dose until Day  183 of %CfB  in 
serum type I collagen C -telopeptide  
BLQ  below the limit of quantification  
BMD  bone mineral density  
BMI  body mass index  
%CfB  percent change from baseline  
CFR  Code of Federal Regulations  
CI confidence interval  
COVID -[ADDRESS_1065270] research organisation  
DXA  dual energy X -ray absorptiometry  
DNA  deoxyribonucleic acid  
ECG  electrocardiogram  
eCRF  electronic case report form(s)  
EDC  electronic data capture  
eGFR  estimated glomerular filtration rate  
EMA  European Medicines Agency  
EU European Union  
FAS full analysis set  
FcRn  neonatal Fc receptor  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GMR  Geometric Mean Ratio  
GnRH  gonadotropin -releasing hormone  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 109 of 124 28Mar2023  HBcAg  hepatitis B core antigen  
HBsAg  hepatitis B surface antigen  
IB Investigator’s Brochure  
ICE intercurrent event  
ICF informed consent form  
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
IgG immunoglobulin G  
IMP investigational medicinal product  
INN international non -proprietary names  
IRB Institutional R eview Board  
IRT interactive response technology  
MAPKs  mitogen activated protein kinases  
MCAR  missing completely at random  
M-CSF macrophage -colony stimulating factor  
MDRD  modification of diet in renal disease  
MedDRA  Medical Dictionary for Regulatory Activities  
MI multiple imputation  
MMRM  mixed model for repeated measures  
MNAR  missing non at random  
NAbs  neutralising antibodies  
NK nuclear factor  
OC osteoclast  
ODF  osteoclast differentiation factor  
ONJ osteonecrosis of the jaw  
OPGL  osteoprotegerin ligand  
P1NP  procollagen type 1 N -terminal propeptide  
PD pharmacodynamic(s)  
PK pharmacokinetic(s)  
PPS per protocol analysis set  
PTH  parathyroid hormone  
RANK  receptor activator of nuclear factor kappa -B 
RANKL  receptor activator of nuclear factor kappa -B ligand  
SAE  serious adverse event  
SAP statistical analysis plan  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-[ADDRESS_1065271]  upper limit of normal  
US [LOCATION_002]  
USPI  [INVESTIGATOR_775520].  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 111 of 124 28Mar2023  10.6 Appendix 6: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Non-substantial Amendment 1: 20 Jul 2021  
Overall Rationale for the Amendment  
The protocol is amended to incorporate and implement responses and sugge stions made by [CONTACT_775603].  
Non-Substantial Amendment 1 Summary of Changes : 
Section # and Name  [CONTACT_175084]*  Brief Rationale  
1.3 Schedule of Activities  Reference ‘m’ of Table 1 -1 and 
Reference ‘k’ of Table 1 -2 amended as 
follows :  
“Injection site reaction assessment 
should be done predose and 
approximately  1 hour postdose ,. 
during this 1  hour period. Any 
further assessment of the injection 
site or prolonged observation of the 
participant may be done at the 
discr etion of the Investigator . At the 
discretion of the Investigator another 
assessment of the injection site may be 
done after the initial 1 hour.”  Amended following  
suggestion from the Czech 
Republic  Regulatory 
Authority.  
6.3.[ADDRESS_1065272] paragraph of section amended as 
follows:  
The Investigator should make an 
effort to contact [CONTACT_775544], if possible, prior to 
unblinding .   If the Investigator 
decides that unblinding is warranted, 
the Investigator should make e very 
effort to contact [CONTACT_775604] a 
participant’s study treatment 
assignment unless this could delay 
emergency treatment of the participant.  
If this is not possible and the situation 
is an emergency the Investigator or 
his/her delegated deputy may break the 
blind and contact [CONTACT_775605].     Amended following  
suggestion from the Czech 
Republic Regulatory 
Authority.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 112 of 124 28Mar2023  Section # and Name  [CONTACT_175084]*  Brief Rationale  
6.3.3 Blinding and breaking the blind  Fifth paragraph of section amended as 
follows : 
In all unblinding cases, Parexel 
should contact [CONTACT_136629].   In all unblinding cases, 
Parexel should contact [CONTACT_775606] (< 24 
hours) after unblinding.    Amended following  
suggestion from the Czech 
Republic  Regulatory 
Authority.  
8.4.5. Local Tolerance (Skin 
Examination)  First paragraph of section amended as 
follows:  
On dosing days, injections site reaction 
assessment should be done predose 
(i.e., for exclusion of a pre -existing, not 
IMP injection induc ed condition) and 
approximately  1 hour postdose ;.  At 
during this 1 hour  period (i.e., from 
dosing to the injection site 
assessment) the participant will stay 
in the clinic for general safety 
observation.  Any further assessment 
of the injection site or prolonged 
observation of the participant may 
be done at  the discretion of the 
Investigator another assessment of the 
injection site may be done after the 
initial 1 hour .   Amended following  
suggestion from the Czech 
Republic Regulatory 
Authority.  
* Bolded text  is added text, struck -through text  is deleted text.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 113 of 124 28Mar2023  Substantial Amendment 1: 03 Aug 2021  
This amendment is considered to be  substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Overall Rationale for the Amendment  
The protocol is mainly amended to incorporate and implement response s and suggestions made 
by [CONTACT_6581].  
Substantial Amendment 1 Summary of Changes : 
Section # and Name  [CONTACT_775612].  Sponsor request.  
1.1 Synopsis  
1.3 Schedule of Activities (SoA)  
2.2.1  Risk Assessment  
3 Objectives and Endpoints  
8.3.3  Fracture Assessment  
[IP_ADDRESS]  Non-vertebral Fracture  
8.4 Safety Assessments  
[IP_ADDRESS].2  Other Safety Data  
10.1.7  Source Documents  
10.3.1  Definition of Adverse Event  Text added and updated to include 
fracture assessment as adverse event 
evaluation.  Amended following  
suggestion from the United 
States Food and Drug 
Administration (US FDA) . 
1.3 Schedule of Activities (SoA)  
2 Introduction  
6.1 Study Treatments Admini stered  
6.1.1  Study Treatment Devices  
6.1.2  Device -related Complaints  
6.3.3  Blinding and Breaking the 
Blind  
8.5 Adverse Events and Serious 
Adverse Events  
8.5.3  Follow -up of Adverse Events 
and Serious Adverse Events  
10.3 Appendix  3: Adverse Events: 
Definitio ns and Procedures for 
Recording, Evaluating, Follow -up, 
and Reporting  Text added to specify recording 
device -related events.  Amended following  
suggestion from the US FDA . 
Section  6.1 Study Treatments 
Administered (Table  6-1) Packaging and Labelling update d to 
Device Description and additional 
information relating to devices added.  Clarification of devices.  
1.3 Schedule of Activities (SoA)  Period for submission of dual energy 
X-ray absorptiometry and X -ray 
imaging for central independent review 
increased to 10  days.  Increased to allow for 
sufficient time for review.  
1.3 Schedule of Activities (SoA)  
8.4.4  Clinical Safety Laboratory 
Assessments  Text amended to specify urine sample 
analysis in case of abnormal results 
may be sent to the central lab oratory if 
deemed necessary by [CONTACT_10670].  Text added for clarification.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 114 of 124 28Mar2023  Section # and Name  [CONTACT_11029]  
1.3 Schedule of Activities (SoA)  
8.4.5  Local Tolerance (Skin 
Examination)  Text amended to better clarify 
observation period of injection site post 
investigational medicinal product  
administration.  Amended for clarification.  
1.3 Schedule of Activities (SoA)  
9.4.1  General Considerations  Baseline value for bone mineral density 
(BMD) clarified.  Amended following  
suggestion from the US FDA . 
2.2.[ADDRESS_1065273] Prescribing 
Information . 
2.2.1  Risk Assessment  Text added to indicate Investigator 
responsibility for coronavirus disease 
2019 testing in symptomatic and 
asymptomatic participants.  Text added for clarification.  
5.2 Exclusion Criteria  Text added on inclus ion/exclusion of 
participants with a history of childhood 
rickets.  Text added for clarification.  
5.[ADDRESS_1065274], 
Participant 
Discontinuation/Withdrawal from the 
Study  Text added to address management of 
reduction in BMD below a pre -defined 
threshold that may occur during the 
study.  Amended following  
suggestion from the US FDA . 
Text added to establish individual 
stoppi[INVESTIGATOR_3418] (e.g., life -threatening 
treatment -related 
hypersensitivity/allergic reaction).  Text added for clarification.  
8.4.1  Physical Examinations  Text updated to clarify timing of height 
assessment.  Text added for clarification.  
8.7 Immunogenicity Assessment  
8.8 Serum Drug Concentration  Text removed for clarification.  Clarification of text.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 115 of 124 28Mar2023  Section # and Name  [CONTACT_11029]  
9.3 Population for Analysis  
9.4.2  Estimands  
9.4.5  Handling of Missing Data  Text updated to reduce the number of 
participants who discontinue the study 
early and the amount of missing data.  Amended following  
suggestion from the US FDA . 
9.4.2  Estimands  Text updated to include all 
randomisation strati fication factors in 
analysis model.  Amended following  
suggestion from the US FDA . 
10.2 Appendix  2: Clinical Laboratory 
Tests  Removal of erythrocyte sedimentation 
rate. Removed from haematology 
panel as not performed by 
[CONTACT_12115].  
10.3 Appendix  3: Adverse Events: 
Definitions and Procedures for 
Recording, Evaluating, Follow -up, 
and Reporting  
[ADDRESS_1065275].  
10.3.1  Definition of Adver se Event  Definition updated to be in line with 
the International Council for 
Harmonisation Topic E2A (Clinical 
Safety Data Management: Definitions 
and Standards for Expedited 
Reporting).  Amended at Sponsor request.  
Throughout  Minor editorial and document 
formatting revisions.  Minor, therefore have not 
been summarized.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 116 of 124 28Mar2023  Substantial Amendment  2: 10 Jan 2022  
This amendment is considered to be  substantial based on the criteria set forth in Article  10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Overall Rationale for the Amendment : 
The protocol is mainly amended to incorporate and implement  changes  for statistical analysis, 
consistency with supporting study documents and  suggestions made based on  Investigator 
experiences . 
Substantial Amendment 2 Summary of Changes : 
Section # and Name  [CONTACT_11029]  
1.1 Synopsis;  
3 Objectives and Endpoints (Table  3-1) Added text to specify primary 
pharmacodynamic endpoint 
secondary for the [LOCATION_002] 
Food and Drug Administration 
(US FDA) submission.  Text added for clarification.  
1.1 Synopsis;  
4 Overall Design;  
6.3.3  Blinding an d Breaking the Blind  Added text to specify blinded and 
unblinded staff during the Main 
and Transition Periods for 
reporting purposes.  Text added for clarification.  
1.3 Schedule of Activities  (Table  1-1) Deleted pre -visit phone call for 
Screening visit.  Participants will not be contact[CONTACT_775607] 2019 
symptoms and signs.  
1.3 Schedule of Activities  (Table  1-1 
and Table  1-2) Added footnote to specify dual 
energy X -ray absorptiometry 
should be performed before 
dosing at Week 26 and Week 52.  Text added for clarification.  
1.3 Schedule of Activities  (Table  1-1 
and Table  1-2); 
2.2.1  Risk Assessment;  
6.1.2  Medical Device Events;  
6.3.3  Blinding and Breaking the Blind;  
6.[ADDRESS_1065276] 
Compliance;  
8.5 Adverse Events and Serious 
Adverse Events;  
8.5.1  Time Period and Frequency for 
Collecting Adverse Events and Serious 
Adverse Event Information;  
8.5.3  Follow -up of Adverse Events and 
Serious Adverse Events;  
10.3 Adverse Events: Definitions and 
Procedure s for Recording, Evaluating, 
Follow -up, and Reporting  Text and terminology amended to 
align with the Product Complaint 
Procedure document.  Text amended for clarification.  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 117 of 124 28Mar2023  Section # and Name  [CONTACT_11029]  
1.3 Schedule of Activities  (Table  1-1); 
2.2.1  Risk Assessment;  
10.2 Clinical Laboratory Tests 
(Table  10-1) Text amended or deleted for  
severe acute respi[INVESTIGATOR_18960] -2 testing to specify as 
required by [CONTACT_1295].  Text amended or deleted as 
infection may occur at any time 
during the study and shou ld be 
assessed as required by [CONTACT_2243].  
1.3 Schedule of Activities  (Table  1-1); 
8.2.5  Screening Assessment  Text added to specify the 
Screening visit may be conducted 
over more than 1  day during the 
Screening period, as required for 
logistical reasons.  To extent Screening period to 
allow required time to perform 
all requirement assessments to 
determine participant eligibility 
for study participation.  
5.2 Exclusion Criteria  Updated exclusion criterion for 
participants with inadequate renal 
and hepatic function (exclusion 
criterion  25) to specify exception 
for participants with Gilbert’s 
syndrome.  Text added for clarification.  
5.2 Exclusion Criteria;  
6.5.1  Prohibited Therapy  Added antioestrogens, 
aromatase -inhibitors, low 
molecular wei ght heparins, 
vitamin  K, vitamin  K antagonists 
(e.g., warfarin, acenocumarol), 
emtricitabine, tenofovir, adefovir 
and pregabalin as prohibited 
medication.  Pregabalin, antioestrogens, 
aromatase -inhibitors, low 
molecular weight heparins, 
vitamin  K antagosist s (e.g., 
warfarin, acenocumarol), 
emtricitabine, tenofovir added to 
list of prohibited medication due 
to potential effect on bone.  
5.2 Exclusion Criteria;  
7.[ADDRESS_1065277], Participant 
Discontinuation/Withdrawal fro m the 
Study  Added pregnancy and 
breastfeeding as exclusion criteria 
and breastfeeding under 
discontinuation/withdrawal 
criteria.  Added as per request from Italian 
Ethics Committee.  
5.2 Exclusion Criteria;  
10.2 Clinical Laboratory Tests  Amended text to specify 
hepatitis  B exclusion criteria.  Text amended for clarification.  
8.2.4  Prior and Concomitant 
Medication Review  Text updated to define prior and 
concomitant medication 
timeframe.  Text updated for consistency 
with Section  6.5. 
8.5 Adverse Events and  Serious 
Adverse Events  Text added to specify medical 
device events that cause adverse 
events (AEs) and serious adverse 
events (SAEs) will be reported 
following the same periods and 
procedures as study AEs and 
SAEs.  Text added for clarification.  
8.5.4  Regulatory Reporting 
Requirements for Serious Adverse 
Events;  
9.4.4  Additional Analyses;  
10.3.5  Reporting of Serious Adverse 
Events  Added text on reporting device 
events to all Member States in 
which clinical study is being 
conducted.  Text added for clarifica tion. 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 118 of 124 28Mar2023  Section # and Name  [CONTACT_11029]  
9.1 Statistical Hypotheses;  
9.2 Sample Size Determination;  
9.4.1  General Consideration;  
9.4.2  Estimands;  
[IP_ADDRESS]  Supplementary (tertiary) 
estimands;  
[IP_ADDRESS]  Safety;  
9.4.[ADDRESS_1065278] not been 
summarized.  
 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 119 of 124 28Mar2023  Substantial Amendment  3: 19 Jan 2023 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Overall Rationale for the Amendment:  
This protocol is mainly am ended to incorporate and implement 10% increase in the number of 
participants to be enrolled for the Transition Period to meet the requirements of [LOCATION_002] 
(US) Food and Drug Administration (FDA), considering the drop -out is higher than expected.  
Subs tantial Amendment 3 Summary of Changes  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis  
1.2 Schema (Figure 1 -2) 
4.1 Overall Design  
6.1 Study Treatment Administered 
(Table 6 -1) 
6.3.2  Re-randomisation and Participant 
Subset in Transition Period  
9.2 Sample Size Determination  Amended text to implement 10% 
increase of the number of 
participants to be enroll ed during 
the Transition Period  than 
previously.  Participants might withdraw the 
consent right after the Main 
Period that would  trigger lack of 
data from follow -up visits.  
Throughout  Minor editorial and document 
formatting revisions.  Minor, therefore have not been 
summarized.  
 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 120 of 124 28Mar2023  11 References  
1. Investigator’s Brochure, RGB -14, Gedeon Richter, Plc., current version . 
2. Prolia Summary of Product Characteristics. 
https://www.ema.europa.eu/en/medicines/human/EPAR/prolia  
3. Prolia (denosumab) Package Insert. US Approval: [COMPANY_010]; current version , revised: 05/2021. 
https://www.pi.amgen.com/~/media/amgen/repositorysites/pi -amgen -
com/proli a/prolia_pi.pdf . 
4. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis . 
Am. J, Med. 1993; 94(6):646 -50. 
5. Compston JE, McClun MR, Leslie WD. Osteoporosis. Lancet  2019; 393([ZIP_CODE]):364 -76. 
6. Takegami N, Akeda K, Yamada J et al. RANK/RANKL/OPG system in the in terverte bral 
disc. Arthritis Res Ther. 2017; 19(1):121.  
7. Cheng ML, Fong L. Effects of RANKL -Targeted Therapy in Immunity and Cancer. Front 
Oncol. 2014; 3:329.  
8. Renema N, Navet B, Heymann et al. RANK -RANKL signalling in cancer. Biosci Rep. 2016; 
36(4):e00366.  
9. Park JH, Lee NK, Lee SY. Current understanding of RANK signalling in osteoclast 
differentiation and maturation. Mol Cells. 2017; 40(10):[ADDRESS_1065279]. Denosumab: targeting the RANKL  pathway to treat rheumatoid 
arthritis. Expert Opin Biol Ther. 2017; 17(1):119 -29. 
11. Cummings SR, San Martin J, McClung MR et al. FREEDOM Trial. Denosumab for 
prevention of fractures in postmenopausal women with osteoporosis. N. Eng. J. Med. 2009;  
361(8):765 -65. 
12. Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab on bone mineral density and 
bone t urnover in postmenopausal women . J. Clin. Endocrinol. Metab.  2008 ; 93(6) :2149 -57. 
13. Nakamura T, Matsumoto T, Sugimoto T et al. Clinical Trials Express: fracture risk reduction 
with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab 
fracture intervention randomized placebo controlled trial (DIRECT). J. Clin . Endocrinol. 
Metab. 2014;  99(7):2599 -607. 
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 121 of 124 28Mar2023  14. Kendler  DL, Roux C, Benhamou CL et al. Effects of Denosumab on Bone Mineral Density 
and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy. J. 
Bone. Miner. Res. 2010;  25(1):72 -81. 
15. Dolor es S, Rosen CJ, Black DM et al. Pharmacological Mana gement of Osteoporosis in 
Postmenopausal Women: An Endocrine Society Guideline Update. J. Clin. Endocrinol. 
Metab. 2020; 105(3):587 -94. 
16. Genant HK, Chun YW, van Kuijk C et al. Vertebral fracture assessment using a 
semiquant itive technique. J. Bone Min er. Res. 1993;  8(9):1137 -48. 
17. McClun g MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with 
low bone mineral density. N. Eng. J. Med. 2006;  354(8) :821-31. 
18. https://clinicaltrials.gov/ct2/show/results/NCT2053753?view=results  
19. Jakobsen JC, Gluud C , Wettersley J, et al. When and how should multiple imputation be used 
for handling missing data in randomised clinical trials – a practical guide with flowcharts . 
BMC Med . Res. Methodol . 2017; 1 7:162:1 -10. 
20. Lou Y, Jones MP , Sun W. Estimation of causal effects in clinical endpoint bioequivalence 
studies in the presence of intercurrent events: noncompliance and missing data. J Biopharm 
Stat. 2019; 29(1):151 -73. 
21. Guidelines on the Management of Clinical Trials during the COVID -19 (Coronavirus) 
pandemic, EMA, Version 3 (28/04/2020) . 
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol -
10/guidanceclinicaltrials_covid19_en.pdf  
22. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 Public 
Health Em ergency, March 2020, Updated April 16, 2020. https://www.fda.gov/regulatory -
information/search -fda-guidance -documents/fda -guidance -conduct -clinical -trials -medical -
products -during -covid -19-public -health -emergency  
23. FDA Guidance on Current Good Manufacturing Practi ce Requirements for Combination 
Products, January 2017 . https://www.fda.gov/regulatory -information/search -fda-guidance -
documents/current -good -manufacturing -practice -requirements -combination -products  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 122 of 124 28Mar2023  24. FDA Guidance on Postmarketing Safety Reporting for Combination Products, July 2019. 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/postmarketing -
safety -reporting -combination -products  
25. ISO [ZIP_CODE]:2020. Clinical Investigation of Medical Devices for Human Subjects – Good 
Clinical Practice , Version 3. July 2020 . https://www.iso.org/standard/[ZIP_CODE].html  
  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 123 of 124 28Mar2023  Investigator Agreement Page  
Declaration of the National Coordinating Investigator  
[CONTACT_1641]: A Randomised , Double -blind, Multicentre Phase  III Study to Assess the Efficacy and 
Safety of RGB -14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis  
This study protocol was subjected to critical review and has been approved by [CONTACT_1034]. The 
information it contains is consistent with the current risk/benefit evaluation of the investigational 
product as well as with the moral, ethical, and scientific principles governing clinical research as 
set out in the Declaration of Helsinki, as amended in  2013 and the guidelines on GCP . 
National Coordinating Investigator  
 
_____________________________________  _____________________  
Signature        [CONTACT_1782]  
_____________________________________  
Name (block letters)  
_____________________________________  
Title (block letters)  
_____________________________________  
Institution (block letters)  
_____________________________________  
Phone number  
Gedeon Richter Plc.  Clinical Study Protocol  
RGB -14-101  CONFIDENTIAL  
 
Version  5.0 124 of 124 28Mar2023  Declaration of the Investigator  
Title : A Randomised , Double -blind, Multicentre Phase  III Study to Assess the Efficacy and 
Safety of RGB -14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis  
All documentation for this study that is supplied to me and that has not been previously 
published will be kept in the strictest confidence. This documentation includes this study 
protocol, Investigator's Brochure , EDC  system/electronic CRF (eCRF), and other scientific data.  
The study will not be commenced without the prior written approval of a properly constituted 
IRB or IEC. No changes will be made to the study protocol without the prior written approval of 
the Sponsor and the IRB or IEC, except where necessary to eliminate a n immediate hazard to the 
participan ts. 
I have read and understood and agree to abide by [CONTACT_95835].  
Responsible Investigator of the Local Study Centre  
 
_____________________________________  _____________________  
Signature        [CONTACT_1782]  
_____________________________________  
Name (block letters)  
_____________________________________  
Title (block letters)  
_____________________________________  
Institution (block letters)  
_____________________________________  
Phone number  